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Abstract 
Non-alcoholic fatty liver disease (NAFLD) has become the commonest form of chronic liver 
disease in western nations and is rapidly rising in the Asia-Pacific. As yet treatments are limited 
to diet modification and life style change, which is rarely effective.  NAFLD is associated with 
an increasing risk of developing hepatocellular carcinoma (HCC), which is also increasing 
markedly and is a significant cause of death. The disease progression is difficult to study in 
humans as invasive procedures are needed. We have developed a mouse model reflecting the 
human condition to investigate mechanisms of this disease and potential therapeutic 
interventions. We used C3H/He mice, which develop obesity and impaired glucose tolerance 
with age, and explored the effect of an American lifestyle diet. The mice developed features of 
the metabolic syndrome and NAFLD, including non-alcoholic steatohepatitis (NASH), which 
was associated with an increase in DNA damage and the development of HCC.  Interesting 
findings were observed with an anti-oxidant (bucillamine) and an FXR agonist (PX20606), but 
neither prevented HCC development.  
As a key responder to DNA damage, TP53 was explored in the model. In general, TP53 
mutation is reported in around 33% of HCC cases and is usually linked with aflatoxin exposure 
and viral hepatitis infection, but in the Western world the incidence of TP53 mutation is lower. 
In our NAFLD model, all the tumours which developed were of wild-type TP53 status. This 
encouraged us to explore exploiting this pathway by testing the ability of small molecule 
inhibitors of the MDM2-p53 binding interaction to activate p53 in a non-genotoxic manner as 
a potential treatment for TP53 wild-type HCC. Promising results were obtained, with highly 
significant growth inhibitory effects in vitro and in vivo (NSG xenograft model) in TP53 wild-
type liver cancer cell lines through the induction of senescence. Combination studies in vitro 
also showed that the effect of MDM2-p53 binding antagonists could be potentiated by 
inhibition of the WIP1/PPM1D phosphatase. Our study shows that targeting the p53 pathway 
is worthy of further exploration for patients with liver cancer.    
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1.1 Normal anatomy and histology of the Liver 
The liver is one of the largest organs in the human body. It is located in the right hypochondrium 
and it is responsible for metabolic homeostasis. It regulates lipid, protein and carbohydrate 
metabolism, in addition to drug detoxification and bile secretion. 
It weighs about 1400-1600 gram and receives 25% of the cardiac output from a dual blood 
supply (70% from the portal vein and 30% from the hepatic artery). It is divided into two lobes, 
right and left. Each lobe consists of multiple smaller units 1-2 mm in diameter called lobules 
that are hexagonal in shape. In the centre of each lobule there is a central hepatic vein, 
surrounded by a number of portal tracts. Within each portal tract are branches of the hepatic 
artery, portal vein and a bile duct. In between the central vein and the portal tracts are 
hepatocytes arranged in cords or trabeculae, with blood containing sinusoids in between. The 
sinusoids are lined by fenestrated endothelial cells which allow exchange of different materials. 
Adherent to the endothelial cells are Kupffer cells, which are a part of the reticuloendothelial 
system. In the peri-sinusoidal space lie retinol-storing stellate cells, which in time of injury 
transform into collagen producing myofibroblast-like cells (1, 2). 
Blood entering the liver, via hepatic artery and portal vein branches, flows from the portal tracts 
in the lobule periphery towards the terminal hepatic vein. Defined by oxygen content of the 
flowing blood, the acinus is divided into three zones. Zone 1 surrounds the portal tract and gets 
the highest oxygen concentration, with zone three around the central vein receiving the lowest. 
Zone 2 sits between zones 1 and 3. These zones are of importance because they show different 
features related to liver injury and diseases (Figure 1.1) (1). 
 
Figure 1.1: Diagram of a section of the liver showing the portal tract, central vein and the 
3 acinar zones between the portal tract and central vein  (1). 
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1.2 Chronic Liver Disease (NAFLD and NASH) 
 Definition 
Steatosis, derived from the Greek word Stear - which means fat, describes the accumulation of 
fatty acids and lipid in hepatocytes. Non-alcoholic fatty liver disease (NAFLD) is simply 
defined as steatosis which occurs in the absence of intake of alcohol or consumption of <30 g 
of alcohol for men and 20 g for women, or the presence of another chronic liver disease (3, 4). 
It is the most common chronic liver disease worldwide (5). 
NAFLD is a part of a larger spectrum that starts with simple steatosis, but in a minority of 
individuals this can progresses to a more severe form called non-alcoholic steatohepatitis 
(NASH). In addition to steatosis, NASH includes a variable degree of inflammation, hepatocyte 
injury and fibrosis. NASH is more likely to progress to cirrhosis, which eventually might lead 
to the development of liver failure or hepatocellular carcinoma (HCC) (5-8) 
Several studies have shown a strong association between metabolic syndrome (MetS) and 
NAFLD. MetS is defined by the presence of three of the followings abdominal obesity with 
waist circumference (WC) >102 cm in men & ≥88 cm in women; elevated fasting glucose 
≥ 100 mg/dL or impaired glucose tolerance test (defined as a glucose level 140 mg/dl 120 
minutes after ingestion of 75 grams of glucose); elevated blood pressure (BP) ≥130/85 mmHg 
and Hypertriglyceridemia ≥150 mg/dL or Low serum HDL <40 mg/dl for men and <50 mg/dL. 
(9, 10). Statistically speaking, the presence of these conditions will increase NAFLD risk by 
several times (7). The presence of MetS is also associated with an increased incidence of HCC 
(11). 
 
 Epidemiology 
The incidence of NAFLD is increasing all over the world. It has become the commonest form 
of chronic liver disease worldwide (12). In the United States and the western countries where 
obesity (which is defined as a body mass index BMI of > 30 kg/m2) (13) has become extremely 
common; and due to the strong association between NAFLD and obesity; the increasing 
incidence of NAFLD represents a major health problem, affecting up to 30-40% of the 
population (11, 14, 15). Globally it is estimated to affect 25.28% of the world population (16). 
Furthermore, the incidence of obesity is increasing in eastern Asian countries like China, where 
it has risen from 13 to 30 % over the period from 1990 to 2008 (11, 17, 18) (Figure 1.2). 
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NAFLD is more common in males than females (8, 11, 19) and is increasingly recognised as 
starting in early childhood, affecting 8% of toddlers (< 2 years) and 17% of children and 
adolescents in the USA (20). Similar to the pattern in the general population, the obesity in 
childhood is increasing and so is childhood NAFLD (20, 21). NAFLD is now considered the 
most common cause of liver disease in the paediatric age group (22, 23). The incidence of 
NAFLD reportedly reaches 17% in early adulthood (24), but continues throughout life, with the 
highest rate in elderly age groups (>60 years in China) (25, 26). 
In addition to obesity, a strong association is present between NAFLD and type II diabetes - 
which is closely related to obesity - and it is predicted that nearly half of the patients with type 
II diabetes in Europe will eventually develop NAFLD (7, 21). Given the current worldwide rate 
of increase in NAFLD, it is predicted to become the commonest cause of liver transplantation 
(5, 27). 
 
Figure 1.2: Showing the transition through NAFLD to HCC  adapted from Yu et al (11). 
 Pathogenesis 
Because of the changes in the style of modern life throughout the last century, individuals levels 
of activity have reduced and eating habits have changed - with an increase in the consumption 
of fast food that is rich in trans-fatty acids (processed fat), alongside with fructose-rich drinks. 
This dietary excess has resulted in an increased incidence of overweight and obesity, which 
have become major diseases that threaten communities. Their incidence has increased to 
worrying levels, reaching about 50% of the general population in the developed countries, with 
increased NAFLD incidence as a consequence (28-30). Furthermore, one of the most important 
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risk factors for HCC development is morbid obesity (which is defined as a body mass index 
BMI of > 40 kg/m2) (13, 31). 
At least two theories of NAFLD pathogenesis have been proposed. The “two-hit theory” is one, 
in which a first hit represented by the accumulation of fat inside hepatocytes, sensitise them to 
the second hit. The second hit most likely arises as a result of accumulating ‘free’ fatty acids 
(FFA), where the influx exceeds the hepatocyte ability to either store or metabolise them 
properly, leading to oxidative stress, death of hepatocytes and ultimately fibrosis - as part of a 
wound healing response (21, 32). A multi parallel hits theory has also been proposed, in which 
multiple factors act together to cause liver damage and inflammation (33). In the second theory 
the inflammatory response might occur prior to and even promote steatosis (7).  
1.2.3.1 Key processes in NAFLD pathogenesis and progression 
Lipid accumulation in the liver happens due to several factors, including increased fat levels 
due to increased dietary consumption, altered lipolysis, increased fat synthesis (lipogenesis), 
and possibly defective extracellular transport or excretion (33).  
Excess glucose can contribute to lipid accumulation, with obesity, Insulin resistance (IR) and 
type II diabetes closely related. In the normal state, insulin binds to insulin receptor (INSR) and 
causes activation of the insulin substrate-1 (IRS-1) as well as PI3K/Akt pathway. PI3K/Akt 
activates glucose uptake by the cell and activates glycogen synthase leading to glycogen 
synthesis (34).  Insulin resistance (IR) is a major player in NAFLD pathogenesis, contributing 
to  a) increased lipolysis which leads to increased (FFA) that accumulate in the hepatocytes;  b) 
inhibition of glycogen synthesis;  c) stimulated glycolysis which leads to increase glucose levels 
(Hyperglycemia) that stimulate further secretion of insulin from the pancreatic β-cells.  
Accumulation of FFA in hepatocytes promotes an increase in mitochondrial and peroxisomal 
β-oxidation, as well as activation of the transcription factor peroxisome proliferator activator 
receptor (PPAR-α), leading to transcription of genes involved in β-oxidation, which produces 
reactive oxygen species (ROS). Furthermore, the excessive β-oxidation of fat contributes to 
depletion of mitochondrial DNA (mtDNA) and hence disturbs mitochondrial function (Figure 
1.3) (35). 
The accumulated ROS in the presence of steatosis leads to hepatocyte lipid peroxidation, 
endoplasmic reticulum stress (ER stress), disturbed cell functions, cell death, stimulation of 
cytokine derived liver damage (TNF-α mainly) and increased cytokine secretion, all of which 
ultimately lead to fibrosis. ROS also induces JNK1, which inhibits the insulin activation 
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pathway and contributes to IR through inhibition of IRS-1 function, blocking the insulin 
pathway by phosphorylating IRS-1 at an inhibitory site (Ser312 in humans and 307 in mice) 
(Figure 1.3) (21, 36, 37). 
Elevated insulin and glucose also contribute to steatosis through increased transcription of sterol 
regulatory element binding protein (SREBP1c) and other factors which are necessary for lipid 
synthesis (38). SREBP1c is negatively regulated (deacetylated and inactivated) in part by silent 
mating type information regulation 2 homolog 1 (SIRT1), and SIRT1 (which is a member of 
the histone deacetylase (HDAC) family) has a central role in fat metabolism and prevents fat 
accumulation in hepatocytes (39, 40). This negative regulation of SREBP1c by SIRT1 can be 
blocked through inhibition of SIRT1 by miRNA34a. It has been suggested that miRNA34a can 
bind to and inhibit the translation of SIRT1 mRNA and thus inhibit SIRT1 (21, 41). Since 
miRNA34a is a direct transcriptional target of p53, activation of p53 leads to inhibition of 
SIRT1, and consequent release of SREBP1c from the inhibitory effect of SIRT1, promoting 
lipid synthesis and accumulation in hepatocytes leading to steatosis, increased oxidative stress, 
cell injury and inflammation (7, 42-44). 
Apoptosis as an important contributing factor in NAFLD pathogenesis was recently brought to 
our attention. With progression of the disease it was found that p53 levels increase, activating 
both the intrinsic (BAX, PUMA and NOXA) and extrinsic (FAS & TNF related death receptor) 
pathways of apoptosis, mediated by mitochondrial release of cytochrome-C and activation of 
caspase proteolytic cascades (45, 46). FFAs can also cause apoptosis through activation of 
JNK1, that causes increased p53-upregulated modulator of apoptosis (PUMA), and activation 
of BAX, which again lead to mitochondrial dysfunction and caspase-dependent apoptosis 
(Figure 1.3) (47). Engulfment of apoptotic bodies by stellate cells and Kupffer cells leads to 
generation of death ligands and Fas which promote further apoptosis (21, 37). 
 Lipotoxicity induced hepatocellular damage is an important factor in NAFLD pathogenesis 
through induction of apoptosis. It was found that due to the lipotoxic effect of FFAs DR5 is 
activated and can lead to hepatocellular injury through proapoptotic signalling and activation 
of macrophages (48). Lipotoxic injury might be lethal or sublethal to the hepatocytes (Figure 
1.4) (49).  
One of the features of sublethal lipotoxicity and hepatocellular injury is what is called 
hepatocellular ballooning (undead cells). This term describes hepatocytes with cellular 
degeneration marked by swelling of the cells and centrally located nucleus, reticulated 
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cytoplasm, accumulation of ubiquitinated proteins and loss of keratin 8 and 18 (49, 50). These 
cells are implicated in the pathogenesis and are the hallmark of NASH. Another histological 
feature that is linked to sublethal lipotoxic injury is the accumulation of insoluble protein 
inclusions in hepatocytes (Mallory-Denk bodies) that are linked to liver inflammation and 
fibrosis (49). 
Recently it has been implicated that lipotoxicity induces intercellular signalling through 
extracellular vesicles (EV) release (49). EVs include exosomes (which are ~50-100 nm 
diameter membrane bound part of the multivesicular body (MVB)) and microvesicles (which 
are ~50-1000 nm and bud from the plasma membrane) (49). These EVs contain several 
components and mediators including proteins, RNAs, surface receptors, and lipids. EVs bind 
to targeted cells by interacting with surface receptors, followed by internalisation and fusion 
releasing their contents into the cells. Under physiological conditions EVs are released into 
body fluids to reach and exert their action on target cells.  In NASH, lipotoxically-injured 
hepatocytes release EVs which contain heterogeneous compounds of which is the stress kinase 
mixed lineage kinase 3 (MLK3) that causes macrophages chemotaxis and activation in the liver 
through the potent C-X-C motif chemokine ligand 10 (CXCL10) (51). Other compounds in 
these EVs are miRNAs of which miRNA128-3p that regulates liver fibrosis (52), proteins 
inducing angiogenesis like surface protein vannin-1 (VNN1) (53), oxidised mitochondrial DNA 
and DAMPs that leads to inflammation (Figure 1.5) (54).  
Another important factor is gut microbiota which plays important role in NAFLD pathogenesis. 
There are more than 104 microorganisms inside the human gastrointestinal tract that have 
important role in health and disease. Alteration of these commensal bacteria have a role in 
NAFLD development (55). Studies showed monosaccharides absorption through the intestine 
is increased by gut microbiota leading to increased hepatic lipogenesis through the de novo 
pathway and through fasting-induced adipocyte factor suppression (55, 56).  
Gut microbiota causes insulin resistance through overgrowth of bacteria in the small intestine 
that impair intestinal epithelial cells tight junctions (that is a barrier against bacterial 
translocation) leading to increased intestinal permeability (57, 58). Subsequently more bacteria 
and lipopolysaccharides will translocate into the liver through the portal vein with increased 
expression of Toll-like receptor 4 (TLR4) and release of interleukin-8 stimulating inflammation 
of the liver. Not only that but gut microbiota converts choline (which is important in cell 
membrane and liver fat transport) into toxic metabolites (dimethylamine and trimethylamine) 
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that are further converted by the liver into more toxic compound trimethyl oxide leading to liver 
injury and inflammation (59, 60).  
1.2.3.2 Role of Fructose 
Fructose intake in large amounts and for long periods of time is closely related to IR and obesity, 
and hence NAFLD. It causes IR through activation of MAPKinases like MKK7(MAP2K7) and 
MAPK8, which inhibit hepatic glucose uptake and therefore promote glucose accumulation 
extracellularly  (hyperglycemia), with consequent increases in insulin secretion from pancreatic 
cells in response to the elevated blood glucose levels (61). 
Fructose also increases lipid synthesis by activation of both SREBP1c and carbohydrate 
response element binding protein (ChREBP), which control key enzymes like fatty acid 
synthase (FASN) and acetyl-CoA carboxylase (ACC) (61). At the same time fructose also 
causes inhibition of free fatty acid (FFAs) oxidation in the mitochondria. This is due to the fact 
that fructose metabolism leads to production of Acetyl CoA. If Acetyl CoA is produced in large 
amounts, some is converted into Malonyl CoA, which inhibits the mitochondrial oxidation of 
FFAs. Furthermore, some excess fructose is converted into citrate that is a substrate for 
lipogenesis. Thus, excess fructose leads to accumulation of FFAs and inhibits their oxidation. 
These FFAs will accumulate and contribute to steatosis as described above (62, 63) In addition 
to these effects, animal model data suggests that increased intake of fructose may be associated 
with greater levels of necroinflammation and fibrosis in the liver (37). 
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Figure 1.3: Mechanisms of pathogenesis in NAFLD elucidating the role of FFA, IR and 
ROS, adapted from Ferreira et al (21).Increased influx of FFAs into the hepatocytes will 
overwhelm mitochondrial β-oxidation causing an increase in ROS levels and depletion of 
mtDNA. ROS is also increased through TNF-α which is increased in NAFLD patients. FFAs 
also activates protein phosphatase 2A which dephosphorylate and activate the transcriptional 
target FOXO3. FOXO3a causes increased BIM levels, which results in apoptotic pathway 
activation. Endoplasmic reticulum (ER) stress is also increased in NAFLD patient liver cells, 
with accumulation of unfolded protein and inhibition of insulin signalling through 
phosphorylation of IRS-1. JNK and ER stress induced CAAT/enhancer binding homologous 
protein (CHOP) cause upregulation of PUMA, which activates BAX and in turn creates pores 
in the mitochondrial membrane releasing cytochrome c and activating apoptosis through 
caspase activation. ER activates NFKB pathway with more production of TNF-α, which plays 
a role in NASH.   
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Figure 1.4: Lipotoxic injury to the hepatocytes adapted from Ibrahim et al (49). Lipid 
accumulation induces lethal (apoptosis) and sublethal injury of hepatocytes in the form of 
proapoptotic signalling with the release of extracellular vesicles and in the form of ballooning 
of hepatocytes. 
 
Figure 1.5: Extracellular vesicles (lipotoxic-induced hepatocyte-derived) effect on liver 
adapted from Ibrahim et al (49). Lipoptoxic injury induces the release of EVs from hepatocytes 
that contain several mediators that play important role in the pathogenesis of NASH. These 
mediators include miRNA128-3p that induce fibrosis through stellate cell activation. CXCL10 
and ceramide, TRAIL and mitochondrial DNA vesicles induce macrophage accumulation and 
activation. Neovascularisation and endothelial cell migration is stimulated by VNN1.  
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1.2.3.3 Genetic factors 
Genetic factors also play a role in the pathogenesis of NAFLD and may explain differences in 
the rates of progression of NASH in some patients. A single nucleotide polymorphism (SNP) 
in patatin-like phospholipase domain containing protein 3 (PNPLA3), a gene located on 
chromosome 22 that encodes triacylglycerol lipase enzyme, mediating hydrolysis of 
triacylglycerol in adipocytes, is one of the most common genetic variations associated with 
increased steatosis and liver fibrosis in NASH patients, as well as with HCC (64, 65). The 
prevalence of the variant allele of this gene, that affects PNPLA3 function, was also found to 
be increased in Caucasian lean NAFLD patients (66).  
Other genetic variations linked to NAFLD and NASH progression through genome-wide 
association studies are those involved in lipid metabolism like transmembrane 6 superfamily 2 
(TM6SF2) (a transmembrane protein found in the endoplasmic reticulum and Golgi membranes 
and responsible for lipid transport), farnesyl diphosphate farnesyl transferase 1 (FDFT1) 
(important in the production of cholesterol), and glucose metabolism - like glucokinase 
regulator (GCKR). GCKR is an important regulator of glucose uptake and glycolysis and affects 
mitochondrial β-oxidation and fat deposition (64, 65). 
 Grading and staging of NAFLD 
Rather than subjective histological assessments of the severity of NAFLD, grading systems 
which include scores for the semi-quantitative evaluation of the morphological features of 
NAFLD have been proposed, with the aim of promoting consistency and reproducibility (67-
69). These include the Brunt system which refers to the grades of severity of NASH (70), the 
NASH Clinical Research Network’s NAFLD activity score (NASH CRN-NAS), and the 
steatosis, activity, and fibrosis (SAF) scoring system (67, 68, 71). A comparison between the 
three systems is summarized in Table 1.1(69). The NAS CRN scoring system includes several 
parameters which are scored separately and then a total score is calculated. It uses steatosis, 
lobular inflammation and ballooning as criteria for scoring NAFLD; and there is a separate 
stage for fibrosis. The steatosis is given a score between zero and three (0-3), according to the 
percentage of hepatocyte affected, in which zero means <5%, 1= 5-33%, 2= 34-66% and 3= 
>66%. Hepatocellular ballooning (HB) is similarly scored (0-2), with no ballooning, mild or 
few cells with ballooning and moderate or marked ballooning respectively. Lobular 
inflammation (LI) is the third parameter and is scored (0-3) depending on inflammatory foci 
per high power field (0=no foci, 1=<2 foci, 2=2-4 foci and 3=>4 foci). The maximum score is 
8. According to this system, a score of 0-2 excludes NASH, scores of 3-4 suggest borderline 
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NASH, while ≥ 5 defines NASH (71). However, a score of 5 can be achieved in the absence of 
ballooning – thought by many to be a cardinal feature of NASH.  The use of an ‘activity score’ 
centered on ballooning and lobular inflammation, was proposed as part of the SAF scoring 
system as a more accurate way of diagnosing NASH, assuming a grade of at least ‘1’ for 
steatosis.  A SAF activity score of 2, including the presence of both HB and LI, can be used for 
diagnosing NASH (Figure 1.6) (68). 
 
Table 1.1: A comparison between NAFLD scoring systems, adapted from Kleiner & 
Makhlouf 2016 (69). 
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Figure 1.6: Bedossa et al algorithm for the diagnosis of NASH (68). 
 
 
 Management of NAFLD 
The ideal methods to manage NAFLD that researchers have investigated centre on lifestyle 
modifications that include weight loss and exercise (72). Several studies reported the effect of 
body weight loss and healthy diet on improving the state of liver disease in patients with 
NAFLD and NASH - with carbohydrate restricted hypocaloric diet being very effective. A 
Mediterranean diet that is rich in fibres and polyunsaturated fatty acids can improve steatosis 
in 6 weeks in patients with NAFLD.  Exercise, independently of any effect on weight loss, can 
improve insulin resistance (hepatic and peripheral) in patients with NAFLD, in addition to 
improving their cardiovascular status (72, 73). Losing 3-5% of body weight is sufficient to 
improve hepatic steatosis (74), and it has been shown that 40% reduction in hepatic triglyceride 
content can be achieved through rapid loss of body weight (4% within 2 weeks) with caloric 
restriction (75). 
Lifestyle change is unfortunately challenging for many and difficult to maintain in the longer 
term. Another successful modality of treatment in morbidly obese patients is bariatric surgery, 
which can deliver a 25% maintained weight loss, associated with improvement in steatosis and 
steatohepatitis in the majority of patients receiving it (76). Benefit in terms of fibrosis is 
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presently less certain, being improved in some, but with some reports of no change or elevations 
7-40% (77). 
Patients with NASH are widely believed to be those at risk of progressing to fibrosis, cirrhosis 
and HCC (73). Although large number of recent studies clearly indicate that it is those patients 
with stage 2 fibrosis or above that are at highest risk of developing cirrhosis (73) or have a 
higher risk of mortality (78), recently reported and ongoing pharmacological intervention trials 
have and are centred on patients with NASH.  The PIVENS trial compared pioglitazone, 
vitamin-E and placebo and was focused on adults with NASH who had a NAS score of ≥4.  The 
TONIC trial, which compared metformin, vitamin E and placebo, was conducted in children 
with NAFLD and some but not all of them had NASH. Both trials reported a modest histological 
benefit for the antioxidant vitamin-E.  In the PIVENS trial there was improvement in steatosis, 
lobular inflammation and liver enzymes; while the TONIC trial reported improvement in 
NAFLD activity score and reduction in ballooning, but was not successful in reducing liver 
enzymes in the treated individuals. Both trials failed to show any improvement effect on fibrosis 
(79, 80). Unfortunately, long term intake of vitamin E was associated with increased risk of 
prostatic cancer (73). Pioglitazone, which is a peroxisome proliferator- activated receptor 
gamma (PPAR-γ) that belongs to the thiazolidinedione family, is another drug undergoing 
investigation for the treatment of NAFLD. It increases the insulin sensitivity and decreases 
glucose levels (through decreased production and increased consumption) which was shown to 
improve steatosis and inflammation; in a similar but less effective way to vitamin E (81).  
Obeticholic acid which is a potent FXR agonist (Farsenoid X receptor (FXR) is a nuclear 
receptor that is usually activated by bile acid (discussed in more details in chapter 4), is another 
treatment modality for NAFLD. It was found to regulate lipid and glucose metabolism and 
hepatic inflammation. The FLINT trial reported obeticholic acid to improve steatosis, 
inflammation, ballooning and fibrosis, but 20% of patients developed pruritus that was 
significantly associated with improvement in the histological features (82). 
Pentoxifylline, which is a xanthine derivative used to treat pain and cramps and can reduce 
inflammation and fatty acid oxidation, is another cheap well tolerated drug under investigation 
and promising in the treatment of NASH (83). While several drugs are being tested for the 
treatment of NAFLD, liver transplantation is used as a last resort for those patients who develop 
liver failure or HCC (72).  
15 
 
1.3 Hepatocellular Carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide (84). 
Owing to late stage presentation and co-existing underlying liver disease, the prognosis for the 
majority affected is poor, with a 5 year survival of less than 15%. Importantly, while overall 
cancer related deaths have been declining, deaths from HCC have been increasing over the last 
decade (85). 
Asian countries, especially eastern and south eastern ones, have the highest incidence of HCC, 
with China taking the lead in accounting for half of the patients with HCC in the world. Usually 
HCC develops in cirrhotic patients, in those with hepatitis B or C or alcoholic liver disease. 
However, HCC can occur with lesser degree of fibrosis, particularly in men (86, 87). 
The incidence of NAFLD related HCC has been increasing, especially in Western countries 
where it accounts for 4-22% of HCC cases (88).  If the 15-30% of global HCC cases attributed 
to cryptogenic cirrhosis are considered in part NAFLD related, the contribution is even more 
striking. It is estimated that around 50% of cryptogenic cases are attributable to NAFLD (88). 
 Risk factors for HCC 
The vast majority of HCC cases develop in chronically diseased livers, with cirrhosis being the 
major risk factor. Thus, any risk factor for cirrhosis is also considered as a potential risk factor 
for HCC, and these include alcohol intake, hepatitis B virus (HBV) infection, hepatitis C virus 
(HCV) infection, non-alcoholic steatohepatitis (NASH), and primary biliary cirrhosis(89, 90).  
HCC can also develop in non-cirrhotic liver, being reported in pre-cirrhotic CHB, in NAFLD, 
in association with aflatoxin B1 exposure, and also with the hepatic iron overload which occurs 
in those with hemochromatosis (89, 91-93). 
Viral hepatitis contributes the greatest burden overall, with Gurtsevitch et al (94) showing that 
nearly 50% of the global HCC were in HBV infected patients, and 25% were in HCV infected 
patients. Infection with HBV increases the incidence of HCC by 100 times. HBV is a DNA 
double-stranded virus that incorporates in the human genome contributing to mutation and 
chromosomal instability which explain why HBV related HCC can occur in the absence of 
cirrhosis. In addition, however, the consequences caused by the viral infection include an 
inflammatory response, necrosis, healing by scarring, in combination with regeneration. These 
result in cirrhosis, with additional inflammation associated DNA damage increasing mutations 
which disrupt the regulation of cell growth and contribute to HCC development. Specific HBV-
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related genetic abnormalities are recognised, including an integration which encodes for the 
viral protein HBx, which stimulates transcription of NFkB and other kinases that cause 
increased proliferation and inhibition of apoptosis (92).  
HCV on the other hand is an RNA virus that does not incorporate into the host genome. In 
addition to its cirrhosis related risk, however, infection reportedly stimulates oxidative stress 
through its core protein effects on the endoplasmic reticulum and mitochondrial outer 
membrane. The interaction can generate reactive oxygen species, which stimulate the NFkB 
and kinase pathways, affecting gene transcription and conferring additional risk. This can occur 
in the absence or presence of cirrhosis (95). HCV also stimulates the secretion of tumour 
necrosis factor alpha (TNF-α) and Interleukin-6 (IL-6), which induce IR and are involved in 
fibrogenesis (92). 
In Sub-Saharan Africa and Southeast Asia, the ingestion of food contaminated with aflatoxin 
(that is a mycotoxin produced by Aspergillus fungus, due to food storage in conditions of high 
humidity and temperature) leads to high HCC incidence. This toxin binds to DNA in a sequence 
dependent manner inducing a characteristically high incidence of TP53 mutation at codon 249.  
TP53 mutation is detected in half of the HCC cases in sub-Saharan Africa (89, 96).  
Metabolic risk factors are also clearly important. The risk of HCC development is increased 
two-four times by type II diabetes mellitus (97-99), irrespective of the underlying etiology of 
chronic liver disease. In the United States, metabolic disorders had the highest contribution to 
the burden of HCC over the last decade (100). 
Obesity and diabetes act together in a synergistic way to massively increase the incidence of 
HCC, which is increased by 100 times when combined with viral hepatitis B or C infection 
(101). In one study of the link between obesity and HCC, it was alarmingly reported that there 
was a 20-30% increase in the risk of liver cancer with each unit increase in the BMI (102).   
Several epidemiological studies have now confirmed that NAFLD is a strong risk factor for 
HCC development, which might even develop in the early stages of NAFLD. In other words it 
doesn’t need to pass through the usual route starting with steatosis, NASH, cirrhosis ending 
with HCC (103). Recent studies suggest that development of HCC in patients with NAFLD 
quite often presents without NASH or cirrhosis – with reports suggesting that this accounts for 
between 20 and 50% of cases (11, 93, 103, 104).  Some of these reports may be affected by 
reporting bias – as patients without cirrhosis may have better preserved liver function and be 
more likely to be referred to tertiary referral centres.  However, while the risk of HCC is very 
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much greater in patients with cirrhosis, even a relatively small – presently poorly understood – 
risk in obese, diabetic NAFLD patients without cirrhosis, does appear to translate into 
significant numbers of cases, given the prevalence of the at risk population. Common 
aetiologies and risk factors are summarised in greater detail below. 
An additional risk factor is the deposition of iron in the liver which increases the risk of HCC 
development in cirrhotic patients with NASH. Iron deposition causes increased oxidative stress, 
which in patients with haemochromatosis raises the risk for HCC by 200 fold (11). 
In developed countries, due to the improvement in controlling the risk factors for HCC (like 
hepatitis C and B), and due to the high and increasing incidence of obesity, the incidence of 
HCC due to HBV and HCV is decreasing while the incidence of NAFLD induced HCC in those 
countries is rising (87-89). 
 Molecular mechanisms of development of HCC in NAFLD 
In chronic liver disease continuous injury to the hepatocytes will lead to cell death. Due to the 
regeneration capability of the liver, hepatocytes regenerate and proliferate; but unfortunately 
this chronic insult causes continuous division, which may be accompanied by genetic defects 
which contribute to HCC carcinogenesis (105). These include genetic mutations, and epigenetic 
changes (which involves hypo or hypermethylation that may cause activation of oncogenes or 
silencing of tumour suppressor genes respectively). The potential involvement of changes in 
miRNA expression (e.g. of miRNA 139 and 122 in HCC) have also been suggested (106).  
There are several pathways commonly disrupted by these kinds of changes which can contribute 
to carcinogenesis in HCC, including PI3K/Akt, Myc, Wnt/B-catenin, c-Met and hedghog (92, 
106).   
As reported above, obesity and diabetes are the major risk factors for NAFLD. Lipid deposition 
can lead to hepatotoxicity, increased lipid peroxidation and reactive oxidative stress. In addition 
to the lipotoxic effect on increasing oxidative stress, Kupffer cells when activated in NAFLD 
produce large amounts of reactive oxygen species that contributes to the increased oxidative 
stress (107). Oxidative stress is not only a major factor in NAFLD pathogenesis, but may also 
be a major factor in HCC carcinogenesis - through induction of DNA damage as well as 
mitochondrial DNA damage (107-109), associated with the induction of cell injury, apoptosis 
and cellular proliferation (93). 
Recently it was reported that NAFLD induces selective loss of CD4+ T lymphocytes (that 
inhibits HCC initiation and progression) through increased ROS release (110). CD4+ 
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lymphocytes have high ROS levels derived from their high mitochondrial mass, and the 
increased ROS in NAFLD lead to depletion of CD4+ lymphocytes that exerts anti-tumour 
activity, hence increasing the risk of tumour development due to impairment of anti-tumour 
surveillance (110). Additionally, it was found that CD8+ T lymphocytes function is suppressed 
in NAFLD through the accumulation and increased activity of IgA+ cells. This leads to decrease 
in the anti-tumour surveillance exerted by CD8+ lymphocytes and increase in HCC 
development (111).  
Chronic DNA damage induced by oxidative stress induces regeneration through proliferation 
of hepatic progenitor cells, which are also activated by Kupffer cells in chronic liver injury (88, 
112). The chronic injury of hepatocytes in NAFLD also stimulates Hedgehog signalling, 
leading to mobilisation of hepatic progenitor cells to replace the injured hepatocyte as part of 
the healing process. The continuous state of stimulation of the Hedgehog pathway can lead to 
aberrant proliferation and hepatocarcinogenesis (113, 114). 
Abnormal lipid accumulation can also lead to a continuous state of inflammation characterised 
by the release of two factors implicated in the pathogenesis of HCC in NAFLD, namely tumour 
necrosis factor (TNF) and interleukin-6 (IL-6) (103, 115, 116).  TNF activates several pro-
oncogenic pathways, like Nuclear Factor-kappa B (NFkB), c-Jun NH2-terminal kinase (JNK), 
and the mammalian target of rapamycin (mTOR). IL-6 secreted by tumour associated 
macrophages plays a pivotal role through activation of the JAK/STAT3 pathway leading to 
stimulation of cellular proliferation and inhibition of apoptosis (103, 115, 117) (Figure 1.7). 
Additionally IL-6 is a downstream target of FGF19 which is commonly amplified in HCC and 
associated with poor prognosis and this appears to be through activation of JAK/STAT3 
pathway (118). Lipid deposition also leads to disturbance in the levels of adipokines (119), one 
of which is adiponectin. Adiponectin has a strong anti-inflammatory effect and suppressive 
effect on oncogenic pathways. It also negatively regulates angiogenesis (93). Adiponectin 
suppression occurs in NAFLD and exacerbates the Kupffer cell mediated inflammatory 
response towards gut derived endotoxin, which leads to hepatocyte injury and proliferation (93, 
120-122). The lipid related disruptions or disequilibrium between the pro-inflammatory 
cytokines TNF and IL-6 and the anti-inflammatory effect of adiponectin are believed to favour 
the development of NAFLD-HCC (11, 123). 
Leptin is another important adipokine, which is elevated in NAFLD and is known to stimulate 
Kupffer cells and stellate cells, leading to fibrosis and a more progressive NAFLD (119, 124-
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127). In addition, leptin favours immortalisation of hepatocytes through the upregulation of 
telomerase, also promoting HCC development (93, 128). 
NAFLD associated IR and hyperinsulinemia leads to activation of insulin receptor substrate-1 
(IRS-1) and elevated levels of insulin-like growth factor (IGF-1). Both insulin and IGF-1 
promote cell proliferation and have also been implicated in the development of HCC (87, 93, 
129-132). Hyperinsulinemia also promotes deregulation of several signalling pathways, 
including p53, mitogen-activated protein kinase (MAPK), phosphatidylinositol-3 kinase 
(PI3K/Akt), which can inhibit apoptosis and stimulate cell proliferation, further encouraging 
HCC development (11, 93) (Figure 1.7). 
Recently, it was suggested that the tumour suppressor Liver kinase B1 (LKB1) might play an 
oncogenic role in HCC. It was found to be elevated in cirrhotic liver HCC. LKB1 regulates 
proliferation through the Akt pathway, as well as controlling p53 function through 
phosphorylation at Ser 389, preventing its movement into the nucleus and interfering with its 
function. This was demonstrated in an animal model and supported by studies in human tissue 
samples from NASH patients (133). 
 
Figure 1.7: Relation between NAFLD, metabolic syndrome and HCC  adapted from 
Stickel and Hellerbrand 2010, (134).Excess FFAs cause increased lipid peroxidation and ER 
stress which lead to increased ROS and DNA damage and oncogenic reactive aldehydes in 
addition to an inflammatory status with increased secretion of TNF and IL-6. Hyperinsulinemia, 
increased leptin and increased TNF and IL-6 promote inflammatory, proliferative and 
oncogenic pathways and suppress apoptosis. Collectively and with time there is malignant 
transformation and hepatocarcinogenesis.   
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 Morphology of hepatocellular neoplasms  
1.3.3.1 Hepatocellular adenoma (HCA) 
Rare primary benign liver tumour that affects females more than males in their 30-50s and arises 
in non-cirrhotic liver. They are related to the use of oral contraceptives and to the use of anabolic 
steroids. HCA (usually solitary) are well demarcated macroscopically but do not have capsule. 
They are composed of benign hepatocytes that are usually larger and paler than non-neoplastic 
hepatocytes without nuclear pleomorphism or hyperchromasia. The neoplastic hepatocytes are 
arranged in 2-cell thick trabeculae and the acinar architecture is lost (135). 
1.3.3.2 Hepatocellular carcinoma (HCC) 
HCC usually present as a single mass but sometimes as multiple nodules (commonly in cirrhotic 
liver) or diffuse involvement of the liver or they are of massive type with very large size. 
Microscopically, the malignant tumour cells are arranged in several layers (>3 cell-thick) 
trabeculae, or sheets and tubules (pseudoglandular with papillary-like projections) with loss of 
reticulin network (135, 136). Intranuclear pseudoinclusions are often seen in the tumour cells 
caused by cytoplasmic invagination. The cytoplasm of the malignant cells may contain 
Mallory-Denk bodies, pale bodies (which are membrane-bound clusters of granular material), 
α-fetoprotein and α1-antitrypsin containing round hyaline globules, copper or bile pigment. The 
cytological and nuclear pleomorphism vary depending on the degree of differentiation of the 
tumour (135). 
1.3.3.3 Grading of HCC: 
The most commonly used system to grade HCC is the Edmondson and Steiner system that 
consists of 4 grades (137). Grade I, in which malignant tumour cells are small and are arranged 
in trabeculae with abundant cytoplasm and their nuclear irregularity is minimal with close 
similarity to the normal hepatocyte. Grade II, the malignant tumour cells show prominent 
nucleoli, hyperchromatism and their nuclei show more irregularity than grade I. Grade III, 
tumour cells nuclei are angulated and show more pleomorphism than that seen in grade II. 
Grade IV, in which the tumour cells show prominent pleomorphism and anaplastic giant cells 
(136).  
1.3.3.4 Histological variants of HCC: 
Clear cell hepatocellular carcinoma: Male predominance is prominent in this subtype in which 
the tumour cells have clear cytoplasm (hence the name), are arranged in trabeculae and they 
have cytoplasmic fat vesicles (136, 138). 
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Steatohepatitic HCC: This type usually arises in patients with steatohepatitis but it might also 
develop in patients without it. More than 5% of the tumour cells show steatosis in addition to 
the presence of ballooning, Mallory-Denk bodies, fibrosis and inflammatory infiltrates (136, 
139). 
Scirrhous HCC: This subtype shows characteristic fibrosis along the sinusoid-like blood spaces 
with trabecular atrophy. It can be misdiagnosed as cholangiocarcinoma or metastasis. The 
location of this HCC type is subcapsular and pedunculated gross appearance. It has been 
reported that 84% of the cases have remarkable CD8+ve lymphocytic infiltrate (136). 
Sarcomatous HCC: The tumour is composed of spindle-shaped cells with bizzare anaplasia, 
and frequent giant cells. It is difficult to differentiate in appearance from leiomyosarcoma and 
fibrosarcoma (136, 140). 
Fibrolamellar HCC: It is a rare type that occurs in young patients without liver cirrhosis and 
accounts for a minority of cases (<1%) with a better prognosis than HCC. It mimics focal 
nodular hyperplasia due to fibrous septae and occasional calcification in the central scared zone 
(138). Polygonal tumour cells form trabeculae and sheets separated by hyalinised collagenous 
fibres giving a lamellar appearance with frequent cytoplasmic inclusions (eg. PAS-positive 
cytoplasmic globules and ground glass pale bodies) with abundant immunohistochemical 
expression of keratin 19 and keratin 7 (136).  
HCC with lymphoid stroma: This subtype has few identifiable malignant cells and a dense 
stromal inflammatory infiltrate, composed mainly of lymphocytes (CD3+ , CD4+ T 
lymphocytes and CD20+ B lymphocytes), with few macrophages, neutrophils, plasma cells and 
giant cells (141). 
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 Staging of HCC 
Staging systems are used to assess the disease status and extent of spread of the tumour in order 
to be able to predict the prognosis and plan an efficient treatment strategy that aims to extend 
patients life by weighing the benefit of the treatment against the side effects or drawbacks. 
Cancer staging systems - such as the widely used Tumour Node Metastases (TNM) systems – 
consider tumour characteristics predominantly (142).  In patients with HCC, however, staging 
systems need to be combined with some measure of underlying liver function, as this is equally 
important in determining patient fitness for therapy and survival. Several combined staging 
system have been put forward for HCC, but due to the diversity of the disease in different parts 
of the world and among different patients, few have been widely applicable. The Barcelona 
Clinic Liver Cancer (BCLC) staging system (143, 144) is the one now most widely adopted, 
and takes into consideration the tumour stage, liver function and performance status. It is 
recommended by both the European and American Associations for Study of Liver Diseases 
(EASL and AASLD), being a staging system that incorporates a management algorithm to 
guide treatment approaches (See Figure 1.8). This system aids planning of treatment 
approaches accordingly for earlier stages with better prognosis, or in a very late stage with a 
poor prognosis. In those with very advanced stages, supportive care is appropriate, as 
intervention can shorten rather than extend life (145). 
 
Figure 1.8: BCLC staging system with treatment modalities adapted from Tabrizian et al 
(145).CLT: Cadaveric liver transplantation. LDLT living donor transplantation; RF: 
radiofrequency; PEI: percutaneous ethanol injection; TACE: Trans arterial chemoembolization; 
PST: performance status test.    
23 
 
 Treatment and prevention of HCC 
HCC is one of the diseases with the poorest prognosis and despite the improvements in 
treatment modalities the mortality rate is still high because of the late diagnosis and rapid 
progression of the disease, with low sensitivity to chemotherapy and radiotherapy (145, 146). 
Surgical intervention (excision and transplantation) appears to be the only curative treatment in 
early stages of the disease that succeeded in achieving a high 5 year survival rate ranging from 
50 to 75%, but unfortunately it applies for a small percentage of cases and the recurrence rate 
is still very high – being about 70% after 5 years post tumour excision (145, 147-149). 
Resection and transplantation are only applicable in early stages. Orthotopic liver 
transplantation (OLT) removes the diseased organ predisposing to HCC, while disease 
recurrence or de novo HCC are relatively common following resection. OLT, however, is a 
limited resource, determined by donor availability (150, 151). 
Ablation (mostly thermal, which has replaced chemical ablation) is another technique used in 
the treatment of HCC, but is usually preferred for solitary, small lesions <2 cm and in those 
who are not candidates for surgery.  It involves using high radiofrequency ablation (and 
nowadays high frequency microwaves) to induce tumour damage by heating and denaturing it. 
Other modalities like cryo and laser ablations are being tested (152, 153). 
Transarterial chemoembolization (TACE) is used in patients with BCLC stage B HCC by 
injecting chemotherapeutic agent (doxorubicin) into the tumour via the hepatic artery, followed 
by an embolizing agent to keep the doxorubicin localised in order to increase the damage 
inflicted to the tumour. For carefully selected patients treated with TACE, there is a significant 
improvement in the 2 year survival (154-156). Drug eluting beads-TACE (DEB-TACE) and 
Transarterial radioembolization (TARE) with ytterium-90 microspheres are alternative 
locoregional treatment approaches (157, 158). Other options emerging include hepatic artery 
delivered Selective Internal Radiotherapy Treatment (SIRT), as well as Stereotactic Body 
Radiation Therapy (SBRT) (145, 159). 
Systemic cytotoxic chemotherapies have traditionally been of limited use in patients with HCC, 
in part because of the effects on the associated diseased liver, but also because of inherent 
resistance to chemotherapies.  Mechanisms of resistance include elevation of ABC transporters, 
such as p-glycoprotein, which export drugs from cancer cells, as well as cytochromes which 
metabolise drugs and decrease their effectiveness.  Other resistance mechanisms include 
resistance to DNA induced damage, as well as accelerated DNA damage repair. The SHARP 
24 
 
trial (151), published in 2008, followed by the Asia-Pacific trial in 2009 (160), were considered 
a landmark in HCC patient care, as for the first time a systemic therapy was shown to have a 
significant survival benefit. The systemic therapy was Sorafenib, a multi-targeted tyrosine 
kinase inhibitor, with an inhibitory effect on the proliferative and angiogenic capability of the 
tumour. It remains the only first line systemic treatment approved for use in patients with HCC 
(156). Unfortunately, its survival benefit is modest, with a median increase in overall survival 
of only 10-12 weeks (151).  In 2017 FDA (Food and Drug administration agency in USA) 
approved the use of Regorafenib as a second line treatment for patient with HCC progressing 
on or after sorafenib (161). Numerous first and second line trials are exploring the roles of other 
targeted therapies, but it is likely that – owing to tumour heterogeneity – these will be useful 
for subgroups of patients only, possibly in combination with other novel agents or traditional 
therapies.  
Given the difficulties of treating HCC combined with CLD, prevention would be ideal. This 
has been achieved partially, by controlling HCV and HBV infection in parts of the world where 
those two risk factors are endemic. NAFLD treatment and prevention of its progression into 
HCC is the major goal of many researchers nowadays (145). 
 Pre-clinical models of NAFLD 
In an attempt to understand the histopathology of NAFLD and its progression to NASH and 
HCC, several animal models were developed taking in consideration factors behind NAFLD 
pathogenesis. Each animal model succeeded in replicating certain aspects, some of which 
replicated the physiological while others succeeded in replicating the histopathological aspects. 
To achieve this different mice strains and rats and different diet types were used (162).  
As the hallmark of NAFLD is steatosis related to obesity and IR. One group of animal models 
of NAFLD focused on feeding the animals (C57BL/6) a high fat diet (HFD) with a fat content 
ranging between 45-71% (163, 164). They succeeded in inducing obesity and IR and steatosis 
in animal livers in addition to other features of NAFLD like ballooning and MDBs (164). Others 
used mice models with mutations targeting leptin. Leptin regulate satiety, and so defective 
leptin reponbse will lead to hyperphagia, obesity, IR and diabetes. This was achieved by using 
db/db and ob/ob mice strains (165, 166). db/db had homozygous mutation in leptin receptors, 
while ob/ob mice had mutated non-functional leptin. Those two strains mimicked NAFLD but 
fell short of developing NASH (165, 166).  
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Other groups focused on mimicking NASH through induction of NASH by feeding the animals 
a diet deficient in choline and methionine (MCD diet). Choline deficiency (which is stored and 
metabolised in the liver) results in steatosis, increased oxidative stress, changes in cytokines 
and decrease in adipokines (60). Choline deficiency causes slight inflammation and fibrosis 
(60). Choline plus methionine deficiency lead to more extensive inflammation and fibrosis. 
Therefore MCD diet considered a good model for NASH compared to HFD, but it does not 
mimic the metabolic syndrome and obesity induced NAFLD as the mice fed the MCD diet do 
not show IR and show weight loss, with low glucose levels and leptin and triglyceride levels 
(167, 168).To overcome this other groups tried feeding the db/db or ob/ob mice the MCD diet 
(162).   
Some researchers investigated the effect of fructose as a player in NAFLD progression to 
NASH and in fibrosis. They fed the mice high fat high fructose (HFHF) diet. HFHF diet caused 
more fibrosis, more inflammatory cell infiltration, more oxidative stress and more collagen 
compared to HFD model (169).  
 Most of the above mouse models failed to properly recapitulate what happens in human 
NAFLD progression to NASH, fibrosis and HCC development. In addition to the limitations of 
the C57BL/6 HFD fed animal model (failure to show NASH pathology) and MCD diet fed 
models (no obesity and metabolic syndrome), the number of developed tumours was very low, 
2.5% in HFD and 25% in CD-HFD models (162). C3H/He mice are known to develop obesity 
and impaired glucose tolerance test (IGTT) and tendency for development of spontaneous HCC 
by one year of age (170). Selecting this strain to be fed the American life style diet (ALIOS) 
rich in fat and fructose was based on combining the effect of HFD and HF on exacerbation of 
the C3H/He phenotype. This was in a way to resemble human in the development of obesity 
and IGTT with age and exacerbate their tendency to develop HCC with diet. By doing this we 
were aiming at creating an animal model that mimics human progression from NAFLD to 
NASH and HCC.  
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1.4 P53 pathway 
  Structure and function 
P53 is an important cellular protein that was first discovered in 1979. It is encoded by a gene 
called TP53, which is located on the short arm of chromosome 17 and was initially cloned in 
1983 (171). It has several important functions including the transcription of genes involved in 
regulation of cell cycle and programmed cell death, metabolic regulation, DNA repair 
mechanisms, senescence and in the angiogenesis process (172). 
The p53 protein is 53kDa in size and comprises 4 main domains, the N-terminal transcriptional 
transactivation domain, a central sequence specific DNA binding domain and carboxy terminal 
oligomerization (TET) and regulatory (REG) domains (Figure 1.9). 
 
Figure 1.9: p53 structure showing functional domains. The N terminal region includes 
TAD1 and TAD2 transcriptional transactivation domains, there is a central DNA binding 
domain and a C-terminal regulatory region. The conserved regions include boxes I-V. TET is 
the tetramerization domain. NES is a nuclear export sequence and NLS is a nuclear localization 
sequence. (figure adapted from Meek, 2015) (173). 
 
The p53 protein is stabilised and its transcriptional function activated by post-translational 
modifications in response to a range of cellular stresses, but particularly DNA damage. Once it 
is activated it forms tetramers that assemble on consensus-specific DNA binding sites in the 
DNA promotor regions of its target genes to induce their transcription. It either induces cell 
cycle arrest giving the cell enough time to repair the DNA damage or activates programmed 
cell death (apoptosis) to prevent the genetically damaged cell from dividing and propagating 
the genetic defect. This has led to it being referred to as the “guardian of the genome”. 
As a transcription factor it controls the transcription of a number of key genes, one of which is 
the murine double minute 2 (MDM2) gene, that was originally discovered as an amplified 
oncogene in a spontaneously transformed murine 3T3 fibroblast cell line. The MDM2 protein 
has an inhibitory effect on the function of p53 that is exerted through a) binding to the p53 
transactivation domain and preventing it from binding to and transcribing its downstream 
targets (174, 175) and b) acting as an E3 ubiquitin ligase to target p53 for proteasomal 
degradation. MDM2 thus forms a negative feedback autoregulatory loop to restore p53 protein 
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and activity to basal turnover levels if and when the cause of the cellular stress is resolved. This 
feedback is vital in the regulation of p53 function and under normal conditions keeps p53 at 
low level (176, 177). This was demonstrated by the embryonically lethal effect of the absence 
of the MDM2 gene in mice, which can be rescued by TP53 gene deletion (178, 179). In fact 
MDM2 collaborates with another closely related protein called MDM4 or MDMX, which can 
also bind and inhibit p53, but lacks the E3 ligase activity of MDM2. MDMX forms a 
heterodimer with MDM2 and has been reported to enhance  the ubiquitination and degradation 
of p53 (180) (Figure 1.10). 
 
Figure 1.10: Regulation of P53 functions by MDM2 and MDMX. Adapted from Zhao et 
al 2015 (181).The transcriptional activity of p53 is regulated by its downstream transcriptional 
target (MDM2) and by MDMX. They form a complex and bind to p53. The binding by MDM2 
prevents p53 from binding to DNA, as well as acting as an E3 ligase to ubiquitinate p53 and 
cause its proteasomal degradation, MDM2 is also reported to facilitate transport of p53 into the 
cytoplasm. 
 
The activation of p53 is through several mechanisms, which includes activation by ataxia 
telangiectasia mutated (ATM) protein kinase that senses double stranded DNA damage to then 
phosphorylate and activate p53. In addition, ATM phosphorylates the CHEK2 cell cycle 
regulatory protein which also in turn phosphorylates and activates p53. The activation of p53 
can also be mediated by other kinases such as ataxia telangiectasia and RAD3 related (ATR) 
and casein kinase II, or through abnormal growth signals like RAS activation, which requires a 
protein called p14ARF (CDKN2A). The p53 phosphorylation leads to prevention of binding to 
MDM2 and its consequent stabilization and accumulation in the cell as a result of the decrease 
in its degradation. Additional changes in the tertiary structure of p53, through additional post-
translational modifications (phosphorylation, methylation, acetylation, sumoylation, or 
ribosylation) contribute to the regulation of p53 function. The three dimensional structure of 
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the inactivated p53 does not allow the DNA binding domain to bind to the DNA strands, but 
posttranslational modification allows the unfolding and exposure of this domain and hence 
allows it to carry out its transcriptional function (182). 
Both cell cycle arrest and apoptosis by p53 are regulated through well-established mechanisms 
involving the transcriptional control of its target genes. The target genes involved in apoptosis 
include BBC3 (PUMA), NOXA, BAX, tumour protein p53 inducible protein 3 (PIG3), FAS cell 
surface death receptor and others. The p53 protein is also believed to regulate apoptosis through 
non-transcriptional mechanisms (183). Under injurious conditions p53 translocates to the 
mitochondria and induces mitochondrial outer membrane permeabilization (MOMP) which 
leads to the release of proapoptotic factors. This is achieved by direct effect of p53 on the 
antiapoptotic and proapoptotic proteins, as it can bind to and inactivate antiapoptotic Bcl-2 and 
can bind to and activates proapoptotic proteins BAX and BAK, leading to apoptosis (184). 
The regulation of cell cycle arrest in response to stress is another mechanism controlled by p53 
through the transactivation of multiple genes. The CDKN1A gene, encoding the p21WAF1 cyclin-
dependent kinase inhibitor, is one of the main targets of p53 involved in growth arrest at the G1 
and G2 phase cell cycle checkpoints, while growth arrest and DNA damage inducible 45 
(GADD45) is another target gene involved in G2 arrest. The p21WAF1 protein is involved in 
other p53 tumour suppression processes that include senescence, autophagy, regulation of 
cellular metabolism, antioxidant defence and microRNAs (miRNAs) (183, 185). 
Other ways in which p53 functions as a tumour suppressor gene are through regulation of 
metabolic processes in the cell, including carbohydrate, amino acid and lipid metabolism (186, 
187). It is well known that cancer cells use glucose and glycolysis for the generation of energy, 
and also their consumption of glutamine is increased to cover the need for nucleotide synthesis. 
There is also an increase in fat demand for organelle synthesis and energy production, so cancer 
cells synthesize fatty acids and increase their uptake. Several p53 target genes encode proteins 
that are key regulators of these metabolic processes. Depriving the tumours from these 
metabolic demands is an additional mechanism by which p53 can exert an antitumor effect. 
Examples of such targets that p53 regulates are: glucose 6 phosphate dehydrogenase (G6PD), 
TP53-induced glycolysis and apoptosis regulator (TIGAR) and glucose transporter 1, Acyl-CoA 
dehydrogenase family member 11 (Acad11) and Lipin 1, SREBP-1 (187) (Figure 1.11). 
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Figure 1.11: Showing different stimuli that induce p53 function and the end result, 
adapted from  Loughery and Meek (180). 
 
A large number of studies have shown that the TP53 gene is mutated or absent in nearly 50% 
of human cancers, and this mutation leads to loss of the tumour suppressor function of p53. In 
the remaining 50% of cancers, TP53 is intact but there may be inhibition of its function through 
other mechanisms including amplification and/or overexpression of its negative regulator 
MDM2 (172, 188). 
Interestingly, it has been noted that when p53 is mutated, not only it loses the tumour suppressor 
activity, but also it acquires tumour promoting functions what is called gain of function (GOF) 
(189). One mechanism is through mutant p53 dominant-negative regulation of the remaining 
wild type p53 allele (189, 190). The mutant p53 often has a missense mutation that prevents 
p53 from binding to the DNA. This mutant p53 can bind to wild type p53 and forms a non-
functional tetramer that prevents the remaining wild type p53 from performing its 
transcriptional function (189, 190). 
Several mutant p53 GOF examples were illustrated in the lab and in animal models including 
promoting cell survival, proliferation, invasion and migration of malignant tumour cells (189). 
In addition to enhancing cancer metabolism through enhancing lipid metabolism and the 
Warburg effect. These GOF effects can be nuclear or cytoplasmic effects and can be achieved 
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through several mechanisms (189). Examples of nuclear effect is the regulation of 
transcriptional factors and cofactors leading to inhibition of tumour suppressor activities or 
promotion of tumour progression, like binding of mutant p53 to and inhibition of Tap63 and 
Tap73 (p53 family members with tumour suppressive activity) (191). Another mechanism of 
GOF is by regulation of expression of specific genes through regulation of chromatin structure 
leading to increased transcription of targeted genes associated with tumorigenesis and 
progression (189, 192). This was demonstrated through interaction and cooperation of mutant 
p53 and the chromatin remodelling complex (SWI/SNF) and through binding to Pontin (a 
potent helicase and AAA+ ATPase) (192, 193). Cytoplasmic GOF example is through Warburg 
effect stimulation (characteristic of tumour metabolism) through promoting of glucose 
transporter 1 translocation to plasma membrane by the mutant p53(194). 
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 Role of P53 in chronic liver disease 
Several factors play a role in the pathogenesis of chronic liver disease and p53 appears to be 
one of the important ones, in both ALD and NAFLD Multiple studies on rodent models have 
shown that there is upregulation of p53 and induction of apoptosis in NAFLD/NASH, and this 
was clearly evident at the protein level by immunohistochemical staining and western blotting 
showing increased levels of p53, p21 and caspase 3 (45, 195). These studies showed that p53-
deficient mice had lower levels of steatosis, inflammation and fibrosis compared to wild type 
animals in the NAFLD animal model (45, 195). Similar results were reported for the analysis 
of liver samples from NAFLD patients, where p53 was shown to be upregulated 
immunohistochemically. The levels of p53 were higher in NASH patients than those with 
NAFLD, and both were higher than   “normal liver” samples, although the latter were obtained 
from non-tumour areas of patients with colorectal metastasis to the liver (195). This was further 
supported by a study done by Derdak et al which showed that inhibition of p53 by pifithrin -
α p-nitro (PFT) (which is a chemical compound that inhibits p53 binding to DNA) led to 
attenuation of steatosis in murine liver of high fat diet fed animals (196). Another suggested 
p53 regulated mechanism in NAFLD pathogenesis is through regulation of SIRT1 as explained 
before in (1.2.3.1) (40, 41, 44, 197).  
 p53 in HCC 
TP53 is the commonest tumour suppressor gene that is mutated in human cancers, with the vast 
majority of mutations occurring in the DNA binding domain, and about 28% occurring in six 
so called “hot spot” residues in this domain (R175, G245, R248, R249, R273 and R282), five 
of which involve positively charged arginine residues  (183, 198). While the Catalogue of 
Somatic Mutations in Cancer (COSMIC) states that 27% of HCC have a TP53 mutation (199), 
other studies have reported varied percentages of TP53 mutations ranging from 0% to 67%, 
depending on the geographical distribution of cases, being low in western countries and highest 
in sub-Saharan Africa and Southeast Asia (96). 
The reason for higher incidence of TP53 mutations in sub-Saharan Africa and Southeast Asia 
is the exposure to aflatoxin B1 (which causes a point mutation in codon 249Ser resulting in a 
G:C to T:A transversion) and HBV infection. HBx protein binds to p53 and inhibits its 
transcriptional function and might block p53-mediated apoptosis, leading to 
hepatocarcinogenesis (96, 200). Oxidative stress induced by iron and cupper deposition in the 
liver also causes TP53 mutation at codon 249 and 250 (hot spot)in hemochromatosis and Wilson 
disease respectively (200). TP53 mutation is usually associated with poor prognosis (96). 
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 Cell cycle and p53 
Eukaryotic cell division is characterised by replication of the DNA and then dividing into two 
new cells in a cyclical process. The cell cycle is divided into phases that include a gap phase 
(G1), followed by a DNA synthesis (S) phase in which the replication of DNA takes place, and 
then another gap (G2) phase prior to the mitosis (M) phase during which the condensed 
chromosomes separate and cells divide into two daughter cells.  In addition there is a (G0) 
resting phase in which the cells have exited the cell division cycle and are non-proliferating and 
not-growing (201) (see Figure 1.12). 
These phases are regulated by cellular proteins, the key regulators of the cell cycle are cyclin 
dependent kinases (CDK) and cyclins which form a complex together and exert their action 
through phosphorylation of target proteins such as retinoblastoma (RB). CDKs are a family of 
nine serine/ threonine protein kinases. The level of CDKs remain stable during the cell cycle 
but the levels of their activators, the cyclins, change. Cyclin D which has three forms (D1, D2 
and D3) binds to CDK4 and CDK6 to enter into G1 phase, while cyclin E binds to CDK2 to 
progress from G1 to S phase. In S phase cyclin A and CDK2 are required, while cyclin A 
binding to CDK1 is necessary to progress from G2 into M phase which is regulated by cyclin 
B-CDK1 complex (201) (Figure 1.12).  
The activity of CDKs is regulated by inhibitory proteins that inhibit the cell cycle progression, 
and these inhibitory proteins bind to the CDKs or to the CDK-cyclin complex and inhibit its 
action. These CDK inhibitory proteins (CKI) fall into two families, INK4 family which includes 
p15 (CDKN2A/INK4b), p16 (CDKN2A/INK4a), p18 (CDKN2A/INK4c), and p19 
(CDKN2A/INK4d), and the CIP/KIP family which includes p21 (CDKN1A/WAF1/CIP1), p27 
(CDKN3/CIP2) and p57 (CDKN1C/KIP2) (202). The INK4 family inhibits cyclin D interaction 
with CDK4/6 and cause G1 arrest, while CIP/KIP family causes G1 arrest through inhibition 
of cyclin-CDKs complexes and to a lesser extent inhibition of cyclin B-CDK1 complex to cause 
G2 arrest. In addition to that p21 inhibits DNA synthesis through the inhibition of proliferating 
nuclear cell antigen (PCNA) (201) (Figure 1.12). 
As a guardian of the genome, and in response to cellular stress such as DNA damage, p53 can 
induce cell cycle arrest at the G1 or G2 phases through transactivation of downstream targets, 
to allow the cell to survive the stress and repair the damage and prevent its propagation during 
cell division. One of the downstream targets is p21 (CDKN1A/WAF1/CIP1) which is involved 
in growth arrest at the G1 and G2 phase cell cycle checkpoints (185), while GADD45 (another 
downstream target of p53) inhibits cyclinB-CDK1 complex and prevents the G2/M progression 
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leading to G2 arrest. Another way p53 causes arrest at G2 is through an additional downstream 
transcriptional target protein product, 14-3-3-σ (14-3-3σ/YWHAS), which acts by removing 
cyclin B-CDK1 complex from the nucleus (183, 203) (Figure 1.12). 
Ki67 is a nuclear protein found to be expressed in proliferating cells. Its level increases in all 
phases of the cell cycle in proliferating cells (G1, S, G2, and M) and is absent in G0 phase 
although it is not necessary for cell proliferation (204). The exact function of Ki67 is unknown 
but being expressed in only proliferating cells and the high levels of expression in cancer cells 
has led to its use as a proliferation marker and makes it a good diagnostic and prognostic 
biomarker in tumours (205).   
 
Figure 1.12: Phases of the cell cycle showing the sites of cyclin and cyclin dependant 
kinases regulation and their inhibitory CKI adapted from Esfandiari 2015 (201, 206).  
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 P53 and Senescence 
Senescence is a permanent state of growth arrest characterised by loss of proliferation ability 
of the cells in response to growth signals or mitogens. Additionally, senescent cell morphology 
changes and they become larger and flattened and express markers of senescence (p53, p21, 
p16, and senescence associated β-galactosidase (SA-β-Gal)), and senescence associated 
heterochromatic foci (207, 208).  
Senescence can be triggered by several mechanisms. Replicative senescence occurs when there 
is shortening of the telomeres through repeated replication cycles. Oncogene induced 
senescence occurs as a result of persistent growth signals. Reactive oxygen species induced 
senescence occurs as a consequence of accumulation of oxidative DNA damage and involves 
p53. When DNA damage occurs, a DNA damage response (DDR) is initiated which stimulates 
Ataxia Telangiectasia-Mutated (ATM) phosphorylation of p53. Stabilised phosphorylated p53 
leads to increased transcription of its downstream target p21, which suppresses cell growth but 
can also induce cell cycle arrest and senescence. Telomere shortening, if detected as a double 
strand break, can also activate a DDR leading to senescence.  Similarly, increased DNA 
replication stress induced by oncogenic signalling can be associated with DNA damage 
generating a DDR. So, in other words, all three examples of senescence involve triggering of 
DNA damage repair mechanisms lead to activation of a senescence pathway.  Senescence is 
considered as a potent tumour suppressing mechanism. Several studies have shown tumour 
regression after induction of senescence through activation of p53 (209, 210). 
 P53 and apoptosis 
Apoptosis is a programmed cell death mechanism that occurs in normal physiological 
conditions (death of old cells and replacement by new cells) and in pathological conditions. It 
involves a series of active steps that includes condensation of chromatin and the formation of 
apoptotic bodies (budding of plasma membrane) that are engulfed by phagocytes. These events 
happen in response to intrinsic and extrinsic signals, hence the terms intrinsic and extrinsic 
apoptosis.  
In extrinsic apoptosis the stimulation of a family of cell surface death receptors recruit adaptor 
molecules, which in turn activate one of the family of cysteine proteases that target aspartate 
residues (caspases) called the initiators. The initiators in turn activate caspases 3, 6 and 7, 
termed the executioners, which cause lysis of the cellular organelles through proteolytic activity 
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and cellular death. In Intrinsic apoptosis, the whole process is initiated by cellular signals and 
includes the release of mitochondrial apoptotic molecules like cytochrome c (211). 
P53 activation can induce apoptosis through intrinsic and extrinsic pathways and it is known to 
regulate the transcription of more than 100 pro-apoptotic genes (211, 212). Of these genes that 
regulate the extrinsic pathway are tumour necrosis factor receptor superfamily 10A 
(TNFRSF10A/DR4), and 10B (TNFRSF10B/DR5), and (TNFRSF6/FAS). Activation of these 
genes leads to a sequence of events culminating in caspase activation and apoptosis. 
P53 downstream transcriptional target gene products that induce intrinsic apoptosis include 
p53-upregulated mediator of apoptosis (PUMA), BCL-2 associated X protein (BAX) and BCL-
2 antagonist killer 1 (BAK1). The transcribed proteins of these genes bind to and inhibit the 
anti-apoptotic function of BCL-2 family members (like BCL-2, BCL-XL). BAX and BAK form 
pores in the mitochondrial membrane that allow cytochrome c and other molecules to escape to 
the cytoplasm and activate caspases and apoptosis (213). P53 also has a direct effect on this 
pathway, binding to and inhibiting the function of BCL-2 family members (213).  
 
 Targeting MDM2-p53 in cancer 
Although p53 is mutated in nearly 50% of tumours, this percentage varies from very low levels 
of <10% in thyroid cancer and paediatric malignancies to as high as nearly 96% in high grade 
serous ovarian cancers. It is clearly an important tumour suppressor and in some tumours its 
protein expression or function is reduced or suppressed, rather than mutated. Exploiting the p53 
pathway in those wild type cases is an attractive therapeutic target (214). The negative 
regulators of p53 (MDM2 and MDMX) are overexpressed in tumours, ~20% of sarcoma and 
~15% of breast cancer, and this means they inhibit p53 activity and behave as oncogenes. So 
targeting them to release p53 from their inhibitory action has been explored for cancer treatment 
(214). 
One of the earliest attempts to exploit this pathway was in the nineties, when a small synthetic 
peptide homologue of p53 (IP3) was tested in cells that overexpressed MDM2. This peptide 
was an amino-acid substituted version of the N-terminal sequence of p53 which binds to MDM2 
and shown to have a greater affinity to bind to MDM2 than the unsubstituted p53 peptide on 
which it was based. It was used to block MDM2-P53 interaction and stabilise p53. Introduction 
of this peptide into cells led to a reduction in colony formation, and cell cycle arrest and cell 
death in tested cell lines, through increased transcriptional activity of p53 and increased 
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expression of p53 downstream transcriptional targets (215). This proof of concept together with 
the solving of the X-ray crystal structure of a p53 peptide bound to MDM2 stimulated the search 
for small molecule inhibitors of the MDM2-p53 binding interaction, leading to the discovery 
of the Nutlin series of cis-imidazoline compounds, which bound to and blocked the small N-
terminal hydrophobic pocket on MDM2 to which p53 normally binds. The consequent release 
of p53 from MDM2 inhibition stabilised p53 and resulted in activation of its growth inhibitory 
and pro-apoptotic functions (216, 217) (Figure 1.13). One of these compounds was Nutlin-3,  
a racemic mixture of two enantiomers (nutlin-3a and nutlin-3b). Nutlin-3a was found to be 150 
times more potent than nutlin-3b (216). Nutlin treatment showed a dose dependent increase in 
p53 stabilisation and in the expression of p53 downstream targets (p21 and MDM2) selectively 
in p53 wild type cell lines, with cell cycle arrest, growth inhibition and apoptosis, and this was 
achieved both in vitro and in vivo (216). These studies supported the concept of non-genotoxic 
activation of p53 through small molecule inhibitors of the MDM2-p53 interaction.  
 
Figure 1.13: Three-dimensional modelling of Nutlin-3a binding to the p53-binding pocket 
of MDM2. A) MDM2 three-dimensional structure with nutlin-3a bound to it at the p53 binding 
pocket.  B) Nutlin-3a (chemical structure) occupying the p53-binding pocket on MDM2. 
Adapted from Laurie et al 2006 (218). 
 
Although Nutlin-3 was and is a useful tool compound, it does not have pharmacological 
properties suitable for clinical use. RG7112, which is a more potent and orally bioavailable 
Nutlin-based compound developed by Roche, was the first MDM2 inhibitor to be evaluated in 
early phase trials for solid tumours and haematological malignancies. It caused stabilisation of 
p53 and increased levels of p53 downstream targets (CDKN1A, MDM2, BAX, PUMA, FAS, 
TNRSF10B, TP53INP1, ZMAT3 and FDXR). Some patients with haematological malignancies 
achieved complete remission after treatment with this compound (217). It was relatively well 
tolerated, but gastrointestinal symptoms and haematological side effects (neutropenia and 
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thrombocytopenia) were observed, attributed possibly to the role of MDM2 in the survival of 
hematopoietic stem cells (219) and inhibition of megakaryocyte and hematopoietic cells 
through activation of p53 (220). In an attempt to reduce the side effects associated with the use 
of high doses, further development of the small molecule inhibitors led to the emergence of 
more potent compounds with better pharmacological properties, one of which is the Roche 
second generation MDM2 inhibitor RG7388 (Idasanutlin). HDM201, an imidazopyrrolidinone 
developed by Novartis, is one of the most recent and potent MDM2 inhibitors, with high 
selectivity for wild-type p53 cells (221). Encouraging results have been reported in xenograft 
tumour models, and it is already being tested in several ongoing clinical trials (222). Again side 
effects have been reported, with grade 3/4 haematological side effects (anaemia, neutropenia 
and thrombocytopenia that were regimen dependent and of late onset), although gastrointestinal 
side effects may be less severe (217, 221). Several small molecule inhibitors of MDM2 have 
been and are currently undergoing clinical trials - including RG7388, SAR405838, MK-8242, 
AMG232, DS-3032b, HDM201 and CGM097 (217, 221). 
Another modality in exploiting p53 is through gene therapy by transducing cancer cells with 
wild type p53 (223). This can be achieved by replacing the E1 region (of a recombinant human 
serotype 5 adenovirus) by a wild type p53 expression cassette (rAd-p53) and used as a drug 
called Gendicine (223). Gendicine has been authorised as the first licenced gene therapy by the 
China Food and Drug Administration (CFDA) in 2003 (224). Introducing exogenous p53 
expression in tumour cells induces cell death through apoptosis. This was shown in a phase I 
clinical trial involving arterial administration of Gendicine to metastatic colorectal carcinoma 
(225). In HCC this modality has also been tested in a pilot phase II clinical trial in unresectable 
HCC through multiple arterial injections of Gendicine (226), or through transcatheter bronchial 
arterial infusion of gendicine into pulmonary metastatic HCC (227).Recently it has been tested 
in BCLC stage B HCC patient through transarterial chemoembolization combined with 
gendicine gene therapy (TAGE) (223). This gene therapy with wild type p53 is promising and 
the side effects developed with TAGE were of low grade and no special intervention was 
required to treat them (223).  
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 PPM1D /WIP1 
Wild type-p53 induced phosphatase 1 (WIP1) is the protein encoded by the PPM1D gene. It is 
a member of the serine/threonine protein phosphatase 2C (PP2C) family. It is one of the 
downstream targets of p53 and forms an additional negative auto regulatory loop by 
dephosphorylating p53 at serine 15 site and inhibiting its function. The gene is amplified and 
activated by mutation in some cancers and it has oncogenic properties (228, 229). Additionally, 
WIP1 dephosphorylates other upstream p53 pathway proteins - including ATM, p38 MAPK 
and γ-H2AX - abolishing cell cycle checkpoints, inhibiting DNA repair and inhibiting apoptosis 
and senescence (230). WIP1 was also reported to dephosphorylate the negative regulators of 
p53 (MDM2 and MDMX), stabilising them and hence leading to downregulation of p53 see 
(Figure 1.14) (206, 231). 
 
Figure 1.14: Direct and indirect effect of WIP1 on regulation of p53 and DNA repair 
adapted from Esfandiari 2015 (206). 
Several studies have shown that PPM1D/WIP1 is amplified and overexpressed in several solid 
tumours like breast, ovarian, neuroblastoma, medulloblastoma, gastric and pancreatic 
adenocarcinoma. Overexpression of WIP1 at both the mRNA and protein level was found to be 
associated with poor prognosis and shorter patient survival for these tumours (229). In HCC, 
several studies reported that WIP1 was overexpressed in 59% of cases at the protein level and 
65% of cases at the mRNA level; and was found to be associated with larger tumour size, 
advanced stage, recurrence of tumour and shorter survival (228, 229, 232). Si-RNA knockdown 
of WIP1 in HCC cell lines showed inhibition of growth, invasion and migration of HCC cell 
lines.  WIP1 has been proposed as a potential target for the treatment of liver cancer, as well as 
a prognostic marker (229).    
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1.5 Aims of the study: 
1. Explore the effect of diet on the development of HCC in a relevant murine model. 
2. Explore NAFLD progression and HCC grade in association with DNA damage and p53 
expression. 
3. Explore TP53 status in HCC in the dietary murine model. 
4. Explore the impact of dietary interventions on NAFLD, NAFLD stage and HCC 
development in the dietary animal model. 
5. Explore the effect of non-genotoxic activation of p53 through MDM2 inhibition by 
small molecule inhibitors in liver cancer cell lines and a xenograft model. 
6. Explore the effect of chemical inhibition of WIP1 on liver cancer cell lines.  
7. Explore the effect of chemical inhibition of WIP1 on the sensitivity of liver cancer cell 
lines to MDM2 inhibition. 
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 Materials and Methods 
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2.1 General Laboratory Practice  
Every experiment and procedure undertaken in the NICR or in the Medical School laboratories 
were performed following the standards set by Newcastle University to ensure safe working 
with biological and chemical substances in laboratories, which comply with the Control of 
Substances hazardous to Health Regulations 2002 (COSHH) and Biological COSHH 
(BioCOSHH). 
2.2 Animal model design 
An animal model was designed to study fatty liver disease and the risk of HCC development. 
C3H/He male mice were purchased from (Harlan, USA) and 4 mice were allocated in each 
cage. They were divided into two groups, the control (C) and the American Life Style group 
(ALIOS). 
 The control group (n=47) were fed a control diet (TD.110196, Harlan Laboratories, Wisconsin, 
USA) a normal fat diet (6% Soybean oil) with no trans-fat), while the ALIOS group (n=48) was 
fed (TD.110201, Harlan Laboratories, Wisconsin, USA), a high trans-fat diet with a high 
fructose corn syrup equivalent water (42g/L; 45% glucose, 55% fructose) to mimic what is 
served in fast food restaurant chains. Both groups were followed till they were 48-week-old and 
they were culled at 4 time-points (12, 24, 36 and 48 weeks). 
In parallel to the above study we had an intervention study aimed at exploring the impact of 
two different interventions on NAFLD progression into NASH and/or HCC development. Each 
intervention consisted of two groups (C) and (ALIOS) and both received the intervention under 
study. The first intervention was the antioxidant (Bucillamine) (Santen Pharmaceutical, UK) at 
a dose of 10 mg/kg/day (n=22). The second intervention was Farsenoid X-Receptor (FXR) 
agonist (PX20606) (Phenex pharmaceutical, Heidelberg, Germany), for which two doses were 
used: 1 mg/k/day (n=24) and 5 mg/kg/day (n=16).  The study design is shown in Figure 2.1. 
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Figure 2.1: Dietary animal model design. C refers to control and HF refers to High Fat High 
Fructose diet (the ALIOS diet), n=number of mice, FFPE=Formalin Fixed Paraffin Embedded. 
 Animal culling and tissue sampling 
Mice were culled at four specified time points, namely 12, 24, 36 and 48 weeks, where liver 
samples were taken. The samples were divided into three groups, including formalin fixed 
(samples put in tubes containing 10% formaldehyde to fix the tissue for paraffin embedded 
tissue blocks preparation), fresh frozen in liquid nitrogen and another set of samples was put in 
Eppendorf tubes containing RNA later solution to fix the tissue and preserve RNA from 
degradation. Then the formalin fixed and RNA later samples were placed in the refrigerator for 
24 hours to allow penetration of the samples, while the fresh frozen were stored at -80 °C. The 
RNA later preserved samples were subsequently transferred into the -80 °C freezers for long 
term storage, while the formalin fixed samples were processed into paraffin-embedded tissue 
blocks. 
Blood sample was collected from each animal through tail bleed before and after treatment. 
This was achieved through putting the animal in a hot chamber to induce peripheral 
vasodilatation and facilitate blood collection from the tail. This sample was sent to the 
chemistry lab to assess the liver function and lipid profile (MRC Harwell, Oxfordshire, UK). 
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 Tissue processing and section preparation for histopathology study 
After fixing, each sample was processed using the histology lab automatic tissue processor to 
ensure optimal dehydration and replacement of the water in the tissue with paraffin wax in 
paraffin block molds, in order to facilitate 3-5 microns microtome sectioning. This was 
achieved by passing them into jars containing ascending concentrations of ethanol (70, 95 and 
absolute) for 2 hours each; and then passing through xylene jars, with the final step being 
through melted liquid paraffin wax. Then the samples were embedded into paraffin blocks. 
Ten sections (5 µM) were prepared from each case, from which one was stained with 
Hematoxylin and eosin according to a standardized protocol, for histological examination and 
assessment and scoring of the liver disease by a specialist liver pathologist. Another section 
was stained with Sirius red, a special stain used to stain fibrous tissue and to enable the 
histopathologist to assess and score the fibrosis stage. Other slides were used for 
immunohistochemical staining.   
 Scoring of routinely stained liver tissue sections  
Each H&E and Sirius red stained slide was examined under the microscope and NAS and SAF 
scoring systems were used to score fatty liver disease and tumour grade (if present). The scoring 
was done by two independent people, a specialized liver pathologist Dr. Dina Tiniakos and Dr. 
Helen Reeves.  
After examining the liver tissue sections and diagnosing NAFLD/NASH based on the pattern 
of injury and histological features, the disease status was given a score according to the NAS 
and SAF scoring systems of NAFLD (see 1.2.4). The NAS scoring system includes several 
parameters which are scored separately and then a total score was calculated. Steatosis was 
given a score (0-3) according to the percentage of hepatocytes affected; with 0= <5%, 1= 5-
33%, 2= 34-66% and 3= >66%. Hepatocellular ballooning was scored (0-2) with no ballooning, 
mild or few cells with ballooning and moderate or marked ballooning respectively. Lobular 
inflammation is the third parameter and was scored (0-3) depending on inflammatory foci per 
high power field with 0=no foci, 1=<2 foci, 2=2-4 foci and 3= >4 foci. The total maximum 
score is 8. According to this system (0-2) score means there is no NASH, (3-4) indicates 
borderline NASH while ≥ 5 supports the presence of NASH (71). Due to this overlap, the use 
of the activity score (ballooning and lobular inflammation) in the SAF scoring system was more 
accurate in scoring NASH by using a cut off value of 2 for NASH (71).  
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2.3 Immunohistochemistry 
Immunohistochemical staining of the liver sections was done to detect several markers of 
interest in our dietary animal model liver tissue sections; these were: phosphorylated Gamma-
histone H2A variant H2AX (γ-H2AX), which is one of the sensitive early markers of DNA 
damage and repair (233); Ki67 as a marker of proliferation; the tumour suppressor p53, as well 
as the protein product of its downstream transcriptional target, Cdkn1a, referred to as p21.  
The antibodies used were against γ-H2AX at the Ser139 site at a concentration of 1:100 (9718S, 
Cell signalling), Ki67 at 1:1000 (ab16667 (SP6), abcam), p53 CM5P at 1:400 (Novocastra), 
and p21 at a concentration of 1:50 (ab7960, abcam). 
IHC staining was performed by either a manual protocol or with an automated Ventana 
processor (Roche).  
 γ-H2AX and Ki67 manual protocol 
A two-day manual protocol was used for γ-H2AX and Ki67.  Day one included dewaxing and 
rehydration of the tissue sections by passing through Xylene and descending concentrations of 
ethanol, eventually to water, followed by blocking of endogenous peroxidase using 3% H2O2 
in methanol for 15 minutes. Slides were then washed once in PBS for 5 minutes at room 
temperature.  
Antigen retrieval was also on day 1, in EDTA 1mM, microwaved for 15 minutes (power 80).  
Subsequently 300 ml of water was added, and the slides left to cool for 20 minutes at room 
temperature. Slides were then washed in PBS solution for 5 minutes at room temperature on a 
shaker. The tissue was encircled with a wax pen to promote coverage of tissues with the 
minimum of reagents. Avidin activity was blocked with 3 drops of a blocking solution per slide 
for 20 minutes at room temperature (Avidin/Biotin Blocking Kit, reference number SP-2001, 
Vector laboratories), followed by washing in PBS solution 3 times for 5 minutes at room 
temperature.  Biotin was similarly blocked with the same kit. Antigenic sites were then blocked 
with 20% swine serum (diluted in PBS) for 30 minutes at room temperature, prior to adding the 
primary antibody and incubating the slides overnight at 40C. 
On day two, slides were taken out of the refrigerator or the cold room and left to warm up and 
then washed in PBS 3 times for 5 minutes at room temperature. Swine anti rabbit biotinylated 
secondary antibodies were added (polyclonal swine anti-rabbit immunoglobulin, reference 
45 
 
number E0353 Dako), (1:200 dilution in PBS), and left for 60 minutes at room temperature, 
followed by wash in PBS 3 times for 5 minutes at room temperature. 
Three drops of vector Avidin Biotin Complex (ABC) reagent were added per slide (Vector ABC 
tertiary, reference number PK 7100 Vector labs), and left for 45 minutes at room temperature 
to intensify the signal. Slides were then washed 3 times in PBS solution for 5 minutes at room 
temperature. 
Then detection of the immunoreaction was done by adding 100 µl DAB mix (reference number 
SK 4100, Vector labs) which was prepared with 5 ml H2O, 2 drops buffer, 4 drops DAB, 2 
drops H2O2. The development reaction was monitored under the microscope until positive 
brown immunoperoxidase staining was seen. Then the reaction was stopped by adding PBS or 
washing in PBS. 
Then the slides were counter-stained with Haematoxylin for 20 second, followed by washing 
the slides with tap water for 1 minute and dehydration in ascending concentrations of Ethanol, 
in steps of 50%, 70%, 90%, absolute, for 4 minutes in each. This was followed by clearing in 
xylol, twice for 5minutes each time. Slides were mounted with DPX and left to dry. Different 
buffers (PBS, TBS 1X and TBS tween 1X) were tested for the wash and dilution of antibodies 
with no difference in the results, but using TBS-tween facilitated uniform spread of the reagents 
over the tissues. 
 Automated IHC protocols 
Automated IHC staining was performed using an automated system (Ventana machine, Roche) 
with different numbered Ventana protocols. For p53 IHC, protocol number 32 was used, which 
included a mild antigen retrieval. For p21 IHC, different protocols and four different antibodies 
from Abcam and Santa Cruz Biotechnologies companies were tested (ab7960, ab80633, sc-397, 
sc-756) using manual and automated staining techniques but they failed to produce convincing 
staining quality and after 3 months of optimization, anti-p21 antibody (ab7960, Abcam) (which 
gave the best results compared to the rest of the tested antibodies) was chosen and protocol 38 
was used, which included an extended antigen retrieval and a blocking step. Antigen retrieval 
was heat-based as the slides were placed on heat-plates in the Ventana. Further details about 
the reagents and protocols are not disclosed by the manufacturer. After IHC, the slides were 
similarly mounted and left to dry. 
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 Digital Imaging 
The immunostained slides were scanned using an Aperio Digital Imaging system (AperioCS2, 
Leica Biosystems); which is a slide scanning system to capture interactive digital images of the 
slides (20X and 40X magnifications) and store high quality images of the scanned slides onto 
a server that can be accessed and analysed through the internet. 
On the digital images, for each tissue section 30 selected areas were demarcated using Aperio 
Imagescope software.  These included 10 periportal (around the portal tracts), 10 centrilobular 
(around the central vein) and 10 intermediate areas (in between the two). The specified areas 
were analysed using a designed algorithm using Aperio software (Spectrum Version 11.1.0.751 
© Copyright 2006-2011 Aperio Technologies) to calculate the percentage of positively stained 
hepatocytes (Figure 2.2). Details of the algorithm are summarised in Table 2.1. There was a 
negative and positive control slide in each run. The negative control included processing the 
slides through all the immunohistochemical staining steps without adding the primary antibody 
to detect any non-specific binding of the secondary antibodies. The positive control slides were 
prepared from tissue micro array (TMA) of mouse tissue (liver, kidney and spleen) with parp+/+ 
and parp -/- status treated with doxorubicin. 
    
 
Figure 2.2: Aperio algorithm used for scoring immunohistochemical staining. (A) 
Demarcation of liver zones using Aperio tools. (B) Aperio algorithm applied for a γ-H2AX 
stained slide showing the detection of hepatocyte nuclei in the periportal area, with negatively 
stained nuclei bluish in colour and positively stained nuclei in brown (strong positive) and 
orange (moderately positive). 
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Table 2.1: Aperio algorithm details used for scoring IHC stained slides.  
 
  
Aperio algorith parameters Value
Version 9.1
View Width 1000
View Height 1000
Overlap Size 100
Pixel Size (um) 0.504
Averaging Radius (um) 1
Averaging Radius (Pixels) 2
Curvature Threshold 2.5
Segmentation Type 2
Threshold Type 1
Lower Intensity Threshold 0
Upper Intensity Threshold 200
Min Nuclear Size (um^2) 20
Min Nuclear Size (Pixels) 79
Max Nuclear Size (um^2) 1.00E+06
Max Nuclear Size (Pixels) 3.94E+06
Min Roundness 0.249
Min Compactness 0.25
Min Elongation 0.249
Remove Light Objects 0
Weak(1+) Threshold 210
Moderate(2+) Threshold 188
Strong(3+) Threshold 162
Black Threshold 0
Edge Trim Weighted
Markup Image Type Analysis
Nuclear Red OD 0.696858
Nuclear Green OD 0.643073
Nuclear Blue OD 0.317563
Positive Red OD 0.244583
Positive Green OD 0.509334
Positive Blue OD 0.825081
Clear Area Intensity 240
Use Mode Analysis/Tuning
Classifier Type IHC Nuclear
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2.4 Molecular biology methods 
 RNA extraction 
Ribonucleic acid (RNA) was extracted from murine tissue samples as well as from liver cancer 
cell lines. 
 
The RNA later stored murine liver samples were thawed on ice and RNA was extracted using 
an RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. A DNase treatment 
step was included during the extraction to ensure the removal of any DNA, using on-column 
digestion with a RNase-free DNase kit (Qiagen), also according to the manufacturer’s protocol. 
The RNA concentration was determined by measuring the optical density (O.D.) at 260 nm 
with a Nanodrop ND-1000 micro-spectrophotometer (labtech, International). The eluted RNA 
samples (30 µl) were stored at -80 0C. 
 
For cell line work, cells were seeded at a density of 2.5-3 x 105 cells/well in a 6 well plate for 
24 hours and then treated with the compound of interest for 6- and 24-hour time points. At time 
of harvest, the medium was removed and cells were washed with phosphate buffer saline (PBS) 
and cells were trypsinized and collected in Eppendorf tubes. Cell pellets were stored in -80°C 
freezers. RNA was extracted from the pellets using an RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s protocol. A DNAse treatment step with on-column digestion was carried 
out using the RNase-free DNase kit (Qiagen). The RNA concentration was determined by 
measuring the optical density (O.D.) at 260 nm by Nanodrop. 
 
  Reverse transcription 
Reverse transcription system (RT) (Cat. No. A3500, Promega) was used to reverse transcribe 
RNA to generate cDNA from the extracted RNA samples, according to the manufacturer’s 
protocol. 500 ng of RNA was added to a 10 µl reaction mixture, which consisted of 2 µl of 25 
mM MgCl2, 1 µl of RT 10X buffer, 1 µl of 10 mM dNTP mixture, 0.25 µl of Ribonuclease 
Inhibitor, 0.3 µl (15 units) of reverse transcriptase, 0.5 µl of oligo-dT 15 primer, made up to a 
final volume of 10 µl with nuclease-free water (Table 2.2). The samples were incubated at 42°C 
for 1 hour and at 95°C for 5 minutes and then kept at 4°C until storage at -20 oC.  
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Table 2.2: Reagents used for reverse transcription. 
 
 
 Quantitative Real time polymerase chain reaction (qRT-PCR) 
Specific primers sequences were designed or taken from the Harvard Medical School primer 
bank web site and purchased from Invitrogen (Invitrogen, ThermoFisher scientific). The 
purchased primers were diluted in a ratio of 1:10 from 100 µM stocks to a working 
concentration of 10 µM. The primer sets were validated using the absolute quantification 
method with an ABI 7900 sequence detection system and GAPDH was used as a housekeeping 
reference gene. The validated primers were used in a semi-quantitaive real time polymerase 
chain reaction (qRT-PCR) and fold changes relative to a reference sample was calculated using 
RQ manager software (Applied Biosystem, version 1.2, Foster city, USA) and the formula 2-
ΔΔCt, where Ct is the cycle number threshold to reach a given level of product detection. In this 
method a calibrator and a normalizer are used. The calibrator is the control or untreated sample 
while the normalizer is the housekeeping gene. To calculate the fold difference in expression 
of the gene of interest (GOI), the cycle threshold of that GOI is adjusted to the housekeeping 
gene in each of the samples and the calibrator as shown in the equation below (from life 
technologies Real-time PCR handbook): 
          Fold difference = 2-ΔΔCt 
          ΔΔCt                  = ΔCt Sample   - ΔCt Calibrator  
          ΔCt Sample        = ΔCt  GOI of Sample  - ΔCt Normalizer (housekeeping gene) of Sample 
          ΔCt Calibrator   = ΔCt GOI Calibrator - ΔCt Normalizer (housekeeping gene) of Calibrator 
Prior to qRT-PCR, cDNA was thawed on ice and further diluted with 90µl of nuclease-free 
deionised water to ensure a final concentration of 5 nanogram per microliter. A master mix was 
prepared for each set of primers, which consisted of the following components for each 10 µl 
single reaction: 5 µl Platinum SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen), 0.2 
Reagent Volume in µl
MgCl2 magnesium chloride 2
Reverse Transcription 10X Buffer 1
dNTP mix 10 mM 1
Recombinant RNasin® Ribonuclease Inhibitor 0.25
AMV Reverse Transcriptase (HC) 0.3
Oligo(dT)15 Primer 0.5
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µl (10 µM) of each primer (forward and reverse) and 2.6 µl of nuclease-free H2O. Two 
microliters of diluted cDNA (10 ngm) was added to each single reaction well, with 8 µl of 
master mix, to get a total volume of 10µl in each well. The samples were loaded in triplicates 
onto a 384-well reaction plate (MicroAmp optical plate, Applied Biosystems) and the qRT-
PCR reaction was performed using the 7900HT Fast Real-Time PCR System (Applied 
Biosystems, Foster city, CA) with the standard thermal cycle steps (500C for 2 min, 950C for 
10 min followed by 40 cycles of 950C for 15 sec and 600C for 1 min). Triplicate results were 
analyzed with SDS 2.3 software by calculating the relative expression of targeted genes in 
relation to the housekeeping gene (GAPDH) and a calibrator sample.  In the dietary animal 
model study, the calibrator was one of the 12 weeks mice in the control group. For the cell line 
work, the calibrator was the control sample for the treatment condition. The mouse primer 
sequences that were used for the dietary animal model are listed in Table 2.3, while the primer 
sets used for the human liver cancer cell line work are listed in Table 2.4. 
 
Table 2.3: Mouse primer sequences used for qRT-PCR. 
 
Forward GCGTAAACGCTTCGAGATGTT 21
Reverse TTTTTATGGCGGGAAGTAGACTG 23
Forward TAAAGTCCGTTGGAGCGCAAA 21
Reverse CTGCTGCTTCTCGTCATATAACC 23
mMDM4 Forward TTCGGAACAAATTAGTCAGGTGC 23
(MDMX) Reverse GTGCATTACCTCTTTCATGGTGA 23
mP21 Forward CAGATCCACAGCGATATCCAGACA 21
(CDKN1A) Reverse GAAGAGACAACGGCACACTTTGCT 20
Forward TGATTGGCACCGATCCTCG 19
Reverse CCACAGCGTCATATCATCCAG 21
Forward GGTCTTTAAGAGCGACGCTTAT 22
Reverse TTCTGTGTCTTGACCATGCAC 21
Forward CCGAAAGGATGGACACGGTG 20
Reverse TTATCGGGGTCTACGTTGAGC 21
Forward ACCTCCAGGCTTTATACCCTTG 22
Reverse CTTAGCCCCATCCTCAATGGT 21
Forward GGTGCTGAGTATGTCGTGGAGTCTA 25
Reverse GGGCGGAGATGATGACCCTTT 21
mPARP1
mGadd45a
mNudt1
mGAPDH
Primers
Sequence (5’ -> 3’)
length
mTrp53
mMDM2
mSIRT1
The Genes
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Table 2.4: Human primer sequences used for qRT-PCR. 
 
 
Table 2.5: qRT-PCR master mix constituent for each reaction. 
 
  
Forward CAGCACATGACGGAGGTTGT 20
Reverse TCATCCAAATACTCCACACGC 21
Forward AGTAGCAGTGAATCTACAGGGA 22
Reverse CTGATCCAACCAATCACCTGAAT 23
P21 Forward TGTCCGTCAGAACCCATGC 19
(CDKN1A) Reverse AAAGTCGAAGTTCCATCGCTC 21
Forward GAGAGCAGAAGACCGAAAGGA 21
Reverse CAGTGATCGTGCGCTGACT 19
Forward CCCGAGAGGTCTTTTTCCGAG 21
Reverse CCAGCCCATGATGGTTCTGAT 21
PUMA Forward ACCTCAACGCACAGTACGA 19
(BBC3) Reverse CTGGGTAAGGGCAGGAGTC 19
Forward AGATTGTGTGATGAAGGACATGG 23
Reverse TGTTGCTGGTGAGTGTGCATT 21
Forward ATGGAACAACGGGGACAGAAC 21
Reverse CTGCTGGGGAGCTAGGTCT 19
PPM1D Forward TTTCTCGCTTGTCACCTTGC 20
(WIP1) Reverse TTCCAAGAACCACCCCTGAG 20
Forward CAATGACCCCTTCATTGACC 20
Reverse GATCTCGCTCCTGGAAGAT 19
GADD45A
BAX
FAS
TNFRSF10B
GAPDH
The Genes
Primers
Sequence (5’ -> 3’)
length
TP53
MDM2
Reagent Volume in µl
SYBR green 5
Primer Forward 0.2
Primer Reverse 0.2
Nuclease free deionized water 2.6
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2.5 Cell culture methods 
A panel of liver cancer cell lines with different TP53 status was used.  These included TP53 
wild type (p53WT) HepG2 and SK-Hep-1, TP53 mutant (p53MUT) Huh-7, Huh-1, SNU475 and 
SNU182, and TP53 null (p53NULL) Hep3B. SNU475, SNU182 and SK-Hep-1 were from the 
European Collection of Authenticated Cell Cultures (ECACC). HepG2, HuH7 and Hep3B from 
our authenticated Northern Institute for Cancer research cell line bank (see below) were 
originally from the American Type Culture Collection (ATCC). Huh-1 cells were obtained from 
the Japanese Collection of Research Bioresources (JCRB) cell bank (JCRB0199, JCRB). 
Bioware® Brite HepG2-Red-Fluc (HepG2-Luc) cells were purchased from (BW134280, Perkin 
Elmer, USA).  
 Tissue culture practice and authentication of cell lines 
All cell line work was done in class II biological safety sterile cabinets, (Biomat, Medair 
Technologies, MA, USA). To minimise the risk of cross contamination and infection, the cell 
line handling was carried out in accordance with good practice criteria (234). All cell lines were 
authenticated using short tandem repeat DNA profiling (LGC Standards, UK), which uses 
human hypervariable DNA microsatellite regions that consist of a core sequence of 1-6 base 
pair long repeated DNA motifs, to detect cell line unique molecular fingerprints to ensure the 
avoidance of cross contamination and/or genomic instability in the used cell lines (235). 
All cell lines were confirmed mycoplasma infection free on a 3 months basis (LT07-318, 
MycoAlert Mycoplasma Detection Kit, Lonza, UK). All experiments were performed on cell 
lines less than 30 passages from purchase or authentication and this was achieved by 
preservation of early post-authentication passages of several vials cryogenically. 
 Culture of adherent cells 
All cells were maintained in either Dulbecco’s Modified Eagle’s Medium (DMEM) or Ham’s 
F-12 (D6421, Sigma Aldrich, Dorset, UK), apart from SNU475 and SNU 182, which were 
maintained in RPMI-1640 medium (R8758, Sigma Aldrich, Dorset, UK). The media were 
supplemented with final concentrations of 10% heat-treated foetal bovine serum and L-
Glutamine (2mM). All the cells were grown at 37°C and 5% CO2 in air humidified atmosphere 
in Sanyo CO2 incubators. 
When cells were ~70% confluent, the medium was removed, the cells washed with PBS and 
then trypsin-EDTA solution (0.5 gm trypsin / L and 0.2 gm EDTA/L in sterile distilled water) 
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was added to the cell monolayers, followed by incubation for 3-5 minutes at 370C in the 
incubator to detach the cells. To stop the trypsinisation, full growth medium containing serum 
was added and then the cells were re-suspended, diluted and transferred to new flasks or 
experimental plates. 
 Counting cells 
Cell densities were estimated using a Neubauer haemocytometer (Hawksley, Sussex, UK). 
After re-suspension of the trypsinized cells, 10 µl was added to each side of the haemocytometer 
cover slip. The volume of each grid equals 0.1 mm3; ten grids were counted (5 on each side) 
and the average was multiplied by 104 to give us the estimate of cell number in 1 ml, thereby 
allowing appropriate cell densities to be prepared and seeded.  
 Freezing and revival of cells 
Cells to be frozen for storage were ensured to be growing in the exponential phase (~70% 
confluent). After being tryspsinized and collected they were centrifuged at 350 rcf for 5 minutes 
(Mistral 3000i, DJB Labcare). Cell pellets were re-suspended in freezing medium, composed 
of complete growth medium, into which an additional 10% FBS and 10% dimethyl sulfoxide 
(DMSO) (#276855, Sigma) was added. The cell density for freezing was > 106/ml, and 1ml of 
re-suspended cells was divided into aliquots in cryogenic vials (NUNCTM, Rochester, NY, 
USA) and transferred into a cryochamber filled with isopropyl alcohol (Cryo 1ºC freezing 
container, Nalgene) to achieve an approximate -1°C/min rate of cooling when placed at -80˚C. 
For long term storage, vials were transferred into liquid nitrogen (Biosystem, Cryostor).  The 
vials were labelled with (cell line name, date, passage number and the operator name). 
To revive the cells, stored vials were thawed quickly and diluted with fresh medium slowly, 
and then centrifuged at 350 rcf for 5 minutes and the supernatant aspirated. Then the cell pellet 
was re-suspended in fresh medium and transferred into flasks. The medium was removed after 
24 hours together with any dead floating cells and replaced with fresh medium. 
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 Sulfrhodamine B (SRB) assay 
This assay was developed by Skehan et al (236) to estimate cell density in multi-well plates. It 
is based on binding of the SRB dye to amino acids in proteins under mild acidic conditions and 
indirectly reflects the number of cells in the well through estimating the protein contents of the 
well. Cells were seeded in 96 well plates and grown for the specific time points. Cells were then 
fixed with Carnoy’s fixative (3 parts methanol and 1 part acetic acid) (20 µl added to each 100 
µl in each well) and kept at 4°C for up to two weeks. Plates were washed 5 times with distilled 
water (dH2O) and left to dry overnight. Then the wells were stained by adding 100 µl/well of 
0.4% SRB in 1% acetic acid and left for 30 minutes. Unbound SRB was discarded and the plates 
were washed 5 times with 1% acetic acid and left to dry. Protein-bound SRB was then dissolved 
by adding 100 µl/well of 10mM Tris-HCL (pH10.5) solution with mild shaking for 20 minutes 
with a vibrating platform shaker (Titramax 1000, Heidolph), to ensure all the SRB dissolved. 
The optical density was measured at 570nM with FLUO star Omega plate reader. 
 Growth curve 
Cells were seeded in a 96 well plate with different seeding densities (500, 1000, 2000, 3000, 
4000 and 5000 cells /well) with 5-10 intra experimental replicates. Seven plates were seeded (a 
plate was seeded for each day of the week) and a plate was fixed every 24 hours with Carnoy’s 
fixative (20 µl per well) and kept in the fridge. SRB staining was done as described in 2.5.5. 
The doubling time was calculated using Graphpad prism 6 software. 
 Growth inhibition 
Cells were seeded in 96 well plates at the optimum seeding density chosen depending on cell 
line growth curve (seeding densities summarized in Table 2.6) in a 100 µl/well of media. After 
24 hours they were treated by adding 100 µl/well of each concentration of the compound under 
study with a range of concentrations and 3-5 intra-experimental replicates for each 
concentration. A DMSO control with a final concentration of 0.2% was included in each plate. 
After 96 hours of treatment cells were fixed with Carnoy’s fixative and stained with SRB as 
mentioned in 2.5.5. Mean, standard deviation (SD) and standard error of the mean (SEM) was 
calculated using the optical densities of the intra-experimental replicates. The data was 
normalized to the control (DMSO/solvent) and expressed as percentage of growth inhibition. 
Graphpad prism 6 software was used to calculate the 50% growth inhibitory concentration 
(GI50) using (Lowess/spline fit) function and the mean±SEM of GI50 of 3 or more independent 
experiments was calculated. 
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Table 2.6: seeding densities of liver cancer cell lines in 96 well plates 
Cell line Seeding density per well in 96 well 
plate 
HepG2 2000 
SK-Hep-1 1000 
Huh-7 3000 
Hep3B 3000 
Huh-1 3000 
SNU475 3000 
SNU182 3000 
HepG2-Luc 2000 
 
 
 Clonogenic assay 
Cells were seeded in a 6 well plate (seeding densities in Table 2.7) and were allowed to adhere 
for 24 hours and then treated with a solvent control and a range of drug concentrations for 96 
hours in a final concentration of 0.2% DMSO. Then the media containing the drug was gently 
removed and replaced with fresh medium and the cells left to grow to form colonies for 21 days. 
At time of harvest, the media was removed gently and the colonies were fixed with Carnoy’s 
fixative for 5 minutes and the fixative was removed and the plates were left to dry. Subsequently 
they were stained with 0.4% crystal violet dissolved in dH2O for 30 minutes and thereafter the 
plates were washed with gently flowing tap water and left to dry overnight. Visible purple 
stained colonies were counted in each well and the cloning efficiency was calculated using the 
following formula: 
Cloning efficiency= (counted colonies / number of seeded cells) x 100 
The data was normalized to the DMSO control and the concentration of the drug that reduced 
the colony formation by 50% (LC50) was determined using (Lowess/spline fit) function in 
Graphpad prism 6 software. The mean of ≥ 3 repeats was calculated ± SEM and clonogenic 
survival curve was plotted.  
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Table 2.7: Cloning efficiency and seeding density for clonogenic assay of liver cancer cell 
lines 
Cell line Seeding density per well in a 6 well plate Cloning efficiency 
HepG2 500 20-25 % 
SK-Hep-1 300 26-30 % 
Huh-7 1500 8-10 % 
Hep3B 120  60-70 % 
 
2.6 Drugs used in in vitro studies 
 MDM2 inhibitors 
Three MDM2 inhibitors were used during the course of our study (Figure 2.3). Nutlin-3 
(C30H30Cl2N4O4)
 was purchased from NewChem (#548472-68-0,Newcastle, UK) in powder 
form with a molecular weight of 581.5 gm/mol with >98% purity and dissolved in DMSO 
(276855, Sigma) to a final concentration of 10mM and aliquoted and stored at -20 °C. Another 
two potent MDM2 inhibitors were sourced by custom synthesis with the help of Newcastle 
University/Astex Pharmaceuticals Alliance. Idasanutlin, also known as RG7388 or RO5503781 
(C31H29Cl2F2N3O4), is a second generation MDM2 inhibitor that is already in phase III clinical 
trials. This compound was developed by Roche through optimisation of Nutlin. Its molecular 
weight is 615.15 gm/mol. It was dissolved in DMSO to a final concentration of 1mM and stored 
in -20 °C. HDM201 (C26H24Cl2N6O4) is an imidazolopyrrolidinone analogue that was 
developed by Novartis is already in phase I clinical trial. It has a molecular weight of 555.41 
gm/mol. It was dissolved in DMSO to a final concentration of 20mM, from which aliquots of 
lower concentrations were prepared and stored at -20°C. 
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Figure 2.3: Chemical structure of the three MDM2 inhibitors, Nutlin-3 (216), RG7388 
(237) and HDM201 (238). 
 
 
 WIP1 inhibitor 
GSK2830371 (C23H29ClN4O2S) is a selective WIP1 inhibitor, the chemical structure of which 
is shown in Figure 2.4. It has a molecular weight (461.02). It was purchased from Tocris 
(#5140). It was dissolved in DMSO in 10mM aliquots and stored in -20°C. 
 
 
Figure 2.4: the chemical structure of GSK2830371(239). 
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2.7 Western blotting 
 Protein isolation and quantification 
Cells were seeded in a 6 well plate at 2.5 x 105 cells / well for 48 hours and then treated with 
compound of interest at the specified concentration for different time points. Medium was 
removed and cells were washed with 1X PBS. Then 50 µl of SDS lysis buffer (0.0625M Tris-
HCl pH 6.8, 2% SDS (Sigma), 10% Glycerol (Sigma)) was added per well and cells were 
detached with a cell scraper and the lysates collected and transferred into Eppendorf tubes and 
spun down.  Samples were then heated for 10 minutes at 100°C and spun down. Sonication of 
each sample was performed at an amplitude 6 for 10 seconds (Soniprep 150 plus) to fragment 
the DNA and reduce the viscosity of the sample. This was repeated three times for each sample. 
Lysates were then centrifuged at maximum speed for 5 minutes at 4°C and the supernatant 
stored at -20°C until use. 
Protein estimation and quantitation was done using a bicinchoninic acid (BCA) assay kit (Pierce 
BCA protein assay, Thermo scientific Fisher). This assay uses a colorimetric detection system 
based on the reduction of cupric ions Cu+2 to cuprous ions Cu+1 through the effect of reagent B 
in an alkaline medium (biuret reaction). This is followed by detection of the cuprous ions by 
reagent A in the kit, a purple colour is formed, the intensity of which is proportionate to the 
protein concentration in the sample. To perform this assay a standard range of protein 
concentrations 0.2-1.2 mg/ml was prepared from bovine serum albumin (BSA). Protein samples 
were diluted at a ratio of 1:10 and loaded into a 96 well plate in a quadruplicate; water was 
added into the blank wells. A mixture of reagent A and reagent B at a ratio of 50:1 was prepared 
and 190 µl was added into each well. The plate was incubated on a shaker for 1 minute to ensure 
proper mixture of the reagents, and then incubated at 37°C for 30 minutes. The absorbance at 
570 nM was subsequently determined using a FLUOstar Omega plate reader (BMG Labtech). 
A standard curve was plotted for the control samples using the plate reader analysis software 
and the concentration of protein in each well was calculated accordingly. 
 Immunoblotting 
A 20-25 µg aliquot of each sample was mixed with loading buffer in a microfuge tube and 
heated for 10 minutes at 100°C in a dry heating block. After centrifugation and gentle 
resuspension, the samples were loaded into the wells of a Sodium dodecyl sulphate (SDS) 
polyacrylamide gel (Mini-protean TGX 4-20% gradient pre-cast gel, Bio-Rad) immersed in a 
vertical gel electrophoresis tank filled with electrophoresis buffer (1:10 dilution of the stock 
buffer of 144 g Glycine (Sigma G8898), 30 g Tris base (Fisher 10667243) and 10 g SDS (Sigma 
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L3771). A ladder of protein molecular weight markers was loaded instead of a sample in two 
wells on each side of the gel. All the protein targets studied were less than 100 kDa, therefore 
the See Blue pre-stained low molecular weight protein standard (#LC5625, Life Technologies) 
was used. After electrophoretic separation of the samples for 45 minutes at 180 volts, the 
separated proteins underwent a transfer step.  A nitrocellulose 0.45-micron membrane was used 
(#RPN203C, Hybond-C Amersham). For each gel, 2 filter papers and 2 blotting pads and 1 
nitrocellulose membrane were soaked in transfer buffer. Thereafter they were layered with the 
gel in the following sequence from the Cathode probe (black) to the anode probe (transparent): 
1 blotting pad, 1 filter paper, the gel, the membrane, filter paper and blotting pad. Before 
transferring the proteins, air bubbles were removed by passing a roller over the layers. Then the 
transfer of proteins was carried out at 100 Volt for 30 minutes in a tank completely filled with 
the transfer buffer (70.7 g Glycine (Sigma G8898), 15.15 g Tris base (Fisher 10667243), one 
litre methanol 99.9% (Fisher Bioreagents) and distilled water to a final volume of 5 litres). After 
completing the transfer, membranes were blocked with 5% milk in Tris-Buffer Saline solution 
with 1% tween 20 (TBS= 80 g NaCl (Sigma S7653), 24.2 g Tris base (Fisher 10667243), and 
distilled water up to one litre final volume with adjusted PH of 7.6) for 1 hour on a shaker. 
 
The whole membrane or cut membrane was then incubated with the primary antibody of interest 
for the specified time. This was followed by a washing step in TBST for 5 minutes and then the 
membrane was incubated for 1 hour at room temperature with a secondary antibody, which 
could be goat anti-Mouse or anti-Rabbit (according to the primary antibody type) and 
conjugated with horseradish peroxidase (HRP) at a dilution of 1:1000 (Cat No.: 
P0447/P0448Dakocytomation) (Table 2.8). All dilutions were prepared using 5% non-fat milk 
or BSA in 1X TBST solution. 
 
 Immunodetection 
The membrane was washed with TBST three times for 10 minutes each before visualising the 
protein locations with an Enhanced ChemiLuminescence (ECL) system (GE Healthcare Life 
Sciences). ECL contains a chemiluminescence substrate and an oxidising agent mixed at a ratio 
of 1:1 and incubated with the membrane for 1 minute before exposing the membrane to an x-
ray film (Fujifilm) in the dark. Under the effect of the HRP conjugated to the secondary 
antibodies, triplet carbonyl is formed from the substrate and the decay of this triplet to singlet 
emits light that is detected by the x-ray film and the detected signal is proportionate to the 
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amount of the secondary antibody that in turn is proportionate to the target protein content in 
the sample. The x-ray films were then scanned and the results analysed. 
Table 2.8: Antibodies used in western blotting. 
Antibody Species Cat. #, Company Dilution Molecular weight 
kDa 
p53 Mouse M7001, Dako 1:3000 53 
Phosphorylated 
p53 at serine 15 
Rabbit 9284, Cell signalling 1:1000 53 
Acetylated p53 
at lysine 382 
Rabbit #2525, Cell Signalling 1:500 53 
MDM2 Mouse OP40, Merck Millipore 1:1000 90 
p21 Mouse OP64, Calbiochem 1:100 18 
WIP1 Mouse #sc-376257, Santa Cruz 1:200 85 
PARP Mouse C2-10, Trevigen 1:1000 114  
(cleaved PARP 85) 
BAX Rabbit 2772S, Cell Signalling 1:1000 21 
GAPDH Rabbit 2118, Cell signalling 1:1000 35.8 
Β-Actin Mouse A4700, Sigma 1:3000 42 
 
2.8 Fluorescence activated cell sorting (FACS) 
Cells seeded at 250 000 cells per well in 6-well plates were treated after 24 hours, to allow 
recovery and attachment, with 24, 48 or 72 hours drug exposures, after which floating and 
adherent cells were collected together and centrifuged at 500g for 5 minutes. Pellets were then 
fixed with 70% ethanol and stored at 4°C. Cells were then centrifuged at 500g for 5 minutes 
and washed with 1mL PBS, followed by further centrifugation at 500g for 5 minutes, re-
suspension in 250 μl of phosphate buffered saline (PBS) and incubation with 40 μg/mL 
propidium iodide (PI) (Sigma-Aldrich) and 20 μg/mL Ribonuclease A (RNase A) (Sigma-
Aldrich) for 20 minutes in the dark at room temperature. PI is a fluorescent dye that binds to 
double stranded DNA and RNA. RNase A was used to cleave the P-O5 bond in RNA, releasing 
the PI. The retained fluorescent signal is thus from the DNA only and proportionate to the DNA 
content of the cells. 
Samples were processed using a FACS calibur flow cytometer (BD biosciences) after being 
stained with PI. In this machine single cells pass through a tube and intersect with a laser beam 
(488nM). Some of the incident light passes through the cells and is recorded by a sensor. This 
is called forward scatter (FSC) and it reflects the cell volume. Some light gets more broadly 
scattered and is called side scatter (SSC). This reflects granularity of the cell.  The fluorescent 
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signal from the PI (excitation wavelength of 535/617nm) when passed through argon laser beam 
of 488 nm is also detected and recorded. The analyses are described later. 
Before analysing the treated samples, adjusting the settings of the instrument was necessary to 
ensure that the collected signal was from the cells and not from other particles. Therefore 
untreated cells were passed through the machine and the settings were adjusted using CellQuest 
Pro software (Becton Dickinson, Oxford, UK). G1/G0 phase signal intensity was adjusted in 
the region of 200, to allow the recording of events at lower intensity than the G1, namely sub-
G1. 25000 events were recorded per sample (Figure 2.5).  
To analyse cell cycle changes, Cyflogic (1.2.1) (CyFlo Ltd, Turku, Finland) software was used 
to calculate the percentage of cells (events) in each of the three cell cycle phases, G1/G0, S, and 
G2/M,  based on the signal collected that reflects the DNA content of the cells in each phase 
(Figure 2.5). In addition, sub-G1 signals were recorded.  In normal dividing cells there are 3 
phases, G1/G0 phase in which the cells have a single copy of the diploid genome (2N); followed 
by the synthesis phase (S) that will lead to doubling the DNA content (4N) in the G2/M phase. 
Events with signal intensity below the G1/G0 (2N) were considered sub-G1 and reflect dying 
disintegrated (apoptotic) cells. Analysing the cell cycle allows identification of any changes in 
the number of cells in each phase, allowing interpretation of the effects of conditions or 
compounds used on the cell cycle distribution. The analysed data was plotted using GraphPad 
Prism 6 software. 
 
Figure 2.5: Cell cycle analysis and gating of events using CellQuest and Cyflogic software. 
X-axis represent DNA content (signal intensity-major ticks =100) and Y-axis represents the 
frequency or number of events (number of cells) to generate a histogram of the distribution of 
cells in different phases of the cell cycle.  
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2.9 Caspase 3/7 activity assay 
Cells were seeded at 8000 cells/well in a white opaque 96 well plates. After 24 hours they were 
treated with the compound of interest for another 24 hours, prior to the addition of the caspase 
3/7 Glo reagent (Promega) in a 1:1 ratio and incubation for 30 minutes at room temperature. 
The luminescence was measured with a FLUOstar Omega plate reader (BMG Labtech). This 
technique is based on the generation of luminescence through the cleavage of a substrate in the 
assay reagent in the presence of active caspase 3/7 in the wells. The measured luminescence is 
then normalised to the solvent control and the mean of three independent repeats was plotted 
as a relative luminescence ± SEM. 
 
2.10 XTT assay 
XTT is a colorimetric assay that assesses cellular proliferation, viability and cytotoxicity. It is 
based on the cleavage of a tetrazolium salt (water soluble) into a formazan salt in the presence 
of an electron coupling agent, and this process occurs in live cells only and is dependent on 
NAD(P)H production through glycolysis. The cleavage of tetrazolium salts is performed by the 
succinate-tetrazolium reductase system (EC 1.3.99.1), which is part of the respiratory chain in 
the mitochondria. The formed formazan salt is water soluble and gives an orange colour. The 
absorbance of light at 450 nM is measured and reflects the number of viable cells in the well.  
Cells were seeded at 5x103 cell / well in 100 µl per well, in 96 well plates in triplicate for each 
condition. Five plates were seeded and after 24 hour all of the plates, apart from the untreated 
control plate, were treated with cell line specific doses of GI50, 10X GI50 (calculated according 
to the SRB assay) and 1µM of HDM201 alone and in combination with WIP1i (2.5µM). The 
drug solvent was DMSO arranged to be at a final concentration of 0.2% to have minimal effect 
and control samples were treated with this concentration alone. Every 24 hours a plate was 
taken out of the incubator and 50 µl of XTT assay mix (that is a mixture of a 5ml XTT salt and 
a 0.1 ml electron coupling agent) was added per well, prior to incubation for 4 hours. In each 
plate, a triplicate of media-only control was added as a background control. Light absorbance 
was measured at 450 nM wavelength using a FLUOstar Omega plate reader. The blank 
background absorbance was subtracted and data was plotted using GraphPad Prism 6 software.  
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2.11 Senescence associated β-Galactosidase assay (SA-β-Gal) 
β-Galactosidase activity is usually detected at an acidic pH 4.5, using the substrate X-Gal. In 
senescent cells which accumulate β-Galactosidase in their lysosomes, activity can be detected 
at a suboptimal pH 6.0. The development of a blue-green stain results from cleavage of the 
chromogenic X-Gal substrate by the β-galactosidase enzyme (240). This method can be used 
for the indirect detection of senescent cells. 
Cells were seeded in 12 well plates (Corning) and in Nunc chambered coverglass system slides 
(155360, Lab Tek I chambered #1.5 German coverglass system, ThermoFisher scientific, 
USA), at the densities in (Table 2.9), incubated with the drug and DMSO control for 96 hours, 
prior to fixing and staining with an SA-β-Gal kit (CS0030, Sigma) according to the 
manufacturer’s protocol. After development of positive staining, the reagent was removed and 
replaced by PBS, or 70% glycerol for long term storage. Images were captured using the EVOS 
XL cell imaging system (ThermoFisher scientific). Ten high power field images were analysed 
and the percentage of positively stained cells was calculated. The mean of three independent 
repeats was plotted together with the standard error of the mean. 
 
Table 2.9: Seeding densities of HepG2 and SK-Hep-1 for SA-β-Gal assay 
 
  
HepG2 SK-Hep-1 HepG2 SK-Hep-1
DMSO control 7000 5000 20000 10000
WIP1i 7000 5000 - -
MDM2 inhibitor
0.5 GI50 10000 10000 - -
GI50 20000 20000 40000 40000
10X GI50 80000 40000 200000 80000
Cell seeding density per well in 
a 12 well plate
Cell seeding density per 
chambered slide
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2.12 In vivo xenograft study 
All of the in vivo experiments were performed according to the Guidelines for the Welfare of 
Animals in Experimental Neoplasia (Second Edition), set by the United Kingdom Coordinating 
Committee on Cancer Research and national law (241) and after being reviewed and approved 
by the local institutional animal welfare committee.  
 Growth curve of HepG2-Luc in different immunocompromised mice strains 
The ability of HepG2-Luc to form xenografts was tested in two different immunocompromised 
mice strains, NOD SCID gamma (NSG) (Bred in house - Comparative Biology Center, Medical 
School, Newcastle University) and CD1 nude mice (Charles River, UK). NSG mice lack B and 
T lymphocytes and lack natural killer cells, while CD1 nude mice lack the Thymus and T cells. 
8-10 weeks old female mice were allocated into two groups with 5 mice/group of each strain. 
A 50 µl suspension of 107 HepG2-Luc cells in a cocktail of 50% matrigel (BD Biosciences) 
and 50% DMEM medium were injected subcutaneously into the right flank of each mouse (after 
removal of hair for NSG mice with a clipper and hair removal cream). They were left to grow 
with close monitoring of the tumour growth by digital Vernier calliper measurements of the 
largest dimensions of the detectable tumours three times a week. The collected data were plotted 
using GraphPad Prism 6 software to generate a growth curve.  
In parallel to tumour size measurements using the standard Vernier calliper method, and 
because the HepG2-Luc cells have luciferase activity, In Vivo Image Scanning (IVIS) was 
performed once a week by injecting the mice with 100µl per mouse of D-luciferin (3gm/mL) 
intraperitoneally (IP) 10 minutes before scanning the mice. The mice were anaesthetised by 
isoflurane inhalational using a controlled flow anaesthesia machine while IVIS imaging was 
performed. After IP injection, D-luciferin is absorbed into the blood. In HepG2-Luc cell 
xenografts, dependent on the vasculature and substrate delivery, D-luciferin should be oxidised 
under the catalytic effect of luciferase enzyme to generate a light signal. The IVIS scanning 
system detects any photons emitted from the animal and the bioluminescence data can be 
plotted.  
The HepG2-Luc line reportedly had improved luciferase brightness. A new codon-optimized 
luciferase from Luciola Italica (RedLuc) was developed by Perkin Elmer, with a red-shifted 
emission peak wavelength of 617 nm, and approximately 100-fold higher signal intensity 
compared to other firefly luciferases. 
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When the tumours reached a dimension of 10x10 mm, or one of the dimensions exceed 15 mm, 
euthanasia was carried out to comply with ethical standards. 
 Assessing HDM201 effect on HepG2-Luc xenografts 
8-10 weeks old female NOD SCID mice were allocated into 4 cages with 5 mice per cage. A 
50µl volume of 107 HepG2-Luc cells in suspension were injected in a cocktail of 50% matrigel 
and 50% DMEM medium subcutaneously into the right flank of each mouse after hair removal. 
When the tumours were palpable (approximately 5x5 mm), the animals were randomised and 
divided into two groups to receive a single daily dose of either the HDM201 or the control 
vehicle (5% ethanol alcohol in 1% HydroxyPropyl Methyl Cellulose) through oral gavage.  
In the first xenograft study, treated mice received a single daily dose of 25 mg/kg /day for 7 
days. In the follow-up study, mice received 100 mg /kg/day for 10 days. Standard tumour 
measurement with a Vernier calliper and recording of body weight was performed three times 
weekly. To ensure that the measurements were non-biased, the person measuring the tumour 
size and body weight was blinded to the treatment and control groups. When the tumours 
reached a dimension of 10x10 mm or one of the dimensions exceed 15 mm, the animals were 
euthanised. Subcutaneous xenografts were recovered by dissection and divided into two parts, 
one kept in formalin at 4°C for processing into FFPE blocks and the other fresh frozen in liquid 
nitrogen and stored at -80°C. 
2.13 Statistical analysis 
All data were presented as the Mean ± standard error of the mean (SEM) unless otherwise 
specified. The p-value was calculated using Microsoft Office, IBM SPSS 22 and GraphPad 
Prism 6 software with a p-value of < 0.05 considered statistically significant at the 95% 
confidence level. Paired and unpaired t-tests and one-way ANOVA with multiple hypotheses 
correction were used as appropriate for the comparison data type unless otherwise specified.  
  
66 
 
 
 
 
 
 
 
 
 
 
 Characterisation of a dietary induced animal model of 
non-alcoholic fatty liver disease and hepatocellular carcinoma 
– a focus on p53 
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3.1 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the 
western world and is part of a spectrum that involves steatosis and non-alcoholic steatohepatitis 
(NASH), with inflammation and fibrosis leading to cirrhosis in some cases (16, 67). On a 
background of dietary excess and relative inactivity, with dramatically rising levels of the 
metabolic syndrome (obesity, type 2 diabetes (T2DM), and cardiovascular complications), 
NAFLD affects up to 25.42% of the world population (16). It is anticipated NAFLD will 
become the most common cause of liver transplantation in this century (5). NAFLD is also an 
important risk factor for the development of hepatocellular carcinoma (HCC) (5, 16). HCC is 
the second leading cause of cancer related death worldwide with a 5 year survival of less than 
15% (84, 242).
   
In NAFLD the accumulation of free fatty acids (FFA) impairs mitochondrial function and 
causes increase in the reactive oxygen species (ROS). Oxidative stress induced cellular and 
DNA damage reportedly plays a central role in the progression of simple fatty liver to 
steatohepatitis, fibrosis and HCC (243). Lipid accumulation may also lead to a continuous state 
of inflammation through interleukin-6 and tumour necrosis factor and dysregulated adipokine 
levels (244). 
Several animal models have been developed to help understand the pathophysiology of NAFLD 
(245) and a number of these, supported by studies in human NASH, report an upregulation of 
p53 in NAFLD (21, 195). The role of p53 in the development of NAFLD HCC, however, is 
unclear.  Famed as a tumour suppressor and “guardian of the genome”, its inactivation in some 
form might be expected.  In human HCC, the incidence of TP53 mutation is around 30%, 
according to the Catalogue of Somatic Mutations in Cancer (COSMIC) (199). The majority of 
TP53 mutation occurs in the DNA binding domain, frequently caused by aflatoxin B1 exposure 
or viral hepatitis infection which are common in sub-Saharan Africa and East Asia respectively 
(246). The incidence of p53 mutation in NAFLD is not yet known. 
In an attempt to generate an animal model better reflecting the Human condition, including 
progression to NASH, fibrosis and HCC rather than simple fatty liver, we fed the American life 
style (ALIOS (High Fat High Fructose (HF))) diet to a strain of mice with a tendency to 
develop obesity and impaired glucose tolerance with age (C3H/He). Two groups of mice 
received control diet or ALIOS diet, with different time points of exposure, as described in 
detail in the methods section, but as summarised in Table 3.1.   
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Table 3.1: dietary animal model design 
 
 
 
3.2 Hypothesis and aims of the study 
 Hypotheses 
1. The development of HCC in NAFLD is associated with an inflammatory response 
(NASH) and the development of fibrosis. 
2. The development of NASH in NAFLD is associated with oxidative stress, DNA damage 
and a p53 response. 
3. A defective p53 response is associated with development of HCC. 
 
 Aims of the study 
• Explore the development of HCC in the animal model of NAFLD and identify the 
association with the grade and stage of NAFLD. 
• Explore NAFLD progression and HCC grade in association with DNA damage and p53 
expression. 
• Explore TP53 status in HCC in our animal model. 
  
69 
 
3.3 Dietary induced Obesity, NAFLD and HCC 
 The ALIOS diet induced obesity and hepatomegaly in C3H/He mice 
American life style diet (ALIOS (High Fat High Fructose (HF))) fed mice showed a highly 
significant increase in body weight and liver weight compared to the control group fed on a 
normal diet. The liver to body weight ratio was higher in the ALIOS animals compared to the 
control (C) which was associated with more fat accumulation in the ALIOS mice livers (Figure 
3.1). 
The average body weight was (42.49±6.2g), with a range from (28.1g to 57.1g). Body weight 
results showed a significant increase in weight with age in both groups of mice. The body 
weight increased from a mean of (35.16±1.11g) in the 12 weeks age group fed ALIOS diet, to 
(47.25±0.92g) in the 48-weeks group (p<0.0001). The mean body weight in the control group 
increased from (32.05±0.96g) at 12 weeks to (41.31±0.82g) in the 48-weeks (p<0.0001) 
(Figure 3.1; A). 
The difference in the body weight between the control and the ALIOS diet group remained 
significant throughout the whole study with a p value <0.05 (apart from the 12-weeks age group 
in which the difference between ALIOS and control groups was not significant (p=0.054). The 
largest difference was in the 48-weeks (p<0.0001). This shows clearly the effect of diet on 
weight gain. 
Liver weight also increased dramatically with age, with a significantly higher increase in the 
ALIOS (HF) group in comparison to the control group (p<0.0001) (Figure 3.1; B). The average 
liver weight was (2.2 ±0.66 g) with a range from (1.2 to 4.7g). In the control groups the liver 
weight increased from (1.45±0.04g) at 12-weeks, to (1.85±0.06g) at 48-weeks, compared to the 
ALIOS where it increased from (1.75±0.10g) to (2.83±0.12g) at 48-weeks (P< 0.0001 for both 
groups).  
 The development of hepatomegaly more so than body weight was confirmed by significant 
increases in the liver weight (LW) to body weight (BW) ratio in aging and ALIOS diet fed 
mice.  With advancing age, LW/BW ratios (expressed as % of body weight) increased from 
(4.53±0.12) at 12-weeks to (4.48±0.11) at 48-weeks, and from (4.96±0.23) to (6.04±0.2), in 
control and ALIOS diet groups respectively (Figure 3.1; C). 
This liver weight gain correlated significantly with body weight gain, indicating that there was 
gain in weight associated with increase in liver weight, but highlights the liver as an organ in 
70 
 
which gain preferentially occurs in the presence of a high fat diet and lipid accumulation 
(Figure 3.1; D). 
 
Figure 3.1 : The effect of ALIOS diet on body and liver weight. (A) Shows the increase in 
the body weight with age, which was higher in ALIOS (HF) fed animals compared to the control 
group. (B) Shows the increase in liver weight with age, again higher in ALIOS fed animals, 
with the greatest difference between the ALIOS and control at 48-weeks of age. (C) Liver to 
body weight ratio increased in ALIOS fed animals. (D) The correlation between the body and 
liver weight is demonstrated in the scatter plot. Y axis values represent Mean ± SE of the mean. 
* represent p<0.05, *** represents p<0.0001 determined by the t-test.   
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 The ALIOS diet induced NAFLD, NASH and Fibrosis 
Histological grading and staging of NAFLD was described in details in chapter one (1.2.4). The 
main histological parameters that are used in the scoring of NAFLD and NASH include 
steatosis, lobular inflammation, portal inflammation, hepatocellular ballooning and fibrosis (see 
1.2.4, Figure 3.2). 
 
Figure 3.2: Histological parameters used in NAS and SAF scoring systems showing the 
NAFLD changes after feeding ALIOS diet in 48-week-old mouse liver. (A) Steatosis 
(arrows), (B) lobular inflammation (red circle), (C) portal inflammation (red circle), (D) 
ballooning (red circle and black arrow) and (E) fibrosis shown as pink stained fibrous bands 
(arrows). (Sirius red staining for collagen) was used to detect fibrosis in (E) while haematoxylin 
and eosin stain was used in all other slides. CV= central vein, PT =portal tract. 
 
In parallel to the physical parameters that showed increased liver weight, steatosis was 
prominent and highly significant in the ALIOS fed group compared to the control group 
(p<0.0001) (Figure 3.3). In the ALIOS group all mice developed steatosis to a variable extent, 
with 33 cases (68.8%) graded as moderate steatosis and 7 (14.6%) cases graded as severe 
steatosis. In the control group the majority had either no steatosis (21.3%) or mild steatosis 
(36.2%). The remaining 20 cases  (42.6%) had a moderate degree, with none having severe 
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steatosis. These data confirm that C3H/He mice develop NAFLD with age, which is more 
pronounced in mice fed a high fat ALIOS diet. 
The dramatic effect of the ALIOS diet on other histological features of progressive NAFLD 
was also evident. In addition to the highly significant increases in the steatotic grade 
(p<0.0001), microvesicular steatosis (p=0.003), lobular inflammation (p<0.0001) and fibrosis 
stage (p=0.009) were also significantly increased compared to the control diet, as were Mallory 
Denk bodies (p=0.018) and pigented Kupffer cells (0.045) to a lesser degree (Figure 3.3). The 
NASH activity score (NAS) and SAF score also showed highly significant difference between 
the ALIOS and control groups (p<0.0001 in both NAS and SAF) (Figure 3.4). 
 
 
Figure 3.3 : Comparison of liver histological features of NAFLD in control and ALIOS 
diet fed mice at 48 weeks. Features associated with NAFLD progression were more 
pronounced in ALIOS (n= 23) fed mice compared to Controls (C) (n=24).  Y axes values 
represent Mean ± SE of the mean. 
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Figure 3.4: NAS and SAF score comparison between the control and HF diet in 48-week-
old mice. (A) NAS and (B) SAF scoring systems showed highly significant difference between 
ALIOS (HF) and control (C) (p<0.0001). Y axes represent individual mouse scores and the 
horizontal line show the group median values.  
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 The ALIOS diet promoted the development of primary liver tumours 
Not only do C3H/He mice develop obesity and NAFLD with age, they also develop 
spontaneous liver tumours.  In mice fed the ALIOS diet, this phenotype was dramatically 
exacerbated, as mice started to develop tumours at an earlier age (36 weeks), with significantly 
greater numbers and size of tumours by 48 weeks (Figure 3.5). 
 
Figure 3.5: Tumour development in the murine dietary animal model. (A) Liver tumour 
(HCC) in a 48-week-old ALIOS (HF) fed mouse (arrow). (B) Histological section of a mouse 
liver stained with haematoxylin and eosin showing liver tumour (HCC) (arrow). (C)Tumours 
started to appear at 36 weeks of age in the ALIOS fed animals and the number of tumours was 
significantly higher in the ALIOS animals, despite the development of tumours by some of the 
48-week-old control animals. (D) The tumour size in ALIOS (HF) mice was larger compared 
to those in the control animals Y axis values represent Mean ± SE of the mean. *** represents 
p<0.001 determined by t-test.   
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 Characterising tumour development and progression in C3H/He mice 
3.3.4.1 Tumour development associations  
The combined group of 47 mice (control and ALIOS fed mice) were regarded as a single cohort 
for the exploration of gross and histological phenotypic associations with tumour development. 
Gross phenotype associations included body weight, liver weight, liver/body weight ratio and 
visceral adipose tissue weight.  Bivariate associations with tumour number (continuous data) 
are shown in Table 3.2. The correlation was most marked and highly significant for liver 
weight, or liver/body weight ratio.  
Data were similarly assessed in association with histopathology scoring of NAFLD.  
Associations with absence or presence of a tumour were also assessed by Chi square test for 
these categorical variables, as shown in Table 3.2.  Tumours were more likely to develop in 
livers with more fat, but notably also in the presence of lipogranulomas and lobular 
inflammation.  Associations with fibrosis were not as strong.  
Table 3.2: Association of HCC development with phenotypic and liver histopathology 
parameters. 
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Most of the tumours were of low grades (grade 1 & 2) and only two tumours were of high grade 
(3 and 4 respectively) (Table 3.3).   
Table 3.3: Incidence and histological grades of liver tumours 
 
 
 
Figure 3.6: H&E stained mouse liver tissue sections showing NAFLD, HCA and HCC of 
different grades.  (A) Liver tissue sections from a 48-week old mice fed HF diet showing 
steatosis. (B) HCA. Pictures (C, D, E and F) show HCC with grade I, II, III and Grade IV, 
respectively. On the lower right side corner of each picture there is a magnified image showing 
nuclear features. Magnification power 20X and the scale bar = 200 μm. 
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3.3.4.2 Tumour progression – associations with tumour and size 
The number of liver tumours was significantly associated with histological features of more 
advanced NAFLD or NASH. These data are presented in Figure 3.7 and those histological 
features in which the tumour number mean value was significantly different by Kruskal Wallis 
test included steatosis grade (p=0.025), microvesicular steatosis (p=0.01), lobular inflammation 
(p=0.017), fibrosis (p=0.029), as well as highly significant association with the presence of 
lipogranulomas (p=0.001). 
 
Figure 3.7 : The association between tumour numbers and NAFLD progression in the 48-
week-old mice. The number of tumours associated significantly with NAFLD parameters, as 
indicated by significant associations with steatosis (A), lobular inflammation (B), 
microvesicular steatosis (D), Mallory Denk bodies (F) and fibrosis (I). The association also 
approaches significance with pigmented Kupffer cells (H). Y axis values represent Mean ± SE 
of the mean, and p values were calculated according to the Kruskal-Wallis test. 
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Tumours also tended to be larger (assessed here by including the largest single tumour diameter 
in millimetres) in cases with more advanced NAFLD (Figure 3.8).  
 
Figure 3.8 : Tumour size association with NAFLD progression in the 48-week-old mice. 
There was a significant association of the tumour size with steatosis (A), lobular inflammation 
(B), pigmented Kupffer cells (H), Mallory Denk bodies (F). The association was highly 
significant with lipogranulomas (G) and approaches significance with microvesicular steatosis 
(D). Y axis values represent Mean ± SE of the mean, and p values were calculated using the 
Kruskal-Wallis test. 
 
However, including only the cases in which there were tumours, and analysing either by Chi 
Square for tumour size assessed as categorical data (tumours ˂5mm or ≥5mm), or using 
bivariate Spearman correlations considering tumour size as a continuous variable, these 
associations were less striking.  Borderline significant associations with inflammatory activity 
were seen, brought out in the combination NAS and SAF activity scores (Table 3.4). The only 
robust association with size was the presence of Mallory-Denk bodies.   
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Table 3.4 : Association of tumour size with the phenotypic and liver histopathology 
parameters 
 
 
 
3.3.4.3 Binomial Regression Analyses of tumour development and stage 
As many of the factors exacerbated by diet, including obesity and NAFLD stage, were inter-
related, confirming those that were the drivers of tumour development and progression was not 
definitively possible in this model. However, binomial regression analyses centred on either 
tumour development (absent or present), tumour number (1 or >1) or tumour size (<5mm or 
≥5mm) were performed, as summarised in Table 3.5.  
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Table 3.5: Binomial regression analysis of tumour development and stage in the dietary 
animal model. 
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Considering histopathology features and tumour development, the presence of lipogranulomas, 
lobular inflammation, perisinusoidal fibrosis and grade 2 steatosis or above, were each 
significantly associated with tumour development in a univariate analysis (Table 3.5, A). None 
was independently associated with tumour development in a multivariate analysis (Table 3.5, 
B). This included body weight and liver weight, which in the univariate analysis was 
independently associated with the development of tumours, only liver weight was associated 
with tumour development (Table 3.5, B).   
Exploration of factors potentially contributing to increasing tumour numbers, only the presence 
of microvesicular steatosis was significantly associated with greater than 1 tumour, although 
the presence of lipogranulomas and Mallory denk bodies trended towards statistical 
significance.   
In a binomial regression analyses considering associations with larger (≥5mm) versus smaller 
(<5mm) tumours, including factors such as body weight, liver weight and diet, only the 
presence of mallory denk bodies was significantly different (p=0.01). 
In these analyses, the mice were analysed as a cohort where the focus was on those variables 
altered by the diet in a mouse strain susceptible to obesity, impaired glucose tolerance and liver 
tumour development with age - rather than the diet itself (Table 3.5, C).  Notably, binomial 
regression analysis including diet and liver weight supported the importance of liver weight 
rather than the diet itself driving tumour development. Analysis including diet as a variable 
with liver to body weight ratio reached statistical significance (p=0.05).  
  
82 
 
 Hepatocyte DNA damage was increased in aged and ALIOS fed mice 
3.3.5.1 γ-H2AX immunohistochemical analysis 
To explore mechanistic biology in this model of NAFLD and tumour development, we assessed 
DNA damage in liver (FFPE) tissue sections, using immunohistochemical staining with anti-γ-
H2AX antibodies. There were more γ-H2AX positively stained nuclei in the livers of ALIOS 
fed mice compared to those fed control diet at 48 weeks. This measure of DNA damage was 
more prominent in the periportal zones of the liver, in which the fat accumulation was also more 
prominent - supporting a link between fat accumulation and DNA damage (Figure 3.9). 
 
Figure 3.9: DNA damage assessment in the 48-week-old mice. (A) γ-H2AX 
immunohistochemical staining of mouse liver tissue sections showing positively stained 
hepatocyte nuclei (arrows). (B) γ-H2AX detection by IHC in liver zones of 48-week-old mice, 
showed a higher number of positively stained nuclei in the ALIOS fed animals compared to the 
control animals; and this was clear in all the different zones of the liver with the highest 
expression in the periportal area (p<0.0001, t-test). Y axis values represent Mean ± SE of the 
mean. The p value was calculated by t-test.  Key: PT - portal tract; CV - central vein. 
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γ-H2AX assessed immunohistochemically in mice from earlier time points (24-week-old mice) 
revealed a much lower prevalence of DNA damaged hepatocytes, with no significant difference 
between the ALIOS diet (HF) and the control mice (Figure 3.10; A). Thus, hepatocyte DNA 
damage was increased in the 48-week-old mice, especially in the ALIOS fed animals (Figure 
3.10; B). 
 
Figure 3.10: γ-H2AX quantification in liver tissue sections from 24- and 48-week-old mice. 
(A) γ-H2AX IHC staining in 24-week-old mice in all the three liver zones. (B) γ-H2AX IHC 
staining in 48-week-old mice in all the three liver zones. (C) Comparison between 24- and 48-
week-old mice periportal γ-H2AX IHC staining. (D) Comparison between 24- and 48-week-
old mice average γ-H2AX IHC staining of all the three liver zones. Y axis values represent 
Mean ± SE of the mean. The p-value was determined by t-test. 
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3.3.5.2 DNA damage association with NAFLD 
Histological studies confirmed that DNA damage was closely associated with the progression 
of NAFLD (Figure 3.11 and Table 3.6).  Notably, the strongest DNA damage associations 
were not with lobular inflammation, portal inflammation or fibrosis, but rather with steatosis 
grade, the presence of lipogranulomas and liver weight.  Associations with the NAS and SAF 
scores were largely driven by the strong association with steatosis.   
 
Figure 3.11 : Association of DNA damage with the progression of NAFLD in the 48-week-
old mice. DNA damage was reflected and measured immunohistochemically by γ-H2AX 
positivity, which correlated significantly with the progression of NAFLD; as it showed 
significant association with steatosis (A), microvesicular steatosis (D), ballooning (C), and 
lipogranuloma (G). Y axis values represent Mean ± SE of the mean, and p values calculated by 
the Kruskal-Wallis test. 
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Overall, the DNA damage associations appeared to be with NAFLD progression and tumour 
formation, rather than tumour development per se. In a binomial regression considering absence 
or presence of a tumour, γ-H2AX percentage treated as a continuous variable was not 
significantly associated with tumour development in this model.  Considering γ-H2AX as a 
categorical variable with only two categories (above and below the median of 1.48% positive 
hepatocyte nuclei), significance was reached (p=0.037). However, in an analysis combined with 
liver weight, only liver weight was significantly associated with tumour development (γ-H2AX 
p=0.888; liver weight p=0.002, Exp (B) 20.17) 
Table 3.6: Association of γ-H2AX-positive hepatocyte nuclei. 
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 Hepatocyte proliferation was elevated in aged C3H/He mice  
The increase in liver weight in C3H/He aged mice may simply have been a result of fat 
accumulation in hepatocytes.  However, given the strong association between liver weight and 
tumour development, we explored proliferation in these murine livers. To measure this, Ki67 
(as a marker of proliferation detecting all phases of cell cycle) was assessed 
immunohistochemically, expressed as the percentage of positively stained hepatocyte nuclei. 
Counts were compared in periportal, intermediate and centrilobular zones, in mice culled at 
either 24- or 48-weeks of age, fed either control or ALIOS diets.   
The data are summarised in Figure 3.12. The first observation was that the percentage of 
proliferating hepatocytes more than doubled with age in the control mice, from an average of 
about 0.49% in 24-week-old mice, to 1.23% in 48-week-old mice.  The second observation was 
that the percentage of positive hepatocytes was significantly higher in ALIOS fed mice, at both 
time points.  In the younger mice with less severe NAFLD, there was no difference in the liver 
zone distribution. The most striking increase in the older mice was in the periportal zones of 
mice fed the ALIOS diet, indicating a relationship between the level of fat accumulation and 
associated changes in that zone (Figure 3.12).  An example is shown in Figure 3.13. 
 
Figure 3.12: Ki67 quantification in liver tissue sections of 24- and 48-week-old mice. (A) 
Ki67 IHC staining in 24-week-old mice in all the three liver zones. (B) Ki67 IHC staining in 
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48-week-old mice in all the three liver zones. (C) Comparison between 24- and 48-week-old 
mice periportal Ki67 IHC staining. (D) Comparison between 24- and 48-week-old mice average 
Ki67 IHC staining of all the three liver zones. Y axis values represent Mean ± SE of the mean. 
The p-value was determined by t-test. 
 
 
Figure 3.13: Ki67 expression in association with fat accumulation in the periportal zone 
of a 48-week-old mouse fed the ALIOS diet.  Ki67 assessment by immunohistochemical 
staining showed positively stained nuclei (arrows) around the portal tract. Key: PT - portal tract; 
CV - central vein.  
 
Several studies investigated the effect of lipid accumulation on liver regenerative capability 
(247). Some of which showed no effect of mild steatosis on liver regeneration (248, 249), while 
several others showed a decrease in liver regeneration in animal models of chronic steatosis 
(250-252). The mechanism by which steatosis impairs liver regeneration remains unclear (247). 
In our dietary animal we showed an interesting increase in proliferation of hepatocytes 
(reflected by Ki67 positively stained hepatocyte nuclei) in areas of lipid accumulation which 
contradicts these studies and the mechanism needs further exploration but it might be induced 
in part through activation of the Hedgehog signalling pathway in chronically injured hepatocyte 
in NAFLD that induces proliferation (113) (detailed explanation in chapter 7). 
The associations between Ki67 expression and other parameters was also explored. Ki67 
correlated highly significantly with body and liver weight, as well as with some of the 
histological features of progressive NAFLD – including steatosis, lobular inflammation and 
presence of lipogranulomas (Figure 3.14). Currently this data is limited by smaller numbers 
than the others (only 24 of 47 cases analysed). Of note, there was a highly significant association 
between Ki67 and γ-H2AX positive cells in the cases studied.  Despite smaller numbers, the 
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associations between Ki67 positive perpiportal hepatocyte nuclei and tumour development and 
progression, were much more striking than those with γ-H2AX (Table 3.7).  
 
Figure 3.14 : Correlation of Ki67 expression with the histological parameters of NAFLD. 
Ki67 expression assessed by immunohistochemistry correlated significantly with steatosis 
grade (A), lobular inflammation (B), microvesicular steatosis (D) and highly significant 
association with lipogranulomas (G) indicating more proliferation with advancing disease. Y 
axis values represent Mean ± SE of the mean, and p values were measured by Kruskal-Wallis 
test. 
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Table 3.7: Association of Ki67-positive hepatocyte nuclei 
 
  
90 
 
3.4 The p53 pathway in the ALIOS diet induced NAFLD and tumours 
The p53 tumour suppressor protein is often referred to as the ‘gatekeeper’ or “guardian” of the 
genome, as it is part of the normal DNA damage response.  It has a role in the suppression of 
proliferation and programmed cell death.  In NAFLD p53 upregulation has been previously 
reported and p53 is believed to play a role in the pathogenesis of the disease (see 1.4.2) (45, 
195). Given the evidence of an elevation in hepatocyte DNA damage, as well as an apparent 
proliferative state associated with age and enhanced by the ALIOS diet, we explored the 
expression of p53 and some of its key target genes in the liver tissues of these mice.  This was 
investigated for whole tissues at the RNA level, as well as for protein expression and 
distribution by immunohistochemistry. 
 Hepatic tissue p53 mRNA levels were elevated with age rather than with diet. 
In the C3H/He ALIOS diet model, the relative expression of Trp53 mRNA in whole liver tissues 
was significantly upregulated with advancing age (Control diet: p<0.001; ALIOS diet p<0.001, 
t-test, Figure 3.15). The elevations occurred in association with the rising liver weight and 
steatosis, which also occurred with age.  However, there was in fact no significant difference in 
Trp53 whole liver mRNA expression between the ALIOS and control fed groups at any age 
studied.   
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Figure 3.15: Quantification of mRNA levels for p53 pathway genes in whole liver tissue 
extracts from ALIOS dietary animal model mice. qRT-PCR assessment of the expression of 
Trp53 (A) and its downstream targets Mdm2 (B), Cdkn1a (p21) (C) and Gadd45a (D) in the 
dietary animal model in the four age groups (12,24,36, and 48 weeks). There was a significant 
difference in Trp53 and its downstream transcriptional targets expression with age (p<0.001) 
but not with the diet. No significant difference in Trp53 expression with diet at any age group 
(p= 0.43, 0.40, 0.40, 0.95) for the (12, 24, 36 and 48 weeks) age groups respectively. Gapdh 
was used as the house keeping reference gene and a 12-week-old control diet sample as the 
calibrator. Y axis values represent mean ± SEM. 
 
The upregulation of p53-downstream genes Mdm2, Cdkn1a (p21), and Gadd45a correlated 
significantly with rising Trp53 (Figure 3.15; Table 3.8), but again, this was predominantly 
with advancing age rather than with a specific dietary condition (Figure 3.15).  With the 
exception of an elevation of Cdkn1a (p21) mRNA in whole liver tissue of ALIOS fed mice at 
48 weeks of age (p=0.002), none of the studied genes showed a significant whole tissues mRNA 
change associated with diet either. 
Of note, the correlation between Trp53 and its target Cdkn1a (p21) was not as striking or 
significant as that observed with its transcriptionally regulated negative modulator Mdm2, or 
Gadd45.  The relationship between Trp53 mRNA and its targets was more closely assessed 
within the age and dietary categories.  The relationship between Trp53 and its negative 
regulator, Mdm2, persisted with age and different dietary groups.  A strong and significant 
relationship with Cdkn1a (p21) was present in young mice, up to 24 weeks, in both control and 
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ALIOS dietary groups.  At 48 weeks this association was less striking in control diet mice and 
was lost in ALIOS diet mice.  The relationship with Gadd45a was less robust and was only 
evident in larger groups, rather than appearing to be affected by age or diet. 
Table 3.8: Correlations between Trp53 mRNA and its downstream targets at the mRNA 
level.  
 
These data suggest that Trp53 post translational functional status is maintained throughout, as 
the relationship with Mdm2 is never lost.  However, the data also indicate that transcriptional 
regulation of other targets is either reliant on more than p53, or p53 transcriptional control is 
altered.  In the case of Cdkn1a (p21) transcriptional control, this appears to change in the livers 
of mice fed the ALIOS diet. 
Levels of hepatic Trp53 mRNA in the livers of mice at 48 weeks of age were explored in 
association with other liver related phenotypic changes (Table 3.9).  There was little of note, 
with a similar lack of associations between liver Mdm2 mRNA and liver associated features.   
In sharp contrast, there were significant positive associations between Cdkn1a (p21) mRNA 
and both the presence of γ-H2AX and Ki67 positive nuclei.  The average positive nuclei counts 
were considered for this association as they were most likely to associate with whole liver 
mRNA gene expression changes.  Notably, there were more striking and highly significant 
associations with liver phenotype - including with liver weight; steatosis grade, lobular 
inflammation and the presence of either lipogranuloma or perisinusoidal fibrosis. Furthermore, 
there were significant associations with tumour number and tumour size. 
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Table 3.9: Hepatic genes expression associations in 48-week-old mice (bivariate analyses).  
Benjamini–Hochberg procedure with a false discovery rate of 0.25 was used. 
 
In the 48 week mice livers we considered a role for an alternative Cdkn1a (p21) transcriptional 
regulator, the zinc finger tumour suppressor Klf6, which is reported to play a role in NAFLD 
progression (253). However, this was not associated (Spearman correlation 0.153; p=0.326).   
We explored Cdkn1a (p21) mRNA associations with a number of other genes. In all age groups 
of mice irrespective of diet, the strongest positive association was with Nudt1 expression – the 
gene that encodes Nudix hydrolase 1, or 7,8-dihydro-8-oxoguanine triphosphatase (Spearman 
correlation 0.613; p<0.001).  Misincorporation of oxidized nucleoside triphosphates into DNA 
and/or RNA during replication and transcription can cause mutations that may result in 
carcinogenesis. Nudt1 is an enzyme that hydrolyzes oxidized purine nucleoside triphosphates, 
to monophosphates, thereby preventing misincorporation.    
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A 48-week age specific negative association of Cdkn1a (p21) was noted with mRNA expression 
of poly ADP ribose polymerase 1 (Parp1) (Spearman correlation -0.345; p=0.018). Parp1 binds 
to single strand breaks in DNA and initiates repair. Of interest, this gene was negatively 
associated with increasing liver weight. 
While these changes in Cdkn1a (p21) mRNA indicate altered p53 transcriptional control in 
ageing obese mice, the associations with liver phenotypes and other genes are hard to interpret 
in isolation.  As expression of p21 protein is typically associated with growth suppression, 
positive associations with Ki67, liver weight and tumour formation are interesting but may be 
bystander changes associated with a key, as yet, unidentified mechanistic process, rather than 
ones that are functionally relevant.  For further interpretation, exploration at the protein level 
would be essential.  
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 Hepatocyte p53 protein increased with age, diet and NAFLD 
The protein level of an expressed gene does not necessarily reflect the RNA level and we went 
on to perform p53 immunohistochemistry on FFPE liver tissue sections. IHC also enables the 
study of expression more specifically in individual cell types, which whole tissue RNA studies 
do not.  
Considering first the relationship with age, there were quite marked differences in p53 IHC.  In 
the livers of mice at 24 weeks, p53 was hardly detectable – again with little difference between 
ALIOS versus control diet fed mice (Figure 3.16; A).  However, the number of p53 positive 
hepatocyte nuclei was significantly elevated in 48 week old mice, and was associated with the 
presence of γ-H2AX positive nuclei (Figure 3.16, B). 
 
Figure 3.16: p53 quantification in liver tissue section in 24- and 48-week-old mice. (A) p53 
IHC staining in 24-week-old mice in all the three liver zones. (B) p53 IHC staining in 48-week-
old mice in all the three liver zones. (C) Comparison between 24- and 48-week-old mice 
periportal p53 IHC staining. (D) Comparison between 24- and 48-week-old mice average p53 
IHC staining of all the three liver zones. Y axis values represent Mean ± SE of the mean. The 
p-value was determined by t-test. 
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These age-related changes in the frequency of p53 positive hepatocyte complemented the Trp53 
whole liver mRNA data, although there was no significant correlation between the two 
considering all cases and heterogeneous groups.  The numbers of cases within each group 
assessed by IHC was smaller than for RNA, but in the ALIOS fed 48-week animals, the 
association between the Trp53 mRNA and p53 protein trended towards significance (Spearman 
correlation 0.559; p=0.059, n=12) 
In contrast to the whole tissues RNA expression data, there were differences in p53 IHC staining 
between ALIOS diet versus control diet fed mice.  In fact, the level of p53 positive nuclei was 
elevated in all the liver zones of the ALIOS fed animals compared to the control group. The 
highest level of p53 positive nuclei was seen in the periportal area (Figure 3.17) which 
coincides with the areas of fat deposition and DNA damage reflected by the γ-H2AX positivity 
in this area. Thus, there was a spatial correlation between p53 and γ-H2AX positivity (Figure 
3.9). 
 
Figure 3.17: p53 expression in the dietary animal model. Assessment of p53 expression by 
immunohistochemical staining showing positively stained hepatocyte nuclei in the periportal 
area in conjunction of high levels of steatosis (arrows-picture). The graph (right) shows 
significantly higher level of p53 in the livers of ALIOS fed mice compared to the control diet 
and the highest level was detected in the periportal area of the liver in the ALIOS fed animals 
(p<0.0001, t-test, n=12 in each dietary group). Y axis values represent mean ± SEM. Key: PT 
- portal tract; CV - central vein. 
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 Hepatocyte p53 increased with liver weight and NAFLD progression 
The p53 levels showed an increase with features of NAFLD progression to NASH. Mean data 
are presented graphically in Figure 3.18, with Chi2 and bivariate associations on categorical 
and continuous datasets respectively shown in Table 3.10.   
 
Figure 3.18: The relationship of p53 expression with the histological parameters of 
NAFLD in 48-week-old mice. Expression of p53 assessed by immunohistochemistry showed 
a significant association with lobular inflammation (B), portal inflammation (E) microvesicular 
steatosis (D) fibrosis stage (I) and Mallory Denk bodies (F) and a very highly significant 
association with lipogranulomas (G). Y axis values represent Mean ± SE of the mean, and p 
values were calculated by the Kruskal Wallis test. 
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Table 3.10: Associations with immunohistochemistry %positive p53 hepatocytes. 
 
 
There were also significant associations with γ-H2AX positive hepatocytes. In combination, 
these data support an increase in p53 – possibly as a result of post-translational changes, given 
the lack of diet associated changes at an mRNA level - in response to injury. However, the 
growth and tumour suppressor functions of p53 were not evident, given significant positive 
associations with Ki67 positive proliferating hepatocytes and tumour development (Table 
3.10).  This suggest an additional layer of p53 dysfunction. 
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  p21 immunohistochemical analysis 
The level of p21 protein as a downstream target of p53 and a regulator of cell cycle was 
assessed. The percentage of p21 positively stained nuclei was higher in all liver zones in the 
ALIOS mice at 48 weeks compared to the control but the difference failed to reach statistical 
significance (Figure 3.19). The pattern of p21 positive nuclei increased in the livers of 48-
week-old mice fed the high fat diet with NAFLD was similar to that of p53, but again not 
significant (Figure 3.20).  
 
Figure 3.19 : p21 expression in dietary animal model. (A) 48-week-old control animal liver 
tissue section with very low expression of p21 and nearly all the hepatocyte nuclei in the section 
were negative. (B) 48-week-old ALIOS mouse liver tissue sections showing high number of 
p21 positive nuclei especially around the portal tract (Arrows). Power 20X. (C) P21 expression 
in liver zones in the dietary groups. (D) Periportal p21 expression in the ALIOS (HF) group 
compared to the control. Y axis values represent Mean ± SEM of the mean.  The p-value was 
calculated by t-test. Key: PT - portal tract; CV - central vein. 
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Figure 3.20 : p53 and p21 association with NAFLD histological parameters in the 48-week-
old mice. Immunohistochemical staining for p53 and p21 plotted against the histological 
parameters. The expression of p21 followed similar patterns as to p53, although the associations 
were not statistically significant. (Y axis values represent Mean ± SE of the mean). 
 
It was important to try to clarify the relationships of Trp53 mRNA and protein to those of p21 
detected by IHC.  As noted previously, the association between Trp53 mRNA and Cdkn1a 
(p21) mRNA was lost in ALIOS fed mice at 48 weeks and the relationship between Trp53 
mRNA and p53 protein was not robust.  However, a strong and significant association was 
evident between the % of p53 positive nuclei (average of all zones) and whole liver Cdkn1a 
(p21) mRNA (Pearson correlation 0.631; p=0.001, n=24 :12 control diet and 12 ALIOS diet 
mice at 48 weeks). This data suggests that when present, p53 protein upregulated Cdkn1a (p21) 
transcription appropriately. What was lacking was any correlation between Cdkn1a (p21) 
mRNA and p21 protein (Spearman correlation -0.062; p=0.773, n=24). 
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Generally, p21 protein was detected in very few hepatocytes by IHC. In 4 cases, it was 
undetectable and in an additional 13/24 cases it was present in <1% of hepatocyte nuclei.  In 7 
cases it was clearly detected in >1% of hepatocyte nuclei, with the highest % positivity being 
13%.  Associations were explored, as summarised in Table 3.11.  There appeared to be a 
positive association with the presence of γ-H2AX positive nuclei.  There were no clear 
associations with liver weight, NAFLD histopathology or presence, or numbers of liver 
tumours. 
 
Table 3.11: Association with % positive p21 hepatocyte nuclei 
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3.5 DNA damage and p53 in ALIOS diet induced hepatocarcinogenesis 
The mouse tumour tissues were graded histologically on H&E sections as previously described 
and the FFPE tissues were also available for additional immunohistochemistry to assess γ-
H2AX, Ki67 and p53.  As described in the methods, tissues for RNA extraction were saved for 
some of the larger tumours.  A small number of qRT-PCR analyses were performed on these 
tissues. Some of the tumours and those of a parallel experiment were saved for later RNA-Seq 
analysis, which has recently been performed. Analyses are ongoing and not a substantial aspect 
of this thesis. Some reference to these data will be included, largely in the context of 
interpretation of the p53 data.  
 DNA damage was markedly increased in HCC compared to background tissues  
γ-H2AX assessment in tumour sections showed variable levels of detection but it was 
significantly higher in the tumours compared to the peritumoural areas (p<0.001), supporting 
the presence of more DNA damage in the tumour cells than the normal hepatocytes (Figure 
3.21). 
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Figure 3.21: γ-H2AX expression in tumours in the dietary animal model. (A) Expression 
of γ-H2AX in liver tumours individually and in their normal peritumoural periportal area. (B) 
Highly significant difference (p<0.0001) between the mean percentage of γ-H2AX positive 
nuclei in tumours versus the mean value in normal peritumoural areas.  The p-value was 
calculated by Wilcoxon test. (C) Representative image of mouse liver tissue section from a HF 
fed 48-week-old mouse showing high number of γ-H2AX positively stained nuclei in the 
tumour (red circle) compared to the background liver.  
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 Proliferation was markedly increased in HCC compared to background tissues 
All of the tumours showed high levels of proliferation compared to the peritumoural area, 
reflected by the high percentage of Ki67 positive nuclei, which was significantly higher in the 
tumours than in the peritumoural area (p<0.001) (Figure 3.22). 
 
Figure 3.22 : Proliferative status in tumour samples in the dietary animal model. Different 
tumours showed different levels of expression of Ki67 as shown in (A), and the level of 
expression in the tumours was higher than the peritumoural areas (B). Values represent Mean 
± SE of the mean; p-value was determined by Wilcoxon test. (C) Representative image of 
mouse liver tissue section from a HF fed 48-week-old mouse showing high number of Ki67 
positively stained nuclei in the tumour (red circle) compared to the background liver.   
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 p53 and transcriptional target gene mRNA levels in tumour versus non-tumour 
regions of the liver 
In a small number (n=4) of the larger tumours, RNA was extracted and expression levels and 
associations of Trp53 and its target genes were explored by qRT-PCR. There was an increase 
in the Trp53 mRNA and that of its downstream transcriptional target genes, in tumours 
compared to non-tumour tissues. These changes included a 2.2 fold increase for Trp53, a 3.34 
fold increase in Mdm2 and 1.6 fold increase in Gadd45a. The most dramatic increase was that 
of Cdkn1a (p21), with a 22.27 fold higher level in the tumours (Figure 3.23).  
 
Figure 3.23: qRT-PCR analysis of Trp53 mRNA expression and that of its downstream 
transcriptional targets, in tumour versus non-tumour areas of the livers. 
 
RNASeq analyses were performed in 23 non-tumour and 8 tumour samples.  With a focus on 
p53 and p21 expression, similar changes were observed (Table 3.12).  Sequence analyses on 
RNAseq data confirmed that all tumours were p53 wild type, without any evidence of p53 
mutation.   
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Table 3.12: Fold change differences between tumours and non-tumour liver for mRNA 
expression of Trp53, its downstream transcriptional targets, together with alpha-
fetoprotein (Afp) and glypican-3 (Gpc3) in the dietary animal model (RNAseq data). 
 
 
 
 p53 and transcriptional target gene protein levels in tumour versus non-tumour 
liver 
Levels of p53 protein were assessed by IHC in 22 pairs of tumour versus non-tumour tissues.  
Staining for p53 was typically detected in less than 2-3 % of hepatocytes in non-tumour tissues. 
In about one third of cancers, p53 was either undetected or present at very low levels.  In the 
majority of the 22 tumours assessed (14/22; 64%) p53 was detectable. In 9/22 (41%) it was 
present in at least 5% of tumour cells, while in 4/22 (18%) it was present in over 7.5% of tumour 
cells. In one tumour, p53 expression was present in greater than 20% of nuclei (Figure 3.24).  
An increase in p53 is consistent with the observation of elevated DNA damage – as suggested 
by increased detection of γ-H2AX positive nuclei in the tumours.  However, this was not 
associated with a suppression of proliferation, which would suggest that the increased p53 was 
either insufficient or ineffective for suppressing proliferation and growth of the tumours.  To 
explore this further, p21 at the protein level was assessed in tumours using (IHC and western 
blot analysis).  
 
Gene name
Non-Tumours 
(Normalised 
log2 values)
Tumours 
(Normalised 
log2 values)
Difference 
between tumours 
and non-tumours
Fold difference 
between tumours 
and non-tumours
p value (t-test) Adjusted p value
Trp53 9.1 9.8 0.8 1.7 1.09*E-12 4.99*E-08
Cdkn1a 6.8 10.6 3.8 13.6 2*E-07 0.009
Mdm2 9.5 10.7 1.3 2.4 9.5*E-06 0.435
Gadd45a 8.0 8.1 -0.1 1.0 0.9 41213.7
Ppm1D 7.1 7.3 0.2 1.1 0.01 457.93
Afp 5.1 13.0 8.0 292.8 5.4*E-20 2.47*E-15
Gpc3 4.9 12.4 7.6 190.8 1.5*E-15 6.87*E-11
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Figure 3.24 : p53 expression by immunohistochemistry in HCCs. (A) Different tumours 
showed different levels of expression of p53 protein. The percentage of p53 positive nuclei was 
significantly higher in the tumours than the normal peritumoural areas (p=0.026). (B) Shows 
the mean percentage positivity values. The p-value was calculated by the Wilcoxon test. 
 
Despite the markedly elevated expression of Cdkn1a (p21) mRNA in the tumours analysed, the 
majority (82 %) had very low levels of p21 protein detectable by IHC. In 50 % of cases, the 
levels of p21 detected by IHC was higher than in non-tumour tissues, and modest increases 
were noted in a small number of the tumours large enough for protein extraction and western 
blot (Figure 3.27).  Overall, however, there was no significant difference between the 
percentage of p21 positive cells in the tumours and the peritumoural areas, for all the cases 
analysed by IHC (Figure 3.25).  Similar to the non-tumour tissues, there was no correlation 
between p53 and p21 protein detection (Figure 3.26, Table 3.11). Of the 10 tumours with 
>2.5% p53 positive nuclei, 7 had little or no detected expression of p21.   
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Figure 3.25: Immunohistochemical detection of p21 in HCCs.  (A) The individual cases 
showing percentage p21 positive nuclei in tumour versus its peritumoural counterpart. (B) 
Comparison of mean levels of p21 expression between tumours and the peritumoural areas, 
showing there was no significant difference; p-value was determined by Wilcoxon test.   
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Figure 3.26 : Dual expression of p53 and p21 in liver tumour samples. shows the variable 
levels of expression of p53 in liver tumour samples and in the same samples this was generally 
not reflected by concomitant expression of p21; despite the latter being a downstream target of 
p53 it was expressed in a very low percentage of cells even in the tumours that showed high 
percentage of p53 positive staining.  
 
 
Figure 3.27: Western blot of 48-week-old mice liver samples demonstrating increase in 
p21 protein levels in tumours compared to their peritumoural counterpart, in comparison 
to a control sample and a diethylnitrosamine (DEN) induced liver tumour sample. 
GAPDH was used as a loading control reference protein. The control was a mouse embryonic 
fibroblast cell line (NIH3T3) treated with an MDM2 inhibitor. 
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3.5.4.1 Tumour summary  
In all of the tumours analysed by RNASeq, Trp53 mRNA expression levels were elevated 
relative to non tumour tissues.  IHC analyses indicate that in up to one third, the elevated mRNA 
does not translate into increased levels of p53 protein positive tumour cells.  Irrespective of this, 
the vast majority of tumours appeared to have markedly elevated levels of Cdkn1a(p21) mRNA.  
However, the mRNA increase only occasionally translated into higher levels of p21 protein 
detection by IHC (Figure 3.25), although the Western blot analysis appeared to show a more 
consistent increase in p21 protein levels in the tumour samples compared with non-tumour liver 
(Figure 3.27).  In summary, these data suggest that a p53 DNA damage response was evident 
in the tumours, with increased p53 mRNA and protein expression in the majority of cases, 
together with increases in p53 transcriptional target gene mRNA, including dramatic elevations 
in Cdkn1a (p21), with some evidence of increased p21 protein detection by Western blot 
analysis of a limited sample of larger ALIOS tumours. However, these increases in p21 
expression were clearly unable or insufficient to prevent the proliferation of tumour cells and 
growth of the tumours.  
In addition to the γ-H2AX evidence of elevated DNA damage in the tumours, was the 
additionally notable evidence of high levels of Ki67 positive proliferating tumour cells. While 
the lack of an effective inhibition of proliferation despite the p53 response is likely to be a key 
factor, the specific driver of proliferation in the tumours remains to be established.  Preliminary 
analysis of the tumour RNASeq data indicated that 74% of tumours had acquired mutations in 
either Hras (59%) or Kras (15%) as one of the likely candidates involved (Table 3.13).    
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Table 3.13: RNA sequence analysis data showing Ras mutation details in the animal model 
tumours. 
 
 
  
Tumour ID VarID (chr:loc:ref:alt) Protein_
position
Gene 
_Symbol
Amino_acids Codons Reads     
AD
Reads     
DP
T3 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 111,27 138
T4 chr6:145234355:T:G 61 Kras Q/H caA/caC 61,42 103
T5 chr7:141192230:C:A 117 Hras K/N aaG/aaT 164,57 221
T7 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 115,56 171
T8 chr6:145234341:G:A 66 Kras A/V gCa/gTa 23,12 35
T9 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 84,66 150
T11 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 97,81 178
T12 chr7:141192550:T:A 61 Hras Q/L cAa/cTa 127,86 213
T13 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 87,66 153
T14 chr7:141192230:C:G 117 Hras K/N aaG/aaC 118,101 219
T15 chr7:141192550:T:A 61 Hras Q/L cAa/cTa 101,93 194
T16 chr7:141192550:T:C 61 Hras Q/R cAa/cGa 105,87 192
T17 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 79,70 149
T18 chr7:141192550:T:A 61 Hras Q/L cAa/cTa 96,74 170
T19 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 139,65 204
T20 chr7:141192550:T:A 61 Hras Q/L cAa/cTa 107,78 185
T21 chr6:145246772:C:G 12 Kras G/R Ggt/Cgt 29,17 46
T24 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 234,175 409
T26 chr7:141192551:G:T 61 Hras Q/K Caa/Aaa 100,69 169
T27 chr6:145234355:T:G 61 Kras Q/H caA/caC 57,50 107
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3.6 Discussion 
 The impact of ALIOS diet on C3H/He mice 
NAFLD has emerged in the last few years as a major global health challenge, particularly in 
more affluent developed countries. It is closely connected with obesity and type II diabetes (11, 
13). As these have increased, with obesity affecting nearly 25% of the global population, so has 
the incidence of NAFLD (16). NAFLD doesn’t spare race or age group. In many, simple 
steatosis persists without progression to more advanced disease.  If there is progression, it is 
usually a slow process that takes place over many years. Ultimately, however, it can progress 
to cirrhosis and promote the development of HCC (5).  
Due to the alarming increase in incidence of NAFLD in the population, understanding its 
pathogenesis and why the disease progresses in some but not in others, has become a priority 
in the field of liver disease research. In humans, due to the slow progression and long course of 
the disease, as well as the ethical obstacles associated with repeated liver biopsy, studying the 
temporal relationships with the disease is challenging.  The study of the disease in animal 
models which mimic what happens in human body, but over a shorter period of time, can aid 
the understanding of key mechanisms and also permit their manipulation to test causality. 
In our model we tried to recapitulate what happens in human disease, by exposing mice with a 
predisposition to developing obesity and impaired glucose tolerance to high fat and fructose 
containing diet, imitating the Western lifestyle diet represented by the high fat fast food and 
fructose-sweetened beverages. The goal was to define a relevant model and explore key 
demographic and histopathological features associated with NAFLD-HCC development, as 
well as to explore further the contribution of p53. 
The impact of the ALIOS diet on the liver was first explored by Tetri et al 2008 (254), with a 
similar diet assessed by Charlton et al 2011 (255).  Both groups of researchers showed that the 
diet resulted in a prominent gain of body and liver weight, with steatosis. Our data recapitulated 
these findings.  Our histological assessment confirmed a pattern of steatosis typical of animal 
models and  paediatric NAFLD (256), with distribution of more marked steatosis in the 
periportal (zone 1) hepatocytes, extending to zones 2 and 3 as the disease progressed.  In human 
adult NAFLD, more prominent steatosis is usually evident around the central vein (Zone 3), 
involving zones 2 and 1 as disease progresses.  The explanation for this difference is presently 
unknown (257).  
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The index study by Tetri et al, was relatively short term (16 weeks only) and while there was 
some evidence of ‘NASH’, there was little evidence of progression to portal inflammation or 
fibrosis. The Charlton et al model was accompanied by a higher degree of inflammation and 
ballooning degeneration.  The Newsome Group were the first to publish the effect of a more 
prolonged diet (12 months), describing a more progressive disease and the development of 
small 1-2 mm liver tumours (258). Ganz et al (259) have also reported a Male C57Bl/6 mouse 
model fed high fat high fructose diet for 49 weeks, in which 41% of their mice developed 
tumours, but these were histologically adenomas rather than HCCs. 
Our model takes these studies further by using a different mouse strain – the C3H/He strain – 
whose profile reflects that of humans, in that the mice develop obesity and impaired glucose 
tolerance with age.  These mice are also reported to develop 1-2mm liver tumours at 1 year of 
age. In our model, the introduction of the ALIOS diet exacerbated this phenotype, with liver 
tumours evident from 36 weeks of age. By 1 year, over 80% of the mice fed the ALIOs diet had 
tumours, many of which were over 5mm in size.  
Characterisation of the tumours histologically confirmed that two of the smaller tumours were 
adenomas, but the majority were HCC.  At a molecular level, a pilot study performed by our 
group prior to this one had confirmed marked increases in expression of the tumour markers 
AFP and Glypican-3 using RT-PCR (260). RNASeq data from the tumours characterised in this 
model confirmed very dramatic increases in expression of these marker genes. The histological 
phenotype was described as a steatohepatitic one – in keeping with the steatohepatitic-HCC 
(SH-HCC) phenotype that has been described more commonly in patients with HCC arising on 
the background of the metabolic syndrome (261). There is the possibility that these HCC arise 
from the malignant transformation of benign adenomas (262). The model created should enable 
us to define the malignant transformation process of these tumours in more detail.  Our major 
aim, however, was to create a model in which we could assess the environment promoting the 
development and progression of HCC on a background of NAFLD and the metabolic syndrome.  
Notably these mice do develop more tumours in association with progressive NAFLD, but none 
of the mice had advanced fibrosis compatible with cirrhosis.  While cirrhosis remains the key 
risk factor for development of HCC in chronic liver disease, the development in the absence of 
cirrhosis in individuals with the metabolic syndrome is increasingly reported (93, 263). Our 
model may facilitate the understanding of HCC development in the absence of cirrhosis in obese 
individuals.   
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 Predictors of HCC development – liver size and histology 
While hard to dissociate all of the inter-related features associated with HCC development, the 
tendency to develop HCC was already there, associated with age, and exacerbated by the 
ALIOS diet.  Combining the dietary groups of mice gave a range of phenotypic changes as seen 
in human individuals and enabled us to study histological and mechanistic associations with 
HCC development, number of HCC and HCC. While age and diet were clearly a risk factors 
for tumour development, binomial regression indicated that liver weight itself was particularly 
important.  Within the histopathological assessments which are related to each other, it appeared 
that steatosis grade was important.  While lobular inflammation was related to the development 
and progression of HCC size, it was notable that it was the presence of lipogranulomas that was 
the most consistent and highly significant histopathological feature associated with both HCC 
development and progression.   
Lipogranulomas can be histologically “defined as a space-occupying, compact collections of 
macrophages, including lipophages, surrounding a single or multiple fat droplets” (264), 
which are present in a number of different conditions including fatty liver disease 
(265). In addition to these histologically defined accumulations of macrophages – possibly 
recruited from the circulation (266), increases in pigmented Kupffer cells, which are resident 
macrophages, were also documented, but less consistently. Associations with elevations in 
macrophages have been  reported in other mouse models of liver disease (259, 267) and 
macrophages have been proposed by some as the real accomplice or determinant of NAFLD 
pathogenesis and progression (67, 268).   Activated macrophages produce different cytokines 
(e.g. IL-1β, IL-6 , IL-8 and TNF) that induce inflammation and fibrosis in the liver – both 
factors associated with the risk of development of HCC (269).  Macrophages are now known 
to exist in a continuous spectrum of phenotypes which can be either anti- or pro-tumour 
development, although they are usually referred to by the simplified nomenclature of M1 
(classically activated, anti-tumour) and M2 (alternatively activated, pro-tumour) macrophages 
(270). The transition between pro- and anti-tumour phenotypes is thought to be flexible, 
adapting to or dependent on signals from the local microenvironment, with profound effects on 
tumoural immunity via production of pro/anti-inflammatory mediators and expression of 
inhibitory molecules against T cells and NK cells (271).    
Our data raises the profile of lipogranulomas or macrophages as worthy of further 
characterisation in human NAFLD and HCC.  Although ‘lobular inflammation’ and ‘portal 
inflammation’ were less robustly associated with tumour development in our model, activated 
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CD8+ T lymphocytes and natural killer cells reportedly play important roles in NASH and HCC 
development in other models. Selective loss of chronic inflammatory cells such as CD4+ T 
lymphocytes induced by NAFLD through increased ROS production, or even recruitment and 
activation of acute inflammatory cells such as neutrophils may be key (110, 272, 273).  A role 
for the cytokine IL-17 has also recently been proposed as a critical link (274).  The contributions 
of these immune cells and regulatory cytokines in our own model will be worthy of further 
study, possibly with the opportunity to assess a regulatory component linked back to 
macrophages within lipogranulomas.  
 Predictors of HCC development – a focus on γ-H2AX and Ki67 
Wang et al 2009 (275) and several other researchers have previously shown an increase in the 
positive nuclear immunohistochemical staining for γ-H2AX in mouse liver tissue sections with 
advancing age, around central veins in particular rather than periportal areas. Our model showed 
similar results in aged mice on the control diet, although at the 48-week time point studied the 
increases in the percentage of positively stained nuclei were similar in all regions.  In the ALIOS 
fed mice, the percentage of positive nuclei was markedly increased, with the highest level of γ-
H2AX around the portal tracts – the areas with the highest degree of steatosis, linking fat 
accumulation to DNA damage. This is not the region of NASH associated ‘lobular 
inflammation’ and suggests that increased steatosis itself may be causally linked with DNA 
damage.  An excess of FFAs in hepatocytes can impair mitochondrial function and release of 
ROS, which can in turn cause DNA damage, potentially mediated and amplified through 
autocatalytic chain reactions of lipid peroxidation (276). Exploration of other markers of 
oxidative stress and damage related to oxidative stress were attempted (4HNE, PAR and 8-
oxoguanosine), but failed technically. The antibodies used were mouse monoclonal antibodies 
and non-specific binding to mouse liver tissues persisted despite the use of kits to block 
endogenous mouse IgG. Alternative rabbit polyclonal antibodies were also explored but their 
specificity was poor.   
An increase in hepatocyte p53 protein levels with progressive NAFLD in this model was in 
concordance with a previous report in high fat fed animals’ livers (259).  A positive correlation 
between the degree of steatosis and the level of p53 expression in human liver has also been 
documented (195), and an indirect role for p53 in the regulation of lipid metabolism via 
induction of miRNA34a and inhibition of SIRT1 has been proposed (21, 196).  Using γ-H2AX 
positive nuclei as a marker defining DNA damage, we have shown an association with a 
concomitant highly significant increase of p53 positive nuclei in periportal areas with fat 
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accumulation, in keeping with a DNA damage induced p53 response.  Of note, γ-H2AX positive 
nuclei and p53 were detected in the areas of highest fat accumulation, associated with the 
presence of lipogranulomata and not necessarily lobular or portal tract inflammation. In 
combination, the data suggests that increasing steatosis, presumably associated with elevated 
levels of FFA accumulation and oxidative stress associated DNA damage, were associated with 
stabilisation of p53 protein and elevated expression of its target gene Cdkn1a(p21) – in non- 
tumour liver. Why increased expression of this negative growth regulator nevertheless appeared 
to be associated with a proliferative response, as reflected by high Ki67 levels, was less clear.  
 Malignant transformation – a focus on γ-H2AX, Ki67, p53 and Ras  
Although elevations in the order of 2-5-fold of γ-H2AX, Ki-67 and p53 in non-tumour tissues 
were each associated with HCC development and progression, the changes comparing non-
tumour and tumour liver were much more dramatic.  Ki67 positive nuclei reached 15-20% in 
some tumours, with a mean value of 10% in the tumours studied. The percentage of γ-H2AX 
positive nuclei was also elevated in tumours, frequently in the order of 10-fold.  On this 
background, the p53 data needs careful consideration.  In the 22 HCC studied with IHC, p53 
(despite high levels at the RNA level) was either not detected or detected at low levels by IHC, 
in 8/22 (36%) of cases.  In these, p21 was absent or very low in 6 and present in 2-3% of nuclei 
in the other two.  However, markedly elevated levels of Cdkn1a(p21) mRNA in all the tumours 
regardless of p53 protein detected by IHC suggest either an intact relationship between p53 and 
Cdkn1a(p21) mRNA beyond the sensitivity of p53 detection by IHC, or other factors promoting 
transcriptional increases in Cdkn1a(p21).  Furthermore, whether p53 positive nuclei were 
present or not in tumours had little impact in general on p21 protein, which was barely detected 
in 7/10 (70%) of these cases.  Thus, irrespective of p53 expression or not, p21 protein was not 
detected. RNAseq analysis confirmed the wild type status of the Trp53 transcripts expressed in 
the tumours. These data suggest that the Trp53 sequence was normal, but that its downstream 
negative growth regulatory functions – in terms of induction of stable p21 and growth 
suppression - were ineffective. This may be in keeping with recent evidence that p21 is not an 
effector of the tumour suppressor properties of p53 (118).  
Although further analyses are ongoing, our preliminary assessment, including RNAseq data, 
suggest evasion of the inhibitory effects of p53 and p21 as a consequence of upregulated 
proliferative responses.  These were evident in non-tumour tissues in association with liver 
weight, steatosis and inflammation (largely macrophages), but in the tumours the exacerbated 
phenotype was associated with acquired Hras or Kras mutation in a majority (74%) of the 
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tumours. The reported incidence of Ras mutation in human HCCs is <10%, but the Ras/MAPK 
pathway is activated in 50-100% of cases (277-279).  This is in concordance with previous 
reports of acquired Ras mutations in aging obese C3H mice (277), suggesting this is a pro-
tumorigenic pathway of major importance in metabolic syndrome-associated cancer.  
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 The impact of interventions in the ALIOS C3H/He 
mouse model of NAFLD and HCC 
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4.1 Introduction 
Despite the tremendous increase in the rate of NAFLD, to date there is no approved 
pharmacological treatment. Several compounds are being explored in clinical trials and 
generally the hope is that prevention of the progression of NAFLD to cirrhosis will also 
diminish the risk of HCC (243, 280).  Treatments preventing the progression of NAFLD to 
cirrhosis would not necessarily prevent the development of HCC that arises in the absence of 
cirrhosis.  While the risk of HCC is very much higher in cirrhotic individuals, the prevalence 
of obesity and earlier stages of NAFLD is so high, that even the much smaller risk associated 
with these stages translates into a significant number of patients.  Reported evidence indicates 
that 20-50% of patients presenting with NAFLD-HCC develop it in the absence of cirrhosis 
(93, 263, 281) and the driving mechanisms are unclear.  Roles for NASH and inflammation 
associated damage are suspected.   
The model we developed was one associated with NAFLD progression to NASH and fibrosis 
but fell short of cirrhosis.  The data presented in chapter 3 supports a potential role for 
inflammation and NASH, but also raises the potential contribution of steatosis itself, liver 
weight and lipogranulomas – arising in a background of elevated proliferation in these obese 
C3H/He mice.  
In the hope of confirming HCC preventive strategies, we assessed two candidate interventions.  
Given the prevalence of DNA damage and its proposed role in the development of HCC, we 
firstly explored the role of Bucillamine, a drug with anti-oxidant properties that has been safely 
used for the treatment of rheumatoid arthritis in Japan for many years. Secondly, we studied the 
impact of a bile acid like drug, PX20606, which is a ligand and agonist for the Farsenoid X 
receptor (FXR). FXR promotes the conversion of cholesterol to bile acids in the liver and its 
excretion in bile, but also regulates lipid metabolism.  Details and doses of the bucillamine and 
FXR agonist used are summarised in Table 4.1. 
Table 4.1: design of the interventions used in the dietary animal model. 
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4.2 Aims of the study in this chapter 
• Explore the impact of antioxidant (Bucillamine) on NAFLD, NAFLD stage and HCC 
development. 
• Explore the impact of FXR agonist (PX20606) on NAFLD, NAFLD stage and HCC 
development.  
• Explore the impact of the interventions on hepatocyte DNA damage and proliferation. 
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4.3 The impact of bucillamine on the dietary animal model  
 Background 
Bucillamine is an oral drug with an antioxidant activity and has been used as a first line 
treatment for Rheumatoid arthritis (RA) in Asia (Japan) (282, 283) for a number of years.  It is 
also being assessed now in phase II clinical trials for the treatment of gout (284, 285), as well 
as for cysteinuria. Bucillamine (N-(2-mercapto-2-methylpropionyl)-L-cysteine) (Figure 4.1) is 
a cysteine derived compound and can pass into the cell rapidly via pathways involving the 
metabolism of the amino acid cysteine. These include the biosynthesis of glutathione (GSH). 
Intracellular reduced GSH acts as a major defence against oxidative stress, as it can be 
converted into the oxidised form GSSG and water by glutathione peroxidase, in the presence 
of free radicals and hydrogen peroxide (286-289).  Bucillamine possesses two thiol groups that 
can be donated to replenish GSH. Bucillamine metabolites also have antioxidant activity 
through a single thiol group. Additionally, bucillamine may have an immunomodifying effect 
through inhibition of interleukin-6 (287, 290). 
 
Figure 4.1: Chemical structure of bucillamine(287). 
 
To explore the effect of bucillamine in our dietary animal model, it was mixed into food pellets 
to deliver an estimated dose of 10 mg/kg/day.  The dose was estimated according to the average 
daily food intake of the animals.  A control group (n=11) and an ALIOS diet (High Fat High 
Fructose (HF)) group (n=11) were supplemented with bucillamine from the age of 24 weeks 
until 48 weeks, prior to cull as described in methods section 2.2. 
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 The impact of bucillamine on body and liver weight 
In the presence of bucillamine, the increase in body weight induced by the ALIOS (HF) diet 
was less marked. In this smaller group of animals (n=11 per group), the difference failed to 
reach statistical significance. The effect of the ALIOS diet on liver weight persisted, however, 
with a highly significant increase in either absence or presence of bucillamine (Figure 4.2; A 
and B).  
 
Figure 4.2: The effect of bucillamine on body and liver weight compared to the effect of 
ALIOS diet. The p value was determined by one-way ANOVA with multiple comparison 
correction (A=<0.001, B=<0.001). There was no significant effect of bucillamine on neither the 
body weight (A) nor the liver weight (B) compared to the diet alone groups.  
123 
 
 The effect of bucillamine on the lipid profile and liver function 
Bucillamine did not affect the levels of total serum cholesterol (Figure 4.3; A) but a quite 
marked and significant decrease in the serum triglyceride levels in the bucillamine treated 
ALIOS (HF) group was noted (Figure 4.3; B). Liver enzymes also showed some effects, with 
modest increases in alanine aminotransferase (ALT) in both of the bucillamine treated groups, 
and an overall increase in aspartate aminotransferase (AST) in the bucillamine treated control 
diet group. Alkaline phosphatase (ALP) levels, which were increased by the ALIOS diet, were 
further significantly increased in both dietary groups in the presence of bucillamine (Figure 
4.3; E). 
 
Figure 4.3: The effect of bucillamine on lipid profile and liver enzymes. Lipid profile 
represented by total cholesterol (A) and triglycerides (B). Liver enzymes tested were ALT-
Alanine aminotransferase (C), AST-Aspartate aminotransferase (D) and ALP-Alkaline 
phosphatase (E). ns=not significant. Y axis values represent Mean ± SE of the mean. The p 
value was determined by one-way ANOVA with multiple comparison correction (A=0.94, 
B=0.019, C=0.39, D=0.025, E=<0.001).  
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 The effect of bucillamine on NAFLD histopathology 
The impact of bucillamine on NAFLD histopathology is summarised in Table 4.2 with 
categorical data sets and Chi2 tests. The trends are also demonstrated graphically in Figure 4.4. 
There was a significant reduction of steatosis grade in the control diet group, although this was 
not evident in the ALIOS. The most remarkable effect of bucillamine on the histological 
parameters was the disappearance of hepatocellular ballooning and Mallory Denk bodies in 
both the control and the ALIOS groups respectively compared to diet alone groups.  There was 
also a reduction in pigmented Kupffer cells in both bucillamine treated groups. Low level 
lobular inflammation was modestly increased in the bucillamine control diet group, but there 
was no impact on the higher starting baseline in the bucillamine ALIOS fed group. Fibrosis as 
a less subjective and more permanent biomarker of severity was also impacted and reduced by 
bucillamine.  Consequent to these changes in the component parts, both the NAS and SAF 
combination scoring systems confirmed marked and highly significant reductions in the 
presence of bucillamine (Figure 4.5). Notably, there was little impact of bucillamine on 
lipogranulomas, megamitochondria, or portal inflammation. 
 
Figure 4.4: Effect of bucillamine on the histological parameters of NAFLD. Bucillamine 
significantly reduced steatosis (A), ballooning (C) and fibrosis (I) in the control group and 
reduced ballooning (C), Mallory Denk bodies (F) and fibrosis stage (I) in the ALIOS (HF) 
group. It caused increase in the lobular inflammation (B) in the control group. Y axis values 
represent Mean ± SE of the mean; the p value was determined by one-way ANOVA with 
multiple comparison correction. 
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Figure 4.5: the effect of bucillamine on the histological scoring systems. Bucillamine 
reduced NAS score (A) (p=0.026, 0.087) and SAF score (B) (p=0.025, 0.001) in both the control 
and high fat groups. Y axis values represent individual values + the median; the p value was 
determined by one-way ANOVA with multiple comparison correction (A=<0.001, B <0.001). 
 
 
 
Table 4.2: The impact of bucillamine on the histological parameters. 
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 Quantification of DNA damage in the bucillamine treated group 
Bucillamine treatment resulted in a highly significant reduction in the percentage of γ-H2AX 
positive nuclei (DNA damage), in both the bucillamine control and ALIOS (HF) groups 
(p<0.0001) supporting the hypothesis that the DNA damage resulted from oxidative free radical 
processes (Figure 4.6). Although markedly reduced in number, significant correlations between 
γ-H2AX positive nuclei and liver weight (p<0.0001), steatosis (p<0.0001), lipogranuloma 
(p<0.0001), lobular inflammation (p=0.008) and the histological scoring NAS (p<0.0001) and 
SAF (p<0.0001) persisted (Table 4.3). 
 
 
Figure 4.6: γ-H2AX immunohistochemical staining of the periportal area in the diet alone 
and the bucillamine treated groups. Y axis values represent Mean ± SE of the mean. The p 
value was determined by one-way ANOVA with multiple comparison correction (p=<0.001). 
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Table 4.3: Associations of γ-H2AX immunohistochemical staining of the periportal area 
with the phenotypic parameters, liver histopathology and tumours in bucillamine treated 
groups. 
 
  
<0.36% ≥0.36%  P value correlation p value
Body weight (Continuous variable) 0.517 0.014
Liver weight (Continuous variable) 0.7 <0.001
Visceral Adipose Tissue 0.537 0.012
Steatosis grade (0/1/2/3) 7/4/0/0 1/2/6/2 0.003 0.79 <0.001
Microvesicular Steatosis grade (0/1) 11/0 9/2 0.138 0.22 0.31
Hepatocellular ballooning score (0/1/2) 11/0/0 11/0/0 - - -
Mallory Denk bodies (None/present) 11/0 11/0 - - -
Megamitochondria (None/present) 11/0 9/2 0.138 0.224 0.31
Lipogranuloma (None/present) 8/3 1/10 0.002 0.685 <0.001
Lobular Inflammation score (0/1/2) 1/10/0/0 0/6/4/1 0.06 0.547 0.008
Portal Inflammation score (0/1/2) 9/2/0 8/1/2 0.58 0.189 0.4
Pigmented Kupffer cells (None/present) 11/0 8/3 0.062 0.324 0.14
Apoptotic cells (None/present) 10/1 9/2 0.534 0.094 0.67
Perisinusoidal fibrosis score(0/1) 8/2 5/5 0.16 0.309 0.18
Periportal fibrosis score (0/1/2) 10/0 7/3 0.06 0.389 0.09
Fibrosis stage (0/1/2/3) 8/2/0 5/2/3 0.277 0.357 0.12
NAS score (˂3, ≥3) 11/0 1/10 <0.001 0.842 <0.001
SAF activity (<2 either LI or B/>2 both LI & B) 11/0 11/0 - 0.748 <0.001
Tumour (absent/present) 5/6 3/8 0.375 0.253 0.255
Tumour number (continuous) 0.298 0.178
Tumour Number (1/ >1; n=14) 2/4 2/6 0.733 0.309 0.162
Tumour size (continuous) 0.253 0.256
Tumour size (<5mm/≥5mm); n=14 4/2 5/3 0.872 0.259 0.244
Tumour grade (1/2/3/4) 0/5/0/0 1/1/2/0 0.045 0.12 0.759
Gross Phenotype Parameters
Histopathology Parameters
Tumour development, progression and grade
γ-H2AX (% positive hepatocyte nuclei)(periportal)
Chi2 Spearman rho
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 Proliferative status in the bucillamine treated group 
In contrast to the bucillamine associated reduction in γ-H2AX-positive hepatocyte nuclei, there 
was no significant effect of bucillamine treatment on the number of Ki67-positive hepatocyte 
nuclei detected by IHC in either control or ALIOS (HF) diet bucillamine treated animals 
(Figure 4.7).  The numbers of Ki67-positive nuclei, reflecting levels of proliferation, remained 
highly significantly associated with steatosis (p<0.0001), presence of lipogranuloma 
(p<0.0001), lobular inflammation (p=0.037), and γ-H2AX-positive nuclei (p<0.0001) (Table 
4.4).  
 
Figure 4.7: Ki67 immunohistochemical staining of the periportal area in the diet alone 
and the bucillamine treated groups. Y axis values represent Mean ± SE of the mean. The p 
value was determined by one-way ANOVA with multiple comparison correction (p=<0.001). 
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Table 4.4: Associations of Ki67 immunohistochemical staining of the periportal area with 
the phenotypic parameters, liver histopathology and γ-H2AX in bucillamine treated 
groups. 
 
  
<2.015% ≥2.015%  P value correlation p value
Body weight (Continuous variable) 0.446 0.037
Liver weight (Continuous variable) 0.787 <0.001
Visceral Adipose Tissue 0.540 0.012
Steatosis grade (0/1/2/3) 7/4/0/0 1/2/6/2 0.002 0.731 <0.001
Microvesicular Steatosis grade (0/1) 11/0 9/2 0.138 0.274 0.21
Hepatocellular ballooning score (0/1/2) 11/0/0 11/0/0 - - -
Mallory Denk bodies (None/present) 11/0 11/0 - - -
Megamitochondria (None/present) 11/0 9/2 0.138 0.274 0.21
Lipogranuloma (None/present) 8/3 1/10 0.002 0.722 <0.001
Lobular Inflammation score (0/1/2) 0/11/0/0 1/5/4/1 0.013 0.447 0.037
Portal Inflammation score (0/1/2) 10/1/0 7/2/2 0.375 0.154 0.493
Pigmented Kupffer cells (None/present) 11/0 8/3 0.062 0.178 0.429
Apoptotic cells (None/present) 10/1 9/2 0.534 0.031 0.89
Perisinusoidal fibrosis score(0/1) 7/3 6/4 0.639 0.173 0.466
Periportal fibrosis score (0/1/2) 10/0 7/3 0.06 0.231 0.328
Fibrosis stage (0/1/2/3) 7/3/0 6/1/3 0.19 0.203 0.391
NAS score (˂3, ≥3) 11/0 1/10 <0.001 0.82 <0.001
SAF activity (<2 either LI or B/>2 both LI & B) 11/0 11/0 - 0.677 0.001
Tumour (absent/present) 6/5 2/9 0.076 0.231 0.301
Tumour number (continuous) 0.327 0.138
Tumour Number (1/ >1; n=14) 2/3 2/7 0.480 0.315 0.154
Tumour size (continuous) 0.325 0.140
Tumour size (<5mm/≥5mm); n=14 4/1 5/4 0.360 0.350 0.111
Tumour grade (1/2/3/4) 0/4/0/0 1/2/2/0 0.286 0.558 0.119
γ-H2AX % positive (above/below median) 10/1 1/10 <0.001 0.781 <0.001
Gross Phenotype Parameters
Histopathology Parameters
Tumour development, progression and grade
Immunohistochemical markers
Ki67 (% positive hepatocyte nuclei)(periportal)
Chi2 Spearman rho
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 Association of bucillamine with HCC 
Notably, despite the abrogation of NASH and dramatic reductions in DNA damage assessed by 
γ-H2AX positive nuclei, there was no reduction in either the development of tumours, numbers 
of tumours or size of tumours in the bucillamine treated animals (Figure 4.8; A and B). In the 
bucillamine groups alone, numbers were relatively small (n=22) and correlations between 
tumour development, tumour number or tumour size, with either physical parameters or 
histological features, were not significant (Table 4.5 and Table 4.6). 
 
 
Figure 4.8: The effect of bucillamine treatment on tumour development in the murine 
dietary animal model. Y axis values represent Mean ± SE of the mean. The p value was 
determined by one-way ANOVA with multiple comparison correction (A=0.001, B=<0.001). 
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Table 4.5: Effect of bucillamine on HCC development in C3H/He mice. 
 
Table 4.6: Effect of bucillamine on tumour size in C3H/He mice. 
 
No Yes Correlation p value
Body weight 0.335 0.127
Liver weight 0.277 0212
Liver/body weight ratio 0.268 0.228
Visceral adipose tissue weight 0.138 0.551
Steatosis grade (0/1/2/3) 4/4/4/0 4/4/4/2 0.619 0.249 0.263
Microvesicular Steatosis grade (0/1) 8/0 12/2 0.262 0.239 0.284
Hepatocellular ballooning score (B)(0/1/2) 8/0/0 14/0/0 - - -
Mallory Denk bodies (None/present) 8/0 14/0 - - -
Megamitochondria (None/present) 8/0 12/2 0.262 0.239 0.284
Lipogranuloma (None/present) 5/3 4/10 0.119 0.332 0.131
Lobular Inflammation score (LI) (0/1/2/3) 0/7/1/0 1/9/3/1 0.847 0.114 0.612
Portal Inflammation score (0/1/2) 8/0/0 9/3/2 0.233 0.407 0.06
Pigmented Kupffer cells (None/present) 8/0 11/3 0.159 0.3 0.174
Apoptotic cells (None/present) 7/1 12/2 0.907 0.025 0.912
Perisinusoidal fibrosis score(0/1) 5/2 8/5 0.658 0.099 0.678
Periportal fibrosis score (0/1/2) 7/0/0 10/3/0 0.168 0.308 0.186
Fibrosis stage (0/1/2/3) 5/2/0/0 8/2/3/0 0.524 0.161 0.497
NAS score (sum) 0.221 0.324
NAS score (<3/≥3) 3/2 6/8 0.145 0.311 0.16
SAF score (sum) 0.183 0.415
SAF activity (<2 either LI or B/>2 both LI & B) 8/0 14/0 - - -
Histological Parameters
Tumour
Chi 2
Spearman rho
Gross Phenotype Parameters
<5mm ≥5mm
n=9 n=5
Body weight -0.204 0.485
Liver weight 0.337 0.239
Liver/body weight ratio 0.611 0.02
Visceral adipose tissue weight -0.149 0.628
Steatosis grade (0/1/2/3) 3/2/2/2 1/2/2/0 0.705 -0.038 0.897
Microvesicular Steatosis grade (0/1) 7/2 5/0 0.255 -0.304 0.290
Hepatocellular ballooning score (0/1/2) 9/0/0 5/0/0 - - -
Mallory Denk bodies (None/present) 9/0 5/0 - - -
Megamitochondria (None/present) 7/2 5/0 0.255 -0.304 0.290
Lipogranuloma (None/present) 3/6 1/4 0.597 0.141 0.630
Lobular Inflammation score (0/1/2/3) 0/7/1/1 1/2/2/0 0.44 -0.022 0.941
Portal Inflammation score (0/1/2) 6/1/2 3/2/0 0.316 -0.022 0.941
Pigmented Kupffer cells (None/present) 6/3 5/0 0.145 -0.389 0.169
Apoptotic cells (None/present) 7/2 5/0 0.255 -0.304 0.290
Perisinusoidal fibrosis score(0/1) 5/3 3/2 0.928 0.025 0.935
Periportal fibrosis score (0/1/2) 6/2/0 4/1/0 0.835 -0.058 0.851
Fibrosis stage (0/1/2/3) 5/1/2/0 3/1/1/0 0.928 0.001 1
NAS score (sum) 0.075 0.798
NAS score (<3/≥3) 4/5 2/3 0.872 0.293 0.186
SAF score (sum) -0.056 0.848
SAF activity (<2 either LI or B/>2 both LI & B) 9/0 5/0 - - -
Tumour
Chi 2
Spearman rho
correlation p value
Gross Phenotype Parameters
Histopathology Parameters
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There was no significant difference between the histological grade of the tumours in the 
bucillamine-treated animals compared to no bucillamine and the majority (6/9) were grade 2 
hepatocellular carcinomas. 
 
 Quantification of p53 in the bucillamine treated group 
Bucillamine treatment resulted in a significant reduction in the percentages of p53 IHC stained 
nuclei in the bucillamine ALIOS group compared to the diet alone ALIOS group (p<0.001) 
(Figure 4.9). As before, p53 IHC positive nuclei correlated significantly with the number of 
tumours (p=0.001), size of tumours (p<0.0001), steatosis grade (p=0.019), lipogranuloma 
(p=0.003) and the histological scoring systems NAS (p=0.008) and SAF (p=0.043), in addition 
to the correlation with γ-H2AX (p=0.004) and Ki67 (p=0.005) (Table 4.7). 
 
 
Figure 4.9: p53 immunohistochemical staining of the periportal area in the diet alone and 
the bucillamine treated groups. Y axis values represent Mean ± SE of the mean. The p value 
was determined by one-way ANOVA with multiple comparison correction (p=<0.001). 
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Table 4.7: Associations of p53 immunohistochemical staining of the periportal area with 
the phenotypic parameters, liver histopathology, tumours and immunohistochemical 
markers in the bucillamine treated groups. 
 
  
<0.6% ≥0.6% P value correlation P value
Body weight (Continuous variable) 0.573 0.005
Liver weight (Continuous variable) 0.672 0.001
Visceral Adipose Tissue 0.270 0.273
Steatosis grade (0/1/2/3) 6/2/1/2 2/4/5/0 0.08 0.494 0.019
Microvesicular Steatosis grade (0/1) 10/1 10/1 1 0.224 0.315
Hepatocellular ballooning score (0/1/2) 11/0/0 11/0/0 - - -
Mallory Denk bodies (None/present) 11/0 11/0 - - -
Megamitochondria (None/present) 10/1 10/1 1 0.224 0.315
Lipogranuloma (None/present) 7/4 2/9 0.03 0.598 0.003
Lobular Inflammation score (0/1/2/3) 1/9/0/1 0/7/4/0 0.09 0.386 0.076
Portal Inflammation score (0/1/2) 8/1/2 9/2/0 0.58 0.077 0.733
Pigmented Kupffer cells (None/present) 9/2 10/1 0.534 0.063 0.782
Apoptotic cells (None/present) 8/3 11/0 0.062 -0.261 0.24
Perisinusoidal fibrosis score(0/1) 6/4 7/3 0.639 0.009 0.97
Periportal fibrosis score (0/1/2) 8/2 9/1 0.531 0.14 0.54
Fibrosis stage (0/1/2/3) 6/2/2 7/2/1 0.81 0.045 0.851
NAS score (˂3, ≥3) 8/3 4/7 0.087 0.59 0.008
SAF activity (<2 either LI or B/>2 both LI & B) 11/0 11/0 - 0.436 0.043
γ-H2AX IHC periportal (median) 7/4 4/7 0.201 0.480 0.024
γ-H2AX IHC periportal (continuous) 0.588 0.004
Ki67 IHC periportal (median) 7/4 4/7 0.201 0.523 0.012
Ki67 IHC periportal  (continuous) 0.573 0.005
Tumour (no,yes) 7/4 1/10 0.008 0.701 <0.001
Tumour number (continuous) 0.659   0.001
Tumour Number (1/ >1; n=14) 1/3 3/7 0.852 0.666   0.001
Tumour size (continuous) 0.693 <0.001
Tumour size (5mm/ ≥5mm); n=14 3/1 6/4 0.597 0.716 <0.001
Tumour grade (1/2/3/4) 1/2/0/0 0/4/2/0 0.405 0.697   0.037
Tumour development, progression and grade
p53 IHC (% positive hepatocyte nuclei)(periportal)
Chi2 Spearman rho
Gross Phenotype Parameters
Histopathology Parameters
Immunohistochemical markers
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4.4 The impact of FXR agonist PX20606 on the dietary animal model  
 Background 
FXR is a type II nuclear receptor that is a member of a subfamily of 7 nuclear receptor families 
(291). It is expressed in several organs like the liver, intestine, kidney, adipose tissue and 
muscle. It controls bile acid synthesis and plays a role in carbohydrate and lipid metabolism, 
and insulin sensitivity (292, 293). 
The type II nuclear receptors usually bind to ligands, that are lipophilic and can pass through 
the nuclear pores, derived from either endogenous nutrients (e.g. fatty acids (FAs), bile acids 
(BA), oxysterols) or from exogenous chemicals. These nuclear receptors bind to and form a 
heterodimer with the Retinoid X receptor (RXR) to perform its function as a transcriptional 
factor (291).  
Bile acid (which acts as FXR ligand) is synthesized and secreted by the hepatocytes and then 
stored in the gall bladder to be released into the intestine after meals, aiding the emulsification 
and absorption of fat (293). Most secreted bile acids are re-absorbed from the bowel (terminal 
ileum) (~ 95%) into the portal circulation, returning to the liver in what is called the 
enterohepatic circulation (294) (Figure 4.10).  
According to the “energy vector” concept proposed by Evans and Mangelsdorf (291), lipolysis 
of triacylglycerol (TAG) in white adipose tissue (WAT) during fasting results in the release of 
fatty acids (FAs) into the circulation for use as an energy source by different tissues. When FAs 
reach the liver, they activate PPARα and stimulate FA catabolism. In the fed state, FXR acts as 
a BA regulator and BAs activate FXR receptors in the intestine, where they promote nutrient 
absorption and stimulate FGF19 production. In the fed state, liver FXR stimulates TAG-
lipoprotein clearance (292) and represses cholesterol 7α hydroxylase (CYP7A1), the rate 
limiting step of BA synthesis, via two routes – namely the upregulation of small heterodimer 
partner (SHP) that inhibits CYP7A1 (294), and through the upregulation of FGF19 – that also 
inhibits CYP7A1. Cholesterol reverse transport is also activated through FXR-upregulated 
FGF19, aiding the depletion of excess cholesterol (Figure 4.10). FGF19 also stimulates 
glycogenesis in the liver and excess nutrients are consumed by the muscles or stored in WAT 
under the effect of PPARβ/δ and PPARα respectively (295). In addition to its effect on 
inhibition of bile acid synthesis, regulation of lipid metabolism, FXR also reportedly regulates 
intestinal inflammation, inhibits bacterial translocation into the liver, and influences liver 
proliferation and its regenerative capability (293, 296) (Figure 4.10). 
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Figure 4.10: Schematic representation of FXR function. 
 
It has been proposed that hepatic steatosis may be attenuated by FXR activation in rodents and 
humans. In an animal model, hepatic steatosis was more evident in Fxr-null mice fed a high-fat 
diet compared to WT mice (297). Hepatic levels of FXR are reportedly low in NAFLD patients 
(298). 
Several FXR agonist compounds have been developed, the first reaching clinical trials being 
obeticholic acid (OCA), originating from the University of Perugia and GSK scientists in 2002 
(299). Several other FXR agonists have followed, one of which is the compound used in our 
project (PX20606), developed by Phenex pharmaceuticals. PX20606 was reported to have a 
higher liver exposure and more FXR transcriptional activity compared to OCA (300, 301) . Its 
chemical structure is shown in (Figure 4.11).  
This compound was mixed with the food pellets and given to the mice in the dietary model with 
an estimated daily dose of 1mg /kg/day (n=12,12 mice) or 5 mg/kg/day (n=8,8 mice) from the 
age of 24 weeks until 48 weeks. Doses were estimated based on average daily food consumption 
per cage.  
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Figure 4.11: chemical structure of PX20606 FXR agonist(300). 
 
 The effect of PX20606 on body and liver weight 
P20606 treatment did not show any effect on the body weight in the ALIOS (High Fat High 
Fructose (HF)) fed animals (Figure 4.12; A). Liver weight on the other hand showed marked 
and highly significant changes.  In the control diet animals, liver weight increased stepwise with 
1 mg and 5 mg PX20606 doses (Figure 4.12; B). In ALIOS fed mice – compared to a higher 
starting baseline there were significant increases in both PX20606 dose groups, although a 
plateau was reached without further increase between doses (Figure 4.12, B). 
 
Figure 4.12: The effect of PX20606 on body and liver weight compared to the effect of 
ALIOS diet. (A) Shows no significant effect of both 1mg and 5 mg PX20606 on the body 
weight neither in the control nor in the HF fed groups. (B) There was a highly significant 
increase in liver weight in both PX20606 treated control groups compared to the control group 
in diet alone, with significant increase in the liver weight in PX20606 treated ALIOS (HF) 
groups compared to the diet alone HF group. All groups are 48-week-old. Y axis values 
represent Mean ± SE of the mean. The p value was determined by one-way ANOVA with 
multiple comparison correction (A<0.001, B<0.001). 
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 The effect of PX20606 on lipid profile and liver function 
PX20606 reduced cholesterol levels in both dietary groups at the higher 5mg dose but it was 
not statistically significant (Figure 4.13; A). There was also a marked reduction in triglyceride 
level in the 5 mg dose treated ALIOS (HF) group but was not statistically significant (Figure 
4.13; B). 
Rather than reductions, there were some increases in liver enzymes in the PX20606 treated 
animals, often more so in the control groups where the baseline untreated level was lower. In 
the animals receiving 1mg PX20606, the ALP was raised in the ALIOS (HF) group (Figure 
4.13; E).  Aminotransferases and ALP levels were increased in both control and ALIOS groups 
in the mice receiving 5mg PX20606 (Figure 4.13; C, D and E).  
 
Figure 4.13: The effect of PX20606 on lipid profile and liver enzymes. Lipid profile 
represented by total cholesterol (A) and triglycerides (B). Liver enzymes are ALT-Alanine 
aminotransferase (C), AST-Aspartate aminotransferase (D) and ALP-Alkaline phosphatase (E). 
Y axis values represent Mean ± SE of the mean. ns = not significant, p value was determined 
by one-way ANOVA with multiple comparison correction (A=0.25, B=0.18, C<0.001, 
D=0.023, E<0.001).  
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 Histological assessment of the impact of PX20606 
Despite some relatively encouraging improvements in cholesterol and triglyceride levels, the 
PX20606 treatment did not improve histological parameters. In some instances histological 
parameters were worsened – particularly in the control diet group.  The trends are shown in 
Figure 4.14, with categorical datasets and Chi2 tests in (Table 4.8, Table 4.9).  Although some 
of the changes in these relatively small groups of mice were not particularly marked, and there 
were not increases in inflammatory scores, there was a significant and more convincing 
stepwise dose associated increase in fibrosis stage, in both control and ALIOS (HF) diet mice.   
 
Figure 4.14: Effect of PX20606 on the histological parameters of NAFLD. PX20606 did 
not improve the steatosis grade in the ALIOS treated group; however, it had a clear effect on 
the control groups showing a significant increase in the steatosis grade with the dose (p=0.028, 
0.026 respectively). Ballooning was also increased with PX20606 dose in the control groups 
(p=0.84, 0.032 respectively). PX20606 had a clear effect on worsening of fibrosis stage whether 
in the control (p=0.008, 0.098) or ALIOS treated group (0.073, 0.013). It caused increased 
portal inflammation in the 1mg PX20606 treated control group (p=0.025) but not in the 5mg 
PX20606 treated control group (p=1). Y axis values represent Mean ± SE of the mean; p-value 
was determined by one-way ANOVA with multiple comparison correction.  
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Figure 4.15: The effect of PX20606 on the histological scoring system. Y axis values 
represent Mean ± SE of the mean; p-value was determined by one-way ANOVA with multiple 
comparison correction (A<0.001, B<0.001). 
 
 
 
Table 4.8: The impact of PX20606 on the histological parameters in the control treated 
groups (Chi2).  
 
Diet alone C 1mg PX20606 C p value 5mg PX20606 C p value
Steatosis grade (0/1/2/3) 4/10/9/0 0/6/0/6 <0.0001 0/2/3/3 0.019
Microvesicular Steatosis grade (0/1) 23/0 12/0 - 7/1 0.085
Hepatocellular ballooning score (0/1/2) 8/11/4 4/1/7 0.024 0/3/5 0.035
Mallory Denk bodies (None/present) 17/5 4/8 0.012 3/5 0.041
Megamitochondria (None/present) 19/3 8/4 0.175 5/3 0.148
Lipogranuloma (None/present) 21/1 12/0 0.453 6/2 0.099
Lobular Inflammation score (0/1/2/3) 12/11 3/8/1 0.143 1/7 0.05
Portal Inflammation score (0/1/2) 21/2 6/3/3 0.005 6/2 0.236
Pigmented Kupffer cells (None/present) 15/7 4/8 0.051 2/6 0.035
Apoptotic cells (None/present) 19/3 7/5 0.066 4/4 0.037
Perisinusoidal fibrosis score(0/1) 7/16 0/10 0.049 0/8 0.076
Periportal fibrosis score (0/1/2) 17/6 1/9 0.001 4/4 0.213
Fibrosis stage (0/1/2/3) 7/10/6/0 0/1/9/0 0.002 0/4/2/2 0.046
NAS score (˂3, ≥3) 12/11 1/11 0.011 0/8 0.009
SAF activity (<2 either LI or B/>2 both LI & B) 15/8 6/6 0.383 1/7 0.01
Histological parameters PX206096 control groups compared to control diet group
Chi 2
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Table 4.9: The impact of PX20606 on the histological parameters in the ALIOS (HF) 
treated groups (Chi2). 
 
  
Diet alone HF 1mg PX20606 HF p value 5mg PX20606 HF p value
Steatosis grade (0/1/2/3) 1/19/4/0 0/11/1/0 0.762 1/4/2/0 0.418
Microvesicular Steatosis grade (0/1) 16/8 6/6 0.334 7/0 0.076
Hepatocellular ballooning score (0/1/2) 1/21/2 0/7/5 0.046 0/6/1 0.78
Mallory Denk bodies (None/present) 10/14 2/10 0.134 0/7 0.038
Megamitochondria (None/present) 14/10 5/7 0.345 6/1 0.183
Lipogranuloma (None/present) 3/21 5/7 0.047 2/5 0.309
Lobular Inflammation score (0/1/2/3) 1/17/6/0 1/10/1/0 0.446 1/5/1 0.784
Portal Inflammation score (0/1/2) 18/4/2 10/2/0 0.839 4/2/1 0.816
Pigmented Kupffer cells (None/present) 9/15 3/9 0.453 0/7 0.054
Apoptotic cells (None/present) 18/6 11/1 0.234 3/4 0.109
Perisinusoidal fibrosis score(0/1) 0/24 0/12 - 0/7 -
Periportal fibrosis score (0/1/2) 12/11/1 3/9/0 0.261 0/6/1 0.08
Fibrosis stage (0/1/2/3) 0/12/11/1 3/3/6/0 0.006 0/3/4 0.002
NAS score (˂3, ≥3) 0/24 0/12 - 0/7 -
SAF activity (<2 either LI or B/>2 both LI & B) 2/22 1/11 1 1/6 0.639
Histological parameters PX20606 HF groups compared to HF diet group
Chi 2
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 Quantification of hepatocyte DNA damage in PX20606 treated animals 
DNA damage quantification was assessed by measuring the percentage of γ-H2AX positive 
nuclei in the periportal area. There was no statistically significant effect of PX20606 on γ-
H2AX levels in the treated animals (Figure 4.16).  As previously, γ-H2AX staining correlated 
significantly with lipogranuloma (0.017), fibrosis (0.006) and SAF score (0.005) (Table 4.10), 
supporting the association of DNA damage with worsening of NAFLD stage. 
 
 
Figure 4.16: γ-H2AX immunohistochemical staining of the periportal area in the diet 
alone and the PX20606 treated groups. Y axis values represent Mean ± SE of the mean. The 
p value was determined by one-way ANOVA with multiple comparison correction.  
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Table 4.10: Associations of γ-H2AX immunohistochemical staining of the periportal area 
with the phenotypic parameters, liver histopathology and tumours in PX20606 treated 
groups. 
  
  
<1.48% ≥1.48%  P value correlation p value
Body weight (Continuous variable) 0.606 <0.001
Liver weight (Continuous variable) 0.469 0.003
Visceral Adipose Tissue 0.493 0.001
Steatosis grade (0/1/2/3) 0/7/6/6 0/2/12/6 0.101 0.164 0.32
Microvesicular Steatosis grade (0/1) 17/2 15/5 0.239 0.255 0.117
Hepatocellular ballooning score (0/1/2) 4/6/9 0/11/9 0.073 0.088 0.595
Mallory Denk bodies (None/present) 8/11 1/19 0.006 0.265 0.103
Megamitochondria (None/present) 13/6 11/9 0.389 0.201 0.219
Lipogranuloma (None/present) 15/4 10/10 0.06 0.38 0.017
Lobular Inflammation score (0/1/2) 4/14/1 2/16/2 0.643 0.212 0.195
Portal Inflammation score (0/1/2) 11/6/2 15/3/2 0.495 -0.081 0.626
Pigmented Kupffer cells (None/present) 7/12 2/18 0.047 0.411 0.009
Apoptotic cells (None/present) 13/6 12/8 0.584 -0.052 0.752
Perisinusoidal fibrosis score(0/1) 0/18 0/19 _ _ _
Periportal fibrosis score (0/1/2) 5/13/0 3/15/1 0.569 0.198 0.239
Fibrosis stage (0/1/2/3) 0/5/11/2 0/3/6/10 0.035 0.442 0.006
NAS score (˂3, ≥3) 1/18 0/20 0.299 0.289 0.066
SAF activity (<2 either LI or B/>2 both LI & B) 7/12 2/18 0.047 0.445 0.005
Tumour (absent/present) 10/9 4/16 0.034 0.242 0.137
Tumour number (continuous) 0.222 0.175
Tumour Number (1/ >1; n=25) 2/7 5/11 0.629 0.175 0.286
Tumour size (continuous) 0.288 0.076
Tumour size (<5mm/≥5mm); n=25 3/6 6/10 0.835 0.173 0.292
Tumour grade (1/2/3/4) 1/2/2/0 1/9/1/0 0.282 -0.216 0.422
Histopathology Parameters
Tumour development, progression and grade
γ-H2AX (% positive hepatocyte nuclei)(periportal)
Chi
2 Spearman rho
Gross Phenotype Parameters
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 Proliferative status in PX20606 treated animals 
In the control diet mice supplemented with PX20606, there was a dose dependent increase in 
proliferation as measured by Ki67 IHC in periportal areas.  In the ALIOS (HF) mice, where the 
level was already elevated, there was no additional effect of PX20606 treatment on proliferation 
levels (Figure 4.17).  As reported in chapter 3, Ki67 correlated significantly with steatosis 
(p=0.002), fibrosis stage (p=0.007), NAS score (0.026), SAF score (0.006) and γ-H2AX (p< 
0.0001) (Table 4.11). 
 
Figure 4.17: Ki67 immunohistochemical staining of the periportal area in the diet alone 
and the PX20606 treated groups. Y axis values represent Mean ± SE of the mean. The p value 
was determined by one-way ANOVA with multiple comparison correction. 
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Table 4.11: Associations of Ki67 immunohistochemical staining of the periportal area 
with the phenotypic parameters, liver histopathology, tumours and γ-H2AX in PX20606 
treated groups. 
  
  
<2.92% ≥2.92%  P value correlation p value
Body weight (Continuous variable) 0.649 <0.001
Liver weight (Continuous variable) 0.595 <0.001
Visceral Adipose Tissue 0.363 0.023
Steatosis grade (0/1/2/3) 0/8/7/4 0/1/11/8 0.028 0.475 0.002
Microvesicular Steatosis grade (0/1) 18/1 14/6 0.044 0.413 0.009
Hepatocellular ballooning score (0/1/2) 2/7/10 2/10/8 0.811 -0.122 0.459
Mallory Denk bodies (None/present) 5/14 4/16 0.64 0.084 0.612
Megamitochondria (None/present) 14/5 10/10 0.129 0.094 0.571
Lipogranuloma (None/present) 14/5 11/9 0.224 0.216 0.186
Lobular Inflammation score (0/1/2) 3/15/1 3/15/2 0.857 0.154 0.351
Portal Inflammation score (0/1/2) 13/4/2 13/5/2 0.958 0.039 0.813
Pigmented Kupffer cells (None/present) 7/12 2/18 0.047 0.346 0.031
Apoptotic cells (None/present) 12/7 13/7 0.905 -0.017 0.92
Perisinusoidal fibrosis score(0/1) 0/18 0/19 - - -
Periportal fibrosis score (0/1/2) 5/13/0 3/15/1 0.569 0.242 0.149
Fibrosis stage (0/1/2/3) 5/10/3 3/7/9 0.142 0.435 0.007
NAS score (˂3, ≥3) 0/19 1/19 0.323 0.356 0.026
SAF activity (<2 either LI or B/>2 both LI & B) 4/15 5/15 0.77 0.436 0.006
Tumour (absent/present) 6/13 8/12 0.584 0.009 0.954
Tumour number (continuous) -0.126 0.444
Tumour Number (1/ >1;n=25) 2/11 5/7 0.144 -0.118 0.476
Tumour size (continuous) 0.018 0.917
Tumour size (<5mm/≥5mm); n=25 5/8 4/8 0.790 0.067 0.684
Tumour grade (1/2/3/4) 1/6/2/0 1/5/1/0 0.915 0.169 0.531
γ-H2AX % positive (above/below median) 15/4 4/16 <0.001 0.649 <0.001
Gross Phenotype Parameters
Histopathology Parameters
Tumour development, progression and grade
Immunohistochemical markers
Ki67 (% positive hepatocyte nuclei)(periportal)
Chi2 Spearman rho
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 The impact of PX20606 on HCC in C3H/He mice 
PX20606 treatment did not reduce tumour development, tumour number or tumour size.  On 
the contrary, PX20606 treatment in the control diet group was associated with an increase in 
both the numbers and size of tumours (Figure 4.18). 
 
Figure 4.18: The effect of PX20606 treatment on tumour development in the murine 
dietary animal model. (A) PX20606 treatment did not decrease the number of tumours in the 
HF group but there was a significant increase in the number of tumours in the 5 mg PX20606 
treated group compared to the control group of diet alone. (B) There was a significant increase 
in the size of tumours in the 5 mg PX20606 treated control compared to the diet alone control 
group. Y axis values represent Mean ± SE of the mean. The p value was determined by one-
way ANOVA with multiple comparison correction. 
 
As in the standard model without intervention, steatosis and lipogranuloma remained strongly 
associated with tumour development and size (Table 3.2, Table 3.4). In the PX20606 treated 
animals, there were also associations with hepatocellular ballooning (p= 0.017) and Mallory 
Denk bodies (0.028) (Table 4.12).   
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Table 4.12: Effect of PX20606 on tumour development in C3H/He mice 
  
Table 4.13: Effect of PX20606 on HCC size in C3H/He mice 
  
No Yes Correlation p value
Body weight 0.116 0.477
Liver weight 0.410 0.009
Liver/body weight ratio 0.472 0.002
Visceral adipose tissue weight 0.337 0.033
Steatosis grade (0/1/2/3) 0/3/3/8 0/6/15/4 0.019 -0.299 0.064
Microvesicular Steatosis grade (0/1) 12/2 20/5 0.656 -0.071 0.666
Hepatocellular ballooning score (B)(0/1/2) 4/4/6 0/13/12 0.017 0.184 0.263
Mallory Denk bodies (None/present) 6/8 3/22 0.028 0.351 0.028
Megamitochondria (None/present) 9/5 15/10 0.792 0.042 0.798
Lipogranuloma (None/present) 13/1 12,13 0.005 0.449 0.004
Lobular Inflammation score (LI) (0/1/2) 3/11/0 3/19/3 0.442 0.213 0.193
Portal Inflammation score (0/1/2) 8/4/2 18/5/2 0.679 -0.154 0.348
Pigmented Kupffer cells (None/present) 2/12 7/18 0.33 -0.156 0.343
Apoptotic cells (None/present) 11/3 14/11 0.159 0.226 0.167
Perisinusoidal fibrosis score(0/1) 0/12 0/25 - - -
Periportal fibrosis score (0/1/2) 2/10/0 6/18/1 0.792 -0.043 0.798
Fibrosis stage (0/1/2/3) 0/2/7/3 0/6/10/9 0.656 0.032 0.850
NAS score (sum) 0.040 0.809
NAS score (<3/≥3) 1/13 0/25 0.167 0.217 0.185
SAF score (sum) 0.139 0.399
SAF activity (<2 either LI or B/>2 both LI & B) 6/8 3/22 0.028 0.351 0.028
Tumour
Chi 2
Spearman rho
Gross Phenotype Parameters
Histological Parameters
<5mm ≥5mm
n=9 n=16
Body weight 0.016 0.939
Liver weight 0.508 0.008
Liver/body weight ratio 0.654 <0.001
Visceral adipose tissue weight 0.069 0.739
Steatosis grade (0/1/2/3) 0/4/3/2 0,2,12,2 0.149 0.185 0.377
Microvesicular Steatosis grade (0/1) 8/1 12/4 0.405 0.167 0.426
Hepatocellular ballooning score (0/1/2) 0/4/5 0/9/7 0.571 -0.113 0.589
Mallory Denk bodies (None/present) 1/8 2/14 0.918 -0.021 0.922
Megamitochondria (None/present) 5/4 10/6 0.734 -0.068 0.747
Lipogranuloma (None/present) 5/4 7/9 0.571 0.113 0.589
Lobular Inflammation score (0/1/2) 1/6/2 2/13/1 0.773 -0.17 0.416
Portal Inflammation score (0/1/2) 5/2/2 13/3/0 0.177 -0.316 0.124
Pigmented Kupffer cells (None/present) 4/5 3/13 0.170 0.275 0.184
Apoptotic cells (None/present) 5/4 9/7 0.973 -0.007 0.975
Perisinusoidal fibrosis score(0/1) 0/9 0/16 - - -
Periportal fibrosis score (0/1/2) 2/6/1 4/12/0 0.589 -0.118 0.574
Fibrosis stage (0/1/2/3) 2/5/2 4/5/7 0.505 0.13 0.537
NAS score (sum) 0.055 0.794
NAS score (<3/≥3) 0/9 0/16 - - -
SAF score (sum) 0.108 0.609
SAF activity (<2 either LI or B/>2 both LI & B) 1/8 2/14 0.918 -0.021 0.922
Gross Phenotype Parameters
Tumour
Chi 2
Spearman rho
correlation p value
Histopathology Parameters
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 Quantification of hepatic p53 in the PX20606 treated animals 
The expression of p53 was assessed by IHC in the periportal areas. In the control diet animals, 
there was an increase in p53 positive nuclei, in keeping with a similar pattern of increased DNA 
damage (γ-H2AX).  In the mice fed the ALIOS diet, where baseline ‘untreated’ levels of p53 
were much higher, PX20606 treatment significantly reduced the percentage of p53 positive 
nuclei (Figure 4.19).  Hepatocyte % p53 positive nuclei did not correlate with any of the 
histological parameters nor with the other immunohistochemical markers (Table 4.14). 
 
Figure 4.19: p53 immunohistochemical staining of the periportal area in the diet alone 
and the PX20606 treated groups. Y axis values represent Mean ± SE of the mean. The p value 
was determined by one-way ANOVA with multiple comparison correction. 
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Table 4.14: Associations of p53 immunohistochemical staining of the periportal area with 
the phenotypic parameters, liver histopathology, tumours and immunohistochemical 
markers in PX20606 treated groups. 
 
  
<0.73% ≥0.73% P value correlation P value
Body weight (Continuous variable) -0.128 0.438
Liver weight (Continuous variable) 0.065 0.693
Visceral Adipose Tissue 0.004 0.980
Steatosis grade (0/1/2/3) 4/8/7 5/10/5 0.767 0.008 0.692
Microvesicular Steatosis grade (0/1) 15/4 17/3 0.622 -0.166 0.312
Hepatocellular ballooning score (0/1/2) 4/7/8 0/10/10 0.127 0.012 0.943
Mallory Denk bodies (None/present) 7/12 2/18 0.047 0.103 0.534
Megamitochondria (None/present) 13/6 11/9 0.389 0.014 0.932
Lipogranuloma (None/present) 13/6 12/8 0.584 -0.038 0.818
Lobular Inflammation score (0/1/2/3) 2/16/1 4/14/2 0.640 -0.202 0.218
Portal Inflammation score (0/1/2) 11/5/3 15/4/1 0.436 -0.178 0.28
Pigmented Kupffer cells (None/present) 4/15 5/15 0.770 0.005 0.974
Apoptotic cells (None/present) 14/5 11/9 0.224 0.142 0.387
Perisinusoidal fibrosis score(0/1) 0/17 0/20 _ _ _
Periportal fibrosis score (0/1/2) 3/14/0 5/14/1 0.835 -0.072 0.673
Fibrosis stage (0/1/2/3) 0/3/7/7 0/5/10/5 0.695 -0.187 0.268
NAS score (˂3, ≥3) 0/19 1/19 0.323 -0.173 0.292
SAF activity (<2 either LI or B/>2 both LI & B) 5/14 4/16 0.64 -0.13 0.431
γ-H2AX IHC periportal (median) 10/9 9/11 0.634 0.027 0.869
γ-H2AX IHC periportal (continuous) -0.089 0.589
Ki67 IHC periportal (median) 10/9 9/11 0.634 0.046 0.783
Ki67 IHC periportal  (continuous) -0.047 0.775
Tumour (no,yes) 9/10 5/15 0.146 0.133 0.420
Tumour number (continuous) 0.120 0.468
Tumour Number (1/ >1; n=25) 4/6 3/12 0.275 0.169 0.304
Tumour size (continuous) 0.139 0.406
Tumour size (<5mm/ ≥5mm) n=25 4/6 5/10 0.365 0.121 0.462
Tumour grade (1/2/3/4) 1/5/1/0 1/6/2/0 0.915 -0.059 0.827
Gross Phenotype Parameters
Histopathology Parameters
Immunohistochemical markers
Tumour development, progression and grade
p53 IHC (% positive hepatocyte nuclei) (periportal)
Chi2 Spearman rho
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4.5 Discussion  
NAFLD and NAFLD derived HCC incidence is increasing around the world and a number of 
studies have and are being performed in an attempt to identify treatments that prevents the 
progression of NAFLD to NASH and fibrosis (280). The optimum treatment for NAFLD would 
be to lose weight and be less sedentary. However, the change in dietary habits and lifestyle 
around the world which have contributed to the increased prevalence of obesity are hard to 
change, with difficulty in compliance to lose weight and maintain weight loss.  With major 
interest from the pharmaceutical industry, several compounds have been explored as treatments 
for NASH in phase II and III clinical trials (280). Our principal focus was to create a relevant 
pre-clinical animal model in which we could assess the impact of candidate therapies on 
NAFLD progression, but also on the development of HCC – albeit in a non-cirrhotic setting.   
Inflammation and oxidative stress are both thought to be important in NAFLD progression.  
Vitamin E targets this axis, but its benefits were marginal in the clinical trial setting and its role 
limited because of its potential side effects. These include elevated cardiovascular risk as well 
as possibly an increased risk of developing other malignancies (prostatic cancer) (79, 280, 302, 
303).  
Bucillamine is a drug with antioxidant activity, with some immune modulating activity (289, 
290), that is already used in clinical practice - for the treatment of rheumatoid arthritis in Japan.  
It is well tolerated and the side effects are already known (pruritus, mucocutaneous lesions and 
gastrointestinal symptoms) (287). Bucillamine is reported to have strong iron and copper 
chelating activity, which might partly explain its success in treating rheumatoid arthritis – where 
serum and synovial levels of iron and copper are reportedly high and contribute to tissue 
damage (288).  
For these reasons – its modes of action and its safety - we selected it as an intervention to study 
in our model of NAFLD progression and HCC development. In chapter 3 data was presented 
showing that steatosis and NASH, associated with a significant increase in the DNA damage 
reflected by the increased γ-H2AX, were significantly correlated with HCC development.  We 
hypothesised that bucillamine would inhibit oxidative stress-induced DNA damage, improve 
NASH, and prevent progression of fibrosis and the development of HCC. 
In this chapter we have shown that bucillamine succeeded in improving the histological status 
of NAFLD in the treated animals – abolishing the cardinal feature of ‘NASH’, which is 
hepatocellular ballooning, as well as the presence of Mallory Denk bodies – which are also a 
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feature of steatohepatitis. Bucillamine also dramatically reduced both the % of hepatic nuclei 
positive for γ-H2AX and for p53, in keeping with it reducing DNA damage.  These effects were 
consistent with previous reports of bucillamine effects in cardiovascular disease models (287).  
Also highly encouraging was that it significantly reduced liver fibrosis. Consequently both of 
the combination NAFLD scoring systems – the NAS and SAF scores – were significantly 
reduced by bucillamine treatment. These pre-clinical animal model data support bucillamine as 
a candidate treatment for NAFLD that would improve NASH and delay the development and 
progression of fibrosis.  
Despite this remarkable effect, bucillamine did not succeed in preventing or reducing either the 
number or size of tumours in the treated mice. Notably, even though DNA damage was reduced, 
bucillamine treatment did not diminish lobular or portal inflammation.  Neither did it impact 
the key features that were associated with HCC development – namely liver weight, grade of 
steatosis, the presence of lipogranulomas and hepatocyte proliferation. These data challenge the 
belief that it is inflammation-induced DNA damage that drives HCC development (273).   DNA 
damage after bucillamine treatment was still evident, but at very low levels.  An alternative 
hypothesis would be that steatosis related hepatocyte injury and a lipogranuloma centred 
inflammatory response creates a proliferative environment that encourages cancer 
development, even in the presence of minimal DNA damage. Further study of this model may 
provide new insight into the mechanisms underlying HCC development in NAFLD patients 
without cirrhosis. It also suggests that bucillamine – and possibly other antioxidants – would 
have little impact on the development of NAFLD related cancer in the absence of cirrhosis. 
 
The other intervention studied was the FXR agonist, PX20606. The FXR bile acid axis is being 
explored as a NASH treatment strategy. Several FXR agonists are currently being assessed in 
clinical trials for NASH (82, 280).  The FLINT study was a multicentre phase IIb clinical trial, 
in which treatment with obeticholic acid was seen to improve NASH (steatosis, lobular 
inflammation, fibrosis) scored histologically and this agent is now being assessed in a phase III 
clinical trial (82). 
PX20606 is reportedly a more potent FXR agonist than obeticholic acid. In our study PX20606 
was associated with an increase in the body weight of control animals, and increases in liver 
weight of both control and high fat fed animals.  These observations were consistent with 
previous reports of increase in body weight (304) and therefore not unexpected in our PX20606 
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treated mice.  Furthermore, there were encouraging reductions in serum triglycerides levels. 
Thereafter the data were not encouraging.   There were some elevations in transaminases and 
ALP, suggesting damage to hepatocytes and biliary cells respectively.  At a histological level, 
there was no improvement in any of the NAFLD criteria that were improved in human NAFLD 
in the FLINT study.  On the contrary, there were increases in steatosis and inflammation.  While 
numbers were small and some of these data were not consistent in control and ALIOS fed 
animals, there were also dose dependent increases in fibrosis stage, in both dietary groups, 
treated with PX20606. FXR is present in stellate cells in the liver and despite the previous 
studies that showed improvement of fibrosis after FXR activation (305), in our model activation 
of FXR was associated with cellular damage and increased fibrosis.  The reasons for this are 
unknown, but given the contrary effects seen with other FXR agonists this should not 
necessarily be assumed to be a ‘class effect’.  Dosing in our animals was also uncertain, as 
PX20606 was administered in the diet rather than by gavage.  It may be that the therapeutic 
window was small and liver injury was associated with overdose.  Although the causes are 
uncertain, 19 deaths associated with incorrect dosing of obeticholic acid as a treatment for 
primary biliary cirrhosis (5mg per day rather than building up to a maximum does of 10mg 
twice weekly) have recently been reported in the USA 
(https://www.fda.gov/Drugs/DrugSafety/ucm576656.htm). 
In regard to FXR and tumour development, our data were also disappointing.  Previous studies 
have reported that Fxr-null mice developed spontaneous HCC by 12-16 months of age (306, 
307). The hypothesis was that an FXR agonist would reduce cancer development. While there 
was no impact of PX20606 in the mice on the ALIOS diet, who nevertheless had greater 
numbers and size of tumours compared to controls, the PX20606 treated control animals 
actually developed more cancers. This effect in the control diet animals was also dose 
dependent and associated with some of the markers of increased injury, as well as being 
associated with increases in liver weight and proliferation, key features shown in Chapter 3 to 
be important indicators for the development of HCC in this dietary model.  
Collectively, these data suggest that FXR agonists should be used cautiously in patients with 
NAFLD.  PX20606 treatment not only worsened NASH, it also promoted cancer development 
in those animals with less severe disease.   
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In conclusion, while our interventional studies failed to prevent the development of HCC in our 
model, they have contributed to our mechanistic understanding.  Furthermore, bucillamine may 
be worthy of exploration as a treatment to delay NAFLD progression to NASH and fibrosis. 
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 MDM2 inhibition for non-genotoxic activation of TP53 
– a novel strategy for the treatment of liver cancer 
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5.1 Introduction 
Hepatocellular carcinoma (HCC) is the 6th commonest cancer, and the second leading cause of 
cancer death worldwide (84).  The cancer typically presents at an advanced stage when there 
are few therapeutic options (308). Coexistent chronic liver disease is present in the majority of 
patients and consequent to a combination of tumour resistance and liver dysfunction, cytotoxic 
therapies have a very limited role. The multikinase inhibitor sorafenib can prolong survival in 
carefully selected individuals, but only by a median of ten weeks (308, 309). Consequently the 
overall 5 year survival is less than 15% (310).  There is a need to identify drivers of HCC 
progression which can be targeted safely in the liver microenvironment. 
The TP53 tumour suppressor gene, dubbed ‘the guardian of the genome’, is frequently 
inactivated in a wide range of common sporadic cancers. In its normal function it is a 
transcription factor that plays an important role in the cellular response to injury or DNA 
damage, regulating a host of downstream transcriptional targets that lead to cell cycle arrest and 
suppression of growth, facilitating repair or inducing apoptosis. TP53 is one of the most 
commonly altered genes in HCC, mutated in about a third of cases according to The Cancer 
Genome Atlas (TCGA – accessed July 2017 (311, 312)).  TP53 mutation is often associated 
with aflatoxin B exposure and chronic viral infection with hepatitis-B (HBV) and hepatitis-C 
(HCV) (311, 312).  The prevalence in the growing numbers of elderly patients with obesity 
associated non-alcoholic fatty liver disease (NAFLD) is uncertain, but possibly TP53 mutation 
is less common (2/11 cases studied in TCGA) in this patient group.  Notably, in many cases 
p53 may be dysfunctional owing to reduced expression or suppressed activity, rather than 
mutation.  While attempts to restore p53 in the presence of mutation have as yet had little impact 
on cancer treatment, there is hope that in the large numbers of patients with dysfunctional wild 
type (WT) p53, restoring levels or function might have therapeutic benefit.  
MDM2 is a transcriptional target of p53, responsible for regulating its effects via a negative 
feedback loop (174, 175, 313). MDM2 is an E3 ubiquitin ligase that binds to the N-terminal 
region of p53, prevents its activation and promotes its degradation.  There is interest, therefore, 
in exploring the effects of restoring p53 activity and/or levels by inhibiting its negative 
regulation by MDM2.  To date, a number of small molecule inhibitors of the p53-MDM2 
interaction have been developed, which lead to stabilisation and release of p53 from the 
inhibitory effect of MDM2.  As yet, none of these agents have entered clinical trials for patients 
with HCC. We have used three different MDM2 inhibitors to explore MDM2-p53 inhibition as 
a potential therapeutic strategy for patients with TP53 WT HCC, namely, Nutlin-3 (216), 
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RG7388 (237) and HDM201 (238, 314-317), the last two of which are already in clinical trials 
in different cancer types. 
 
 
5.2 Aims of the study in this chapter 
To explore the effect of non-genotoxic activation of p53 through MDM2 inhibition by small 
molecule inhibitors in liver cancer cell lines. 
 
 
 
5.3 Growth curves of different liver cancer cell lines 
To select the optimum seeding densities of cells and the appropriate duration of treatment with 
the compounds of interest, growth curves were generated for a panel of liver cancer cell lines 
that were selected for different TP53 status, since our interest was to examine specific p53-
dependence. The TP53 wild type (p53WT) cell lines investigated were HepG2 and SK-Hep-1. 
The p53 defective cell lines used were Huh-7, Huh-1, SNU475 and SNU182 which are TP53 
mutant (p53MUT) and Hep3B which isTP53 null (p53NULL) as shown in Figure 5.1and Table 
5.1. The doubling time range for this panel was 30-48 hours apart from SNU475 and SNU182 
with a longer doubling time of 60-72 hours. Accordingly the optimum length of treatment that 
aimed at covering at least two doubling times was 96 hours for all of the liver cancer cell lines 
apart from SNU182 and SNU475 that were treated for 120 hours, as they were growing slower 
than the rest of the cell lines.  
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Figure 5.1: Growth curves of liver cancer cell lines with different TP53 status. TP53 WT 
cell lines (HepG2 (A) and SK-Hep-1 (B)), TP53 Mutant (Huh-7 (C), Huh-1 (D), SNU182 (E), 
SNU475 (F) and TP53 Null (Hep3B (G)). Six different densities (500 to 5000 cells per well) 
were seeded in 96 well plates for 7 days and then an SRB assay was carried out for each time 
point to monitor the culture growth.  
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5.4 MDM2 inhibitors repressed the proliferation and colony formation of 
liver cancer cell lines in a p53-dependent manner 
 Growth inhibition of p53WT liver cancer cell lines by MDM2 inhibitors 
Cells were exposed to different concentrations (1nM to 10µM) of three structurally different 
small molecule inhibitors of MDM2, namely nutlin-3, RG7388 and HDM201. The effects on 
SRB assay determined growth are summarised in Table 5.1. Nutlin-3 was the least potent of 
the three MDM2 inhibitors with a GI50 of ~2µM; while RG7388 and HDM201 were more potent 
inhibitors compared to nutlin-3, with GI50 values in p53
WT cell lines which were at the Nano 
molar range (≤ 30 nM for HepG2 and ≤ 60 nM for SK-Hep-1). HDM201 showed greater 
specificity at high doses – as evidenced by the absence of growth inhibition in cells with mutant 
or null TP53 background.  The impact of increasing doses of the three MDM2 inhibitors on 
proliferation for the different cell lines is shown in Figure 5.2, where no effect of HDM201 on 
TP53 mutant or null cells were evident at doses up to 10 µM.  The growth curves for 
determination of GI50 doses in HepG2 and SK-Hep-1 p53
WT cells are shown in (Figure 5.2; F 
and G), with HDM201 GI50 doses of 30.7±0.2 nM in HepG2 cells and 60.1±1.5 nM for SK-
Hep-1 cells (Table 5.1). 
Table 5.1: GI50 concentrations of HDM201, RG7388 and Nutlin-3 for the panel of liver 
cancer cell lines of varying TP53 status 
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Figure 5.2: The effect of three MDM2 inhibitors on the growth of liver cancer cell lines. 
(A) SRB growth inhibition assay and (B) Immunoblotting of liver cancer cell lines with 
different TP53 status with the effect at the protein level measured by western blotting after 
incubating with two different concentrations of Nutlin-3 (2 and 5 µM) for 6 hours. (C) and (D) 
shows the growth inhibitory effect of RG7388 on liver cancer cell lines with (D) showing the 
potent effect on p53WT cell lines (HepG2 and SK-Hep-1) treated with RG7388 at nanomolar 
concentrations (SRB); with the effect at the protein level measured by western blotting after 
incubating with 30 and 60 nM shown in (E). The growth inhibitory effect of HDM201 in shown 
in (F) and (G) and at the protein level by western blot (H). All the western blots show 
stabilization of p53 and induction of its downstream targets (p21 and MDM2) in p53WT cell 
lines but not in p53MUT/NULL cell lines. Green colour is used for p53WT cell lines, while red is 
used for p53MUT and blue for p53NULL cell lines. Error bars represent standard error of the mean 
of three independent repeats. GAPDH and β-Actin were used as loading controls in 
immunoblotting. 
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 The effect of MDM2 inhibitors on p53 protein levels and of its downstream targets 
The protein expression of p53 and of its downstream transcriptional targets in liver cancer cell 
lines was assessed by immunoblotting (Figure 5.2). In p53WT cell lines exposed to the three 
MDM2 inhibitors at their GI50 dose, stabilisation of p53 was clearly evident, associated with 
increase in the downstream transcriptional targets MDM2 and p21 after 6 hours (Figure 5.2; 
B, E and H). In contrast, there were no changes in p53 levels nor of its downstream targets in 
either Huh-7 or Hep3B cells, even after exposure to 1000 nM of HDM201 (Figure 5.2; H). 
Time course exposure of p53WT cell lines to increasing doses of MDM2 inhibitors over 24 hours 
showed a dose dependent stabilisation and increase in p53, manifested by the increase in level 
of both total p53 and p53 phosphorylated at the Serine 15 site (pp53Ser15) (Figure 5.3) that was 
evident as early as two hours of exposure to the three MDM2 inhibitors; this increase was 
maintained at 6 and 24 hour time points.   
A dose dependent increase of p53 downstream transcriptional targets (MDM2 and p21) by 
MDM2 inhibitors was observed and was most prominent after 6 hours (Figure 5.3). 
Interestingly, there was no evidence of cleaved PARP nor a change in PARP levels even after 
24 hours in either of the p53WT cell lines (Figure 5.3; C).  
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Figure 5.3: Time course treatment of p53WT cell lines with ~ 0.5, 1 and 2X GI50  doses of 
three different MDM2 inhibitors for 2, 6 and 24 hours. All MDM2 inhibitors (A) Nutlin-3, 
(B) RG7388 and (C) HDM201 showed a similar effect, represented by a dose-dependent 
stabilisation of p53 as early as 2 hours, that increased over 6 hours and subsequently decreased 
by 24 hours. The p53 downstream transcriptional target gene products (p21, MDM2 and WIP1) 
showed a similar dose-dependent increase that was most prominent after 6 hours. GAPDH was 
used as loading control.  
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 Inhibition of colony formation ability of p53WT cell lines by MDM2 inhibitors 
The Colony formation ability of a selected group of liver cancer cell lines (HepG2 and SK-hep-
1 p53WT, Huh-7-p53MUT and Hep3B-p53NULL) was tested in response to a wide dose range of 
the three MDM2 inhibitors. Nutlin-3 (0.007- 5µM), RG7388 (1-80 nM) and HDM201 (5-300 
nM) (Figure 5.4). 
All the three tested MDM2 inhibitors showed inhibition of the ability of the p53WT cell lines to 
form colonies. The 50% clonogenic survival (LC50) doses for Nutlin-3 were 0.96±0.1 µM and 
2.32±0.05 µM for HepG2 & SK-Hep-1 respectively (Figure 5.4; A). The RG7388 LC50 doses 
were 8.59±0.38 nM and 37.15±9.43 nM for HepG2 & SK-Hep-1 respectively (Figure 5.4; B). 
HDM201 LC50 doses were 11.14±1.32 nM and 54.06±5.22 nM for HepG2 & SK-Hep-1 
respectively (Figure 5.4; C). While there was no detectable reduction in colony forming ability 
for the p53MUT/NULL cell lines (Huh-7 and Hep3B) (Figure 5.4). 
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Figure 5.4: Clonogenic survival of liver cancer cell lines treated with three different 
MDM2 inhibitors for 96 hours. (A) nutlin-3 dose range (0.007- 5µM), (B) RG7388 (1-80 nM) 
and (C) HDM201 (5-300 nM) with representative pictures of the colonies to the right of each 
corresponding figure. Error bars represent the standard error of the mean of three independent 
repeats.  
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5.5 The effect of HDM201 on cell cycle distribution in liver cancer cell lines 
Of the three MDM2 inhibitors, HDM201, in addition to being potent was more specific and 
showed growth inhibition of only p53WT cell lines with no detectable effect on p53MUT/NULL cell 
lines even at high doses (1 µM).  This contrasted with RG7388, which had a growth inhibitory 
effect on p53MUT/NULL cell lines at high doses and could be the result of off-target effects. We 
therefore chose to take HDM201 forward for further characterisation of efficacy against liver 
cancer cell lines.  
The growth and clonogenic inhibition properties of HDM201 were explored at a cell cycle level 
using FACS analysis, as shown for 24, 48 and 72-hour treatments in Figure 5.5. GI50 and 10 
times the GI50 doses were used to study the effects of low and high doses of HDM201 compared 
to DMSO controls. In HepG2 cells there was a significant dose dependent increase in G0/G1 
phase cells (p=0.049, for GI50 and p=0.009 for 10X GI50), associated with similar stepwise 
decreases in S phase cells (p=0.01) (Figure 5.5; A). With SK-Hep-1 cells, an increase in G0/G1 
was similarly evident at the lower GI50 dose (p=0.07), but at the higher dose there was a 
prominent and significant increase in cells at G2/M (p=0.02), with fewer cells at G0/G1 
(p=0.01) and S phases (p=0.04) (Figure 5.5; B).  The cell line and dose dependent changes 
observed at 24 hours persisted at 72 hours (Figure 5.5).  There were no HDM201 induced cell 
cycle changes in p53 mutant or null cell lines (Figure 5.5; C and D). 
Notably, there was no detectable Sub-G1 fraction induced by treatment with HDM201, 
suggesting no apoptotic cell death or disintegration for either cell line, even after 72 hours 
treatment (Figure 5.5).   
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Figure 5.5: The effect of HDM201 on cell cycle distribution over 72 hours of treatment. 
(A) HepG2 cell cycle distribution, showing a dose dependent increase in G0/G1 phase with 
reduction in S phase. (B) SK-Hep-1 cell cycle distribution showing an increase in G0/G1 phase 
at the GI50 level but G0/G1 decreases and G2/M phase increases at 10X GI50. (C) and (D) 
showing the cell cycle distribution of Huh-7 and Hep3B cells, with no obvious change in their 
cell cycle distribution, even at a high dose (1µM). Data represent mean ± standard error of the 
mean (SEM) of three independent repeats. 
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Figure 5.6: Cell cycle profile showing the effect of HDM201 on cell cycle distribution in 
liver cancer cell lines. (A) HepG2 cell cycle distribution, showing a dose-dependent increase 
in G0/G1 phase with reduction in S phase. (B) SK-Hep-1 cell cycle distribution showing an 
increase in G0/G1 phase at the GI50 level but G0/G1 decreases and G2/M phase increases at 
10X GI50. (C) and (D) showing the cell cycle distribution of Huh-7 and Hep3B cells, with no 
obvious change in their cell cycle distribution, even at a high dose (1µM). 
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5.6 HDM201 inhibits growth without inducing apoptosis and does not inhibit 
the metabolic activity in p53 WT liver cancer cell lines 
It has been reported that MDM2 inhibitors induce apoptosis in p53WT cell lines in vitro and in 
vivo (318, 319). The absence of detectable change in sub-G1 phase on FACS and the lack of 
PARP cleavage on western blotting (Figure 5.3; C) argued against HDM201 induced apoptosis 
contributing to the reduced cell numbers and colonies.  A caspase 3/7 assay following treatment 
with HDM201 supported this further, as neither p53WT nor p53MUT/NULL showed any detectable 
increase in caspase activity in HDM201 treated cells compared to the DMSO control even at 
high doses up to 10X the GI50 for p53WT cell lines and up to 1µM for p53MUT/NULL  cell lines 
(Figure 5.7).  
Furthermore, an XTT assay, assessing mitochondrial enzymatic activity, confirmed that the 
cells were still metabolically active.  Even at high doses of HDM201 inducing growth 
suppression, the metabolic activity of treated cells was higher than that before starting treatment 
(Figure 5.8; A and B). The overall reductions in measured metabolic activities for different 
HDM201 concentrations can be explained by the growth inhibitory effect of the drug with 
induction of cell cycle arrest and hence fewer number of cells, but the reduced number of cells 
still retain metabolic activity.   
 p53MUT/NULL cells showed no detectable difference in the metabolic activity between any of the 
treatment conditions (Figure 5.8; C and D). 
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Figure 5.7: Apoptotic (caspase 3/7) activity after treatment with HDM201. There was no 
increase in the caspase 3/7 activity in p53WT cell lines treated with GI50 and 10X GI50 for 24hrs 
(A) and (B); nor in the p53MUT/NULL treated with a high dose (1µM) for 24 hours (C) and (D). 
 
Figure 5.8: Metabolic activity measured by XTT assay in liver cancer cell lines after 
treatment with HDM201 for 96 hours. (A) and (B) HepG2 and SK-hep-1 p53WT cell lines 
treated with GI50 and 10X GI50 showed reduction in overall metabolic activity, reflecting the 
growth inhibition by treatment with HDM201, but the growth inhibited cells remained 
metabolically active during and at the end of the treatment period. (C) and (D) p53MUT/NULL 
treated with a high dose (1µM) for 96 hours and the treatment did not have any effect on either 
proliferation or the metabolic activity in those two cell lines. Y-axis represent the optical density 
(OD) at 450 nanometre wavelength. Data represent mean± standard error of the mean (SEM) 
of three independent repeats. 
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5.7 HDM201 increases the transcription of p53 downstream transcriptional 
targets 
Having confirmed HDM201 stabilisation of p53, with increases in its protein level and that of 
downstream transcriptional target gene protein products by western blot, we explored the 
regulation of a broader panel of transcriptionally regulated p53 target genes at the mRNA level 
by qRT-PCR, as shown in Figure 5.9.  The genes included negative regulators of p53 (PPM1D 
and MDM2), cell cycle arrest genes (CDKN1A and GADD45A) and pro-apoptotic genes 
involved in both the intrinsic (BAX and PUMA (BBC3)) and extrinsic pathways (FAS and 
TNFBSF10B). 
In p53WT cell lines there was a significant dose dependent increase in expression of all the 
downstream transcriptional targets of p53 at 6 hours, apart from BAX in HepG2. Notably, the 
highest increases (~ 4 fold for the GI50 and ~ 10 folds for 10XGI50) were for CDKN1A and 
MDM2 at 6 hours (p= 0.01, 0.008 respectively for HepG2; p= <0.0001, 0.002 respectively for 
SK-Hep-1) (Figure 5.9; A and B). The HDM201 induced changes in expression of pro-
apoptotic genes were much more modest than those involved in negative feedback control and 
cell cycle arrest.  The patterns of expression were similar after 24 hours, although increases in 
the expression of CDKN1A and MDM2 were even more marked (~4 fold for the GI50 and >20 
folds for 10XGI50) (Figure 5.9; A and B).  There were no effects on expression of these target 
genes in p53MUT/NULL cell lines, even after exposure to very high doses of HDM201 (Figure 
5.9; C and D). 
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Figure 5.9: qRT-PCR measurement of mRNA expression for TP53 and downstream 
transcriptional targets of p53 in response to HDM201. Different doses of HDM201 were 
used (GI50 and 10X GI50 for p53
WT and 1µM for p53MUT/NULL ) for 6 and 24 hour time points. 
The expression was relative to DMSO control and GAPDH reference gene in (A) HepG2, (B) 
SK-Hep-1, (C) Huh-7 and (D) Hep3B. Data represent mean± standard error of the mean (SEM) 
of three independent repeats.  
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5.8 HDM201 induced cell cycle arrest was associated with induction of 
senescence 
Although there was no evidence for HDM201 inducing apoptosis, and cellular metabolic 
activity was retained, the arrested state of treated cells was not always reversible, particularly 
at 10X GI50 dose, as shown by the time lapse images in Figure 5.10.  Although confluency was 
reached 12 days after drug removal at the G150 dose, at the higher dose scant recovery was 
evident, with many cells viable but not dividing (Figure 5.10; A).  In SK-Hep-1 the cells 
underwent morphological changes with a several-fold increase in size compared to the DMSO 
control. Although at the GI50 dose, confluency was reached 12 days after drug removal, at the 
higher dose the morphological changes persisted, resulting in the formation of giant cells 
(Figure 5.10; B). We therefore investigated the possible induction of senescence. p53WT cells 
incubated with HDM201 at GI50 and 10X GI50 for 96 hours were subsequently stained with SA-
β-Gal, which reports β-Galactosidase accumulation as a green-blue cytoplasmic staining and is 
a widely used marker of cellular senescence (320, 321).  Both p53WT cell lines showed positive 
staining for SA-β-Gal and the intensity of staining and the number of positively stained cells 
was proportionate to the dose of the HDM201 (Figure 5.11).  
Cellular senescence can occur during both G1 and G2 arrest (185, 322, 323). In the p53WT liver 
cancer cell studied, as reported above, G1 or G2 arrest after 96 hours was associated with 
marked induction of p21, a p53 downstream target linked with both cell cycle arrest and the 
induction of senescence.   
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Figure 5.10: Incucyte experiment showing the effect of HDM201 on the cell morphology 
of p53WT cell lines (HepG2 and SK-Hep-1) after treatment with HDM201 for 96 hours. 
The drug was removed after 96hrs and replaced with media and the cells left to grow. Sequential 
images of the cultures were taken every 6 hours. (A) HepG2 and (B) SK-Hep-1. Magnification 
power 10X, Scale bar = 300 µM. 
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Figure 5.11: HDM201 induces senescence in p53WT liver cancer cell lines. SA-β-Gal 
staining of HepG2 and SK-Hep-1 after treatment with DMSO control, or GI50 and 10X GI50 of 
HDM201 for 96 hours, imaged at low power (10X) and high power (40X). Positive cytoplasmic 
staining (blue-green) is evident in a few cells in the DMSO control, but the number of positive 
stained cells and the intensity of staining increases with the dose of HDM201 to include nearly 
all the cells that are treated with the high dose. SK-Hep-1, in addition to blue-green staining, 
showed a change in the morphology of cells at high dose of HDM201, with cells becoming 
larger in size compared to DMSO control. 
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Figure 5.12: Schematic summary representing the p53 pathway and the effect of MDM2 
inhibition, linking p53 activation to downstream transcriptional targets that induce the 
dominant response of cell cycle arrest and senescence, and minimal activation of pro-apoptotic 
genes.  
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5.9 HDM201 inhibits the growth of liver cancer xenografts in vivo 
After confirming that HDM201 induced growth inhibition, cell cycle arrest and senescence of 
p53WT cell lines (HepG2 and SK-Hep-1), we moved on to test whether this growth inhibitory 
effect can be replicated in vivo. Bioware® Brite HepG2-Red-Fluc (HepG2-Luc) luciferase 
transfected cells were purchased from (Perkin Elmer, USA) to be used in an in vivo xenograft 
model. In principle, using this cell line provided the ability to estimate the xenograft tumour 
size by two methods, the standard tumour measurement using Vernier calipers and the use of 
an IVIS imaging system.  
 HepG2-Luc responds to MDM2 inhibitors in the same pattern as HepG2 
The parental cell line that HepG2-Luc was derived from is a HepG2 cell line that was purchased 
from ATCC (HB8065). Parental HepG2 was stably transfected with firefly luciferin gene from 
Luciola Italica (Red-Fluc) using the Red-FLuc-Puro third generation lentivirus vehicle in order 
to express luciferase enzyme and hence generate luminescence in the presence of D-Luciferin 
as a substrate.  
Before starting the xenograft study, we had to ensure that HepG2-Luc cells responded to 
HDM201 compound in the same way that the parental HepG2 cell line; therefore, we 
challenged this cell line with the three MDM2 inhibitors in parallel with the parental HepG2 
cell line. The HepG2-Luc cells responded to all three MDM2 inhibitors in the same way as the 
parental HepG2 cell line (Figure 5.13). Colony formation was inhibited by HDM201 as for the 
HepG2 cell line (Figure 5.13; D). The GI50 and LC50 doses for HepG2-Luc compared to the 
parental HepG2 are shown in Table 5.2.     
Further to this, the caspase 3/7 activity and the mitochondrial activity were assessed in HepG2-
Luc in parallel to the parental HepG2 cell line, and again the results were very similar to the 
parental cell line (Figure 5.14). The same transcriptional profile changes were also shown by 
qRT-PCR assays (Figure 5.15). 
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Table 5.2: The GI50 and LC50 for HepG2-Luc versus parental HepG2 cell lines for the 
three MDM2 inhibitors 
 GI50 LC50 
Cell line Nutlin-3 (µM) RG7388 (µM) HDM201 (µM) HDM201 (µM) 
HepG2 1.71± 0.08 0.015 ± 0.001 0.029 ± 0.001 0.010± 0.001 
HepG2-Luc 1.44± 0.07 0.012 ± 0.001 0.027 ± 0.002 0.009± 0.001 
 
 
 
 
Figure 5.13: Growth inhibition and clonogenic survival of HepG2 and HepG2-Luc cell 
lines. (A), (B) and (C) are SRB growth inhibition assay results for HepG2 versus HepG2-Luc 
after treatment with Nutlin-3, RG7388 and HDM201 respectively for 96 hours. (D) Clonogenic 
survival of HepG2 and HepG2-Luc with a dose range of 5-300 nM of HDM201 treatment for 
96 hours. Error bars represent standard error of the mean of three independent repeats.   
176 
 
 
Figure 5.14: Caspase 3/7 activity and XTT assay for HepG2 and HepG2-Luc cells. (A) 
Caspase 3/7 assay of HepG2 (left) and HepG2-Luc (right) after exposure to GI50 and 10X GI50 
of HDM201 for 24 hours. (B) XTT assay measuring the mitochondrial metabolic activity of 
HepG2 (left) and HepG2-Luc (right) after exposure to GI50 and 10X GI50 and 1µM of HDM201 
for 96 hours. Error bars represent standard error of the mean of three independent repeats. 
 
Figure 5.15: mRNA expression of TP53 and p53 downstream transcriptional targets by 
qRT-PCR in HepG2 and HepG2-Luc in response to HDM201. HepG2 (A) and HepG2-Luc 
(B) were exposed to HDM201 at a GI50 and 10X GI50 for 6 and 24-hour time points to compare 
the changes in levels of expression between the parental cell line (HepG2) and HepG2-Luc. 
The expression was relative to DMSO control and GAPDH used as a reference gene. Error bars 
represent standard error of the mean of three independent repeats.  
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 Establishing a xenograft model with HepG2-Luc in immunocompromised mice 
Preliminary studies done by other PhD students showed that there was variability in HepG2 
xenograft growth in CD1 nude mice. Therefore, we decided to test the growth of HepG2-Luc 
xenografts in two different strains of immunocompromised mice, NOD SCID gamma (NSG) 
(Bred in house) and CD1 nude mice (Charles River, UK). CD1 nude mice were developed from 
the transfer of the nude gene from Crl:NU-Foxn1nu to a CD-1 mouse through a series of crosses 
and backcrosses at Charles River laboratories in 1979. They lack a thymus gland and hence are 
unable to produce T-cells. They therefore exhibit T-cell immunodeficiency. NOD SCID gamma 
mice (NSG) mice are further immunocompromised by lacking T, B and natural killer (NK) cells 
(324).  
After injecting HepG2-Luc cells in the right flank of each mouse of both mice strains (female), 
they were left to grow and monitored closely. Tumour volume was determined by standard 
external calliper measurement of the greatest longitudinal diameter (length) and the greatest 
transverse diameter (width). Then tumour volume was calculated based on calliper 
measurements by the following modified ellipsoidal formula (325, 326): 
Tumour volume = ½ (Length x Width2) 
Growth of HepG2-Luc xenografts NSG was observed in all the 5 injected mice compared to 
only two out of five xenografts in CD-1 nude mice, and these two tumours grew much more 
slowly (Figure 5.16). Therefore we decided to use the NSG mice to test the effect of HDM201 
on HepG2-Luc in vivo. 
 
Figure 5.16: Growth curve of HepG2-Luc xenografts in NSG and CD1 nude mice. (A) 
NSG mice (n=5) showing growth of HepG2-Luc xenografts in all the injected mice. (B) CD1 
nude mice showing failure of growth of the HepG2-Luc xenografts in 3 out of 5 injected mice. 
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 The effect of HDM201 at a dose of 25 mg/kg/day for 7 days on HepG2-Luc xenografts 
When the HepG2-Luc xenografts reached dimensions of 5x5 mm on the flanks of NSG mice, 
the mice were alternately allocated into one of two groups of (10) control and (10) treated. Each 
group consisted of two cages with 5 mice per cage. The treated group received HDM201 once 
a day by oral gavage at a dose of 25 mg/kg/day for 7 days, while the control group received the 
control vehicle by the same route (5% ethanol alcohol in 1% HydroxyPropyl Methyl Cellulose 
(HPMC)) (Figure 5.17; A). This dose frequency was similar to Regimen 2C used in phase I 
clinical trials for different tumours (single daily dose for one week in a 4 week cycle) (314). 
The drug was well tolerated with no signs of toxicity or appreciable body weight loss (Figure 
5.17; B). 
HDM201 at 25mg/kg/day resulted in a significant inhibition of tumour growth, which was most 
prominent on day 12 (p=0.0004) (Figure 5.17; A, C, D and E). The survival time was defined 
by the time in days that the tumour took to reach 4 times the starting volume, which was 
increased from 8.4 days in the control group to 15.26 days in the treated group (p=0.0078) 
(Figure 5.17; F).  
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Figure 5.17: The effect of oral 25 mg/kg/day HDM201 (single daily dose) on HepG2-Luc 
xenografts in NSG mice. (A) the growth curve of the xenografts is represented by the mean of 
the relative tumour volume (RTV) of each tumour to its starting volume before commencing 
treatment on day 0 and stopping it on day 7 (red arrow). (B) The effect of oral HDM201 on the 
body weight of NSG mice bearing the HepG2-Luc xenografts. (C) The volume of xenograft 
tumours (mm3) in both groups (control and treated) on day 0 before starting treatment with 
HDM201. (D) and (E) represent the RTV difference between the control and treated groups on 
day 12 and day 14 with p values on each graph. (F) Survival reflected by the time taken by each 
xenograft to reach 4 times the starting volume with the median survival of each group in a table 
below the graph. The p value was calculated by Log-Rank test, HR = hazard ratio, CI= 
confidence interval. Error bars represent the standard error of the mean.  
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In vivo bioluminescence imaging by IVIS scanning was carried out in parallel as an additional 
method of monitoring tumour growth and estimating response to the intervention (327-329). 
Bioluminescence imaging is based on detection of light emitted from mice and this light is 
generated from luciferase-luciferin reaction in the cells; in our study it was the HepG2-Luc 
xenograft cells, and it has been used in different animal models for neoplasia. Unfortunately 
the IVIS data obtained did not match the caliper measurements data (Figure 5.19; A and B) 
and some of the tumours despite clearly and visibly growing exponentially did not produce a 
bioluminescence signal (Figure 5.19; A) and there was fluctuation of the detected signals over 
several time points that led to a zigzag pattern of the plotted data that did not match the growth 
of the tumours obtained by caliper measurement (Figure 5.19; A and B). Similar problems 
with bioluminescence imaging signals by IVIS scanning have been previously reported (330, 
331); this can be due to several factors including improper absorption of luciferin 
intraperitoneally, improper delivery of luciferin into tumour cells due to variability in the blood 
supply to the xenograft and intratumoural haemorrhage and necrosis. These issues cast doubt 
on the usefulness of the IVIS imaging and we decided to stop further use of the IVIS scanning 
in this experiment and the experiment to follow. 
 
Figure 5.18: HepG2-Luc xenografts tissue sections with H&E and p21 
immunohistochemical staining.  (A) and (B) are H&E stained sections of a control and treated 
mice xenografts respectively and both are showing mitotic index (arrow and zoomed image). 
Immunohistochemical staining for p21 in the xenografts is shown in (C) control and (D) treated 
with no significant difference in the number of p21-positively stained nuclei due to the fact that 
these were end-point xenografts and were not taken after stopping the treatment. 
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Figure 5.19: IVIS scan compared to the standard tumour measurement by caliper. (A) 
IVIS scan data of each individual HepG2-Luc xenograft in each cage in the control and treated 
groups obtained by injecting the NSG mice with D-Luciferin intraperitoneally 10 minutes 
before scanning. (B) Standard caliper measurements data of HepG2-Luc xenograft tumours of 
each individual xenograft in each cage of the control and treated groups.   
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 The effect of HDM201 100 mg/kg/day for 10 days on HepG2-Luc xenografts 
To explore the effects of a higher dose of HDM201 on HepG2 xenografts, the experiment was 
repeated with tumour bearing mice allocated alternately to receive control vehicle by oral 
gavage (n=9 mice) or HDM201 100 mg/kg/day for 10 days (n=9 mice). This dose frequency 
and duration was planned to be partly similar to regimen 2A in a phase I clinical trial for 
different tumours (single daily dose for two weeks in a 4 week cycle) (314); however, treatment 
was discontinued at day 10 as the mice showed signs of toxicity, reflected by loss of body 
weight (range 4%-12%) (Figure 5.20; A and B).  Body weight was subsequently regained 
(Figure 5.20; B). At the higher dose, significant growth inhibition was again observed, as 
shown at day 12 (p=0.03) (Figure 5.20; D) and day 21 (p=0.001) (Figure 5.20; E).  A plateau 
in tumour volume was maintained for approximately 20 days after discontinuation of the drug, 
(Figure 5.20; A) (Figure 5.21), with survival differences of 19.91 days for control vehicle only 
treated mice compared to 41.74 days post treatment with HDM201 (p=0.0017) (Figure 5.20; 
F).  
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Figure 5.20: The effect of oral 100 mg/kg/day HDM201 (single daily dose) on HepG2-Luc 
xenografts in NSG mice. (A) the growth curve of the xenografts represented by the mean of 
the relative tumour volume (RTV) of each tumour to its starting volume before commencing 
treatment on day 0 and stopping it on day 10 (red arrow). (B) The effect of oral HDM201 on 
the body weight of NSG mice bearing the Hepg2-Luc xenografts. (C) The volume of xenograft 
tumours (mm3) in both groups (control and treated) on day 0 before starting treatment with 
HDM201. (D) and (E) represent the relative tumour volume difference between the control and 
treated groups on day 12 and day 21 with p-values on each graph (t-test). (F) Survival reflected 
by the time taken by each xenograft to reach 4 times the starting volume with the median 
survival of each group in a table below the graph. The p value calculated by Log-Rank test, HR 
= hazard ratio, CI= confidence interval. Error bars represent the standard error of the mean. 
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Figure 5.21: the effect of oral HDM201 100 mg/kg/day (single daily dose) on HeG2-Luc 
xenografts in NSG mice. Shows that the effect of 100mg/kg/day HDM201 on slowing tumour 
growth continued to be statistically significant in the treated group compared to the control and 
the statistical significance increased and maintained from day 19 till day 30. Error bars represent 
standard error of the mean (SEM).  
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5.10 Discussion 
Treatment options for patients with advanced primary liver cancers are limited, with barriers to 
progress well recognised and recently reviewed (156). Although the MDM2-p53 pathway is 
frequently dysfunctional in liver cancer (332), TCGA and the Catalogue Of Somatic Mutations 
In Cancer (COSMIC) (199) data indicates that TP53 is directly mutated in only a minority of 
patients.  There is hope, therefore, that activating levels of WT p53 may be of benefit and 
relevant for a substantial proportion of patients – especially if a sustained impact on tumour 
growth can be achieved, in the absence of either systemic or liver related toxicities.  Small 
molecule MDM2-p53 binding antagonists are already in clinical trials, largely as dose finding 
studies in leukaemias, in addition to phase 1 clinical trials for advanced solid tumours and 
lymphomas (https://clinicaltrials.gov/).  
Of the reported MDM2 small molecule inhibitors, only the early tool compound nutlin-3 has 
been previously tested with liver cancer cell lines and reported to cause inhibition of growth 
regardless of the TP53 status of the cells at high doses - possibly an off-target effect mediated 
through p73 (333). The effects of more potent, specific and clinically relevant inhibitors such 
as RG7388 and HDM201 have not been reported in liver cancer cell lines. Therefore, we 
explored all three compounds in liver cancer cell lines with different TP53 status.  
Each of the three compounds induced growth inhibition in p53WT liver cancer cells.  The GI50 
of nutlin-3 was approximately 2 µM for p53WT cell lines. As previously reported, nutlin-3 did 
induce growth inhibition at much higher doses (>20 µM) in two of the p53MUT/NULL cell lines, 
but these are off-target effects at doses outside the physiologically relevant range.  Our focus 
was on more potent, specific and clinically relevant MDM2-p53 inhibitors. Both RG7388 and 
HDM201 demonstrated pronounced growth inhibition, with doses in the nanomolar range for 
p53WTcell lines. Off target growth inhibition of p53MUT/NULL cell line was detectable for 
RG7388, but only after exceeding 150 times the GI50 dose seen with the p53
WT cell lines. 
HDM201 was notable not only for its low GI50 doses with the p53
WT cells (30, 60 nM 
respectively for HepG2 and SK-Hep-1), but also because it had no detectable off target effects 
on growth inhibition of p53MUT/NULL  liver cancer cell lines, even at a dose as high as 10 µM (> 
300 times the GI50 for HepG2 and >150 times the GI50 for SK-Hep-1). Our subsequent and 
more detailed characterisations of specific and potent MDM2 inhibition in these liver cancer 
cells lines focused on HDM201.  Similar to the growth inhibition studies, clonogenic survival 
assays showed that the HDM201 inhibition of colony formation was also limited to p53WT cell 
lines. 
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Exploring additional in vitro effects of HDM201 confirmed increased protein levels of MDM2, 
alongside prominent protein stabilisation of p53 in p53WT cells. As expected, there was no 
transcriptional increase in TP53 mRNA, but increased levels of p53 protein was followed by 
transcriptional and translational increases in MDM2. At the same time, there were marked and 
sustained transcriptional increases in CDKN1A, followed by pronounced increases in the 
translated p21 protein product. These effects were specific to p53WT cells.   
Although there were some relatively small transcriptional increases in pro-apoptotic genes, 
these were not as marked as the changes observed for CDKN1A/p21.  Our analyses of apoptotic 
endpoints showed no evidence of PARP cleavage by western blot, no increases in caspase3/7 
activity and a lack of subG1 signals when cells were analysed by FACS. These collective 
observations indicated that for the HDM201 treated liver cancer cells, increased apoptosis 
played no part in their response. However, the sustained growth inhibition in the presence of 
continued metabolic activity in vitro or cessation of treatment in vivo were indicative of 
senescence, which in vitro was supported by staining for β-galactosidase. Furthermore, we 
found that the increased levels of CDKN1A/p21 at mRNA and protein levels was associated 
with the observed cell cycle arrest and the induction of senescence. It has been reported 
previously that Nutlin-3a causes growth inhibition in p53WT T-cell leukaemia cell lines by 
inducing senescence through induction of p21 protein levels (320), but it has not been 
previously reported that MDM2 inhibition induces senescence in HCC.     
Senescent cells express various secretory proteins, collectively referred to as the senescence 
associated secretory phenotype (SASP), that includes cytokines, chemokines, growth factors 
and matrix-remodelling associated proteases (334). Among these secreted molecules, 
interleukins like IL-1 alpha, IL-6 and IL-8 have an effect in promoting the elimination of 
senescent cells by the immune system. Also, it has been reported that through their secreted 
SASP peptides, senescent fibroblasts and hepatocytes play a role in the differentiation of 
circulating immune cells and their recruitment to tumour sites, thus contributing to tumour 
immune surveillance (210, 335, 336). 
While a treatment that induces cancer cell death may be more attractive at first consideration, 
the restoration of WT p53 in a transgenic inducible animal model was reported to eliminate 
liver cancer, by inducing senescence and triggering an innate anti-tumour response (210, 337).  
Whether this might translate in the human setting is as yet unknown, but the potential is 
exciting.  
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We have extended previous tumour xenograft studies of MDM2-p53 small molecule inhibitors 
(318) to the liver cancer cell line, HepG2.  The growth inhibitory effect of HDM201 was 
reproduced in vivo, with the drug significantly suppressing the rate of tumour growth in a dose-
dependent fashion.  At the higher dose, the suppression of growth was impressively sustained 
for two to three weeks following discontinuation of treatment, before resuming.  These 
observations are in keeping with the induction of growth arrest and senescence. The response 
to repeated treatment is worthy of further exploration, as this may have relevance for clinical 
translation. Furthermore, the impact of immune clearance of senescent cells is not well 
modelled in immunocompromised mice. Immune clearance of cancer cells, achieving sustained 
anti-tumour responses following treatment with MDM2-p53 inhibitors may have translational 
relevance for liver cancer as well as other solid tumours and should be further explored.  
  
In conclusion, we have demonstrated promising results with highly significant growth 
inhibitory effects in vitro and in vivo in p53WT liver cancer cell lines induced by small molecule 
MDM2-p53 binding antagonists. Our study shows that targeting this pathway is worthy of 
further exploration for patients with liver cancer.    
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 Results - The effect of WIP1 inhibitor GSK2830371 as 
a single agent and in combination with MDM2 inhibitors on 
liver cancer cell lines 
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6.1 Introduction 
One of the downstream transcriptional targets of p53 is PPM1D which encodes a wild type-p53 
induced phosphatase (WIP1). It is a member of the PPM family of Ser/Thr phosphatases, WIP1 
functions by dephosphorylating several key DNA damage and stress response proteins (ATM, 
ATR, Chk1, Chk2, H2AX, MDM2 and p53) (230, 338-342). Being a downstream target of p53 
and at the same time acting on p53 makes it part of an auto-regulatory negative feedback loop 
that plays an important role in regulating the function of p53 by dephosphorylating p53 at the 
Ser15 site. Therefore, inhibition of this phosphatase will lead to stabilisation of phosphorylated 
p53. Overexpression of WIP1 is believed to promote tumorigenesis and the inhibition of 
apoptosis and senescence (343, 344). It has been reported that WIP1 is overexpressed at the 
mRNA and protein levels in several solid tumours (e.g breast, ovarian, neuroblastoma, 
medulloblastoma, gastric and pancreatic tumours) and was associated with poor prognosis (228, 
229, 232). PPM1D is amplified in ~ 5% of HCC (TCGA accessed July 2017) (311, 312) and is 
rarely mutated in HCC (1 out of 921 cases) according to the COSMIC data base (199). 
However, it was found to be overexpressed in HCC at the mRNA and protein levels in 65% and 
59% of cases respectively, and was associated with poor prognosis, larger tumour size and 
advanced stage (228, 229, 232).  
GSK2830371 is a small molecule inhibitor of WIP1 (WIP1i). It binds to it and allosterically 
inhibits WIP1 function through binding to a structural flap sub-domain that is unique to WIP1 
and in addition causes ubiquitination of WIP1 which leads to its degradation (239). Several 
studies have reported the growth inhibitory effect of GSK2830371 on several types of cancer, 
whether alone or in combination with MDM2 inhibitors (339, 345, 346) but its effect has not 
previously been tested in liver cancer. Our aim was to test the WIP1i effect as a single agent 
and in combination with MDM2 inhibitors on liver cancer cell lines subsequent to establishing 
the growth inhibitory effect of MDM2 inhibitors on p53WT liver cancer in vitro and in vivo in 
chapter 5. 
 
6.2 Aims of the study in this chapter 
To explore the effect of a small molecule inhibitor of WIP1 (GSK2830371), as a single agent 
and in combination with small molecule MDM2 inhibitors, on liver cancer cell lines.  
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6.3 GSK2830371 has no or minimal effect on liver cancer cell lines when used 
alone at low micromolar doses 
 GSK2830371 effect on the proliferation of liver cancer cell lines 
The effect of WIP1i (GSK2830371) was tested on a panel of liver cancer cell lines with different 
TP53 status, the same panel that was used to test the effect of MDM2 inhibitors in chapter 5. 
Cells were exposed to different concentrations of WIP1i (0.07-10 µM) for 96hours and an SRB 
assay was used to determine the effect of the drug on cell proliferation (Figure 6.1). WIP1i as 
a single agent did not have any growth inhibitory effect on p53MUT/NULL cell lines; but had a 
mild growth inhibitory effect on p53WT cells. For HepG2 (p53WT) a dose of 2.5 µM 
GSK2830371 inhibited proliferation by ~ 23% and this growth inhibitory effect did not exceed 
35% even with the maximum dose used (10 µM). In the other p53WT cell line (SK-Hep-1), 2.5 
µM GSK2830371 had ~15% growth inhibitory effect and at higher doses showed a growth 
inhibitory effect of up to 69.6% at 10 µM, with a GI50 value of 7.49±0.51 µM (Figure 6.1) 
(Table 6.1). 
 
 
Figure 6.1: growth inhibition assay of liver cancer cell lines with different TP53 status 
with WIP1i for 96 hours (SRB assay). p53WT cell lines (Green), p53MUT (Red) and p53NULL 
(blue). Error bars represent the standard error of the mean for three independent repeats. 
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 The effect of GSK2830371 at the protein level in p53WT cell lines 
To investigate the effect of WIP1 inhibition at the protein level in p53WT cell lines (HepG2 & 
SK-Hep-1), cells were seeded in 6 well plates at a density of 3x105 cells/well for 48 hours and 
then treated with a wide range of WIP1i (0.07-10 µM) for 6 hours before collection of cell 
lysates for western blot analysis.  
In addition to a direct inhibitory effect on WIP1 phosphatase activity, GSK2830371 had been 
reported to promote the degradation of WIP1 protein (239) and our western blot results showed 
that this was also evident with HepG2 and SK-Hep-1 cells. Even at very low dose of 
GSK2830371 there was a marked reduction in WIP1 protein level in both of these p53WT cell 
lines (Figure 6.2). Also, there was prominent dose dependent increase in p53 phosphorylated 
at serine 15 (pp53Ser15) which confirmed the inhibitory effect of GSK2830371 on the ability of 
WIP1 to dephosphorylate pp53Ser15. Despite this increased pp53Ser15, the total p53 level did not 
change nor did that of other p53 downstream transcriptional targets, namely MDM2, p21 and 
BAX (Figure 6.2). 
 
Figure 6.2: Immunoblot of HepG2 and SK-Hep-1 cell lines treated with different 
concentrations of GSK2830371 WIP1i (0.07-10 µM) for 6 hours. GAPDH and β-actin were 
used as loading controls. 
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6.4 GSK2830371 potentiates the effect of MDM2 inhibitors on repressing the 
growth of liver cancer cell lines through the p53 pathway 
To assess the effect of WIP1 inhibition on the response to MDM2 inhibitors in liver cancer cell 
lines, GSK2830371 (2.5 µM) was combined with a wide range of MDM2 inhibitors. This dose 
did not have any effect on p53MUT/NULL cells and only a minimal effect on p53WT cell lines when 
used alone (as mentioned above (6.3.1)).  
GSK2830371 potentiated the growth inhibitory response of all the three MDM2 inhibitors in a 
p53 dependent manner. A reduction in the GI50 value was observed for all three MDM2 
inhibitors tested (Nutlin-3, RG7388 and HDM201) in the presence of GSK2830371 (2.5 µM) 
with both p53WT cell lines (HepG2 & SK-Hep-1) as summarised in Table 6.1. For the HepG2 
cell line, the fold reduction in the GI50 was 1.48 for Nutlin-3 (p=0.008), 1.29 for RG7388 
(p=0.01), and 1.79 for HDM201 (p=0.01). The reduction in the GI50 for SK-Hep-1 was more 
pronounced and was by 3.2 fold for Nutlin-3 (p=0.004), 2.84 fold for RG7388 (p=0.01), and 
2.3 fold for HDM201 (p=0.0002) respectively (Figure 6.3) (Table 6.1). In contrast, there was 
no effect of the combination on the proliferation of the p53MUT/NULL cell lines (Figure 6.3). 
 
Table 6.1: GI50 of MDM2 inhibitors alone and in combination with WIP1i (2.5 µM) in 
p53WT liver cancer cell lines 
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Figure 6.3: Combination effect of different MDM2 inhibitors with GSK2830371 WIP1i on liver cancer cell lines. (A) Nutlin-3, (B) RG7388 
and (C) HDM201 alone and in combination with WIP1i 2.5 µM for 96 hours in p53WT cell lines (HepG2 and SK-Hep-1 green coloured) and p53MUT 
(red coloured) and p53NULL (blue coloured) cell lines. The continuous lines represent MDM2 inhibitors alone and the dotted line represents the 
combinations of MDM2i and WIP1i 2.5 µM. Error bars represent standard error of the mean of three independent repeats.
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6.5 The effect of GSK2830371 as a single agent and in combination with 
HDM201 on protein levels in p53WT liver cancer cell lines 
The effects of single agent and combined treatments on the protein levels of p53, its downstream 
regulatory targets and PARP were assessed by immunoblotting (Figure 6.4). As HDM201 was 
the most potent and specific MDM2 inhibitor of the three tested, further combination treatments 
were performed with GSK2830371 WIP1i (2.5 µM) and HDM201. 
GSK2830371 resulted in a prominent reduction of WIP1 protein levels when used alone or in 
combination with HDM201 in both p53WT cell lines (HepG2 and SK-Hep-1) as early as 6 hours 
after treatment (Figure 6.4).  
Stabilization of post-translationally modified p53 by GSK2830371 was clearly evident, 
reflected by phosphorylation at Ser15 and acetylation at Lysine 382, and was more prominent 
after combination of the same dose of WIP1i with HDM201 in both cell lines. The MDM2 and 
p21WAF1 downstream targets of p53 were induced by HDM201 and the induction was more 
prominent in combination treatment compared to HDM201 alone. For BAX the increased effect 
of combination treatment was more evident in SK-Hep-1 than HepG2.  The detection of WIP1 
protein levels was suppressed by the GSK2830371 treatment (Figure 6.4). There was no 
evidence of cleaved PARP nor a change in full-length PARP levels regardless of whether cells 
were exposed to single compounds or to combination. 
 
Figure 6.4: Immunoblot of HepG2 and SK-Hep-1 treated with HDM201 alone and in 
combination with WIP1i (GSK2830371) for 6 hours. The maximum dose of HDM201 used 
represents the approximate GI50 for that cell line (30 nM for HepG2 and 60nM for SK-Hep-1). 
β-Actin was used as a loading control. 
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6.6 The effect of GSK2830371 as a single agent and in combination with 
HDM201 on the clonogenic survival of liver cancer cell lines 
HDM201 had an inhibitory effect on the colony forming ability of p53WT cell lines, as shown 
in chapter 5 (5.4.3). GSK2830371 (2.5µM) potentiated the effect of HDM201, reflected by the 
reduction of clonogenic survival LC50 values for p53
WT cell lines. GSK2830371 (2.5µM) 
significantly reduced the LC50 for SK-Hep-1 by 63.1% (2.72 fold) (p=0.043), from (73.9±20.2) 
to (27.2±6.3) nM; while for HepG2 the LC50 was reduced by 28.3% (1.26 fold) (p=0.07) from 
(11.14±1.3) to (7.9±0.4) nM (Figure 6.5). There was no effect on the colony forming ability of 
p53MUT/NULL cells, whether after exposure to HDM201 alone or in combination with WIP1i. 
 
Figure 6.5: The effect of HDM201 alone and in combination with WIP1i (2.5 µM) on the 
cloning efficiency of liver cancer cell lines after treatment for 96 hours. (A) Clonogenic 
survival of p53WT (HepG2 and SK-Hep-1(green)) and p53MUT/NULL (Huh-7 (red) and Hep3B 
(blue)), the continuous lines represent the effect of HDM201 alone and the interrupted lines 
represent the combination treatment. A wide range of HDM201 was used (1, 2.5, 5, 10, 20, 40, 
80, 156 and 300 nM) alone and in combination with GSK2830371 (2.5µM) WIP1i for 96 hours. 
(B) Selected images of the colonies of both p53WT cell lines (HepG2 and SK-Hep-1) showing 
the media, DMSO control and GSK2830371 (2.5µM) WIP1i alone and three doses of HDM201 
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alone and combination with WIP1i. Error bars represent the mean and the SEM of three 
independent repeats. 
 
6.7 The effect of GSK2830371 on cell cycle distribution when used as a single 
agent and in combination with HDM201 
The GSK2830371 (2.5µM) WIP1i potentiation of the growth and clonogenic inhibitory 
activities of HDM201 (that was shown in 6.4 and 6.6) were explored at a cell cycle level using 
FACS analysis after 24, 48 and 72 hours treatment as shown in Figure 6.6. Compared to DMSO 
control, WIP1i (2.5 µM) on its own did not have any effect on the cell cycle distribution of the 
liver cancer cell lines (Figure 6.6). When GSK2830371 (2.5µM) was combined with the GI50 
and 10X GI50 of HDM201 the cell cycle distribution of the p53
WT cell lines was markedly 
affected. 
With HepG2 cells, compared to HDM201 alone, when GSK2830371 WIP1i (2.5 µM) was 
combined with the GI50 of HDM201 it resulted in a significant increase in the number of cells 
in G0/G1 phase (p=0.001), a decrease in S phase (p=0.01) and G2/M (p=0.01). But when WIP1i 
was combined with 10X GI50 of HDM201 the effect was different, as it resulted in a reduction 
in G0/G1 phase (p=0.002) and an increase in G2/M phase (p=0.002) with no difference in S 
phase (p=0.2). These early changes at 24 hours persisted at 72 hours (Figure 6.6; A). 
For SK-Hep-1, GSK2830371 (2.5µM) WIP1i potentiated the effect of HDM201 whether at the 
GI50 or 10X GI50, resulting in a significant reduction in G0/G1 phase (p=0.02) and S phase 
(p=0.003), and a significant increase in G2/M phase (p=0.02) (Figure 6.6; B). This effect was 
evident as early as 24 hours and persisted at 72 hours. With the p53MUT/NULL cell lines, on the 
other hand, WIP1i did not have any effect on the cell cycle distribution, whether alone or in 
combination with 1 µM HDM201 (Figure 6.6; C and D); indicating that the observed changes 
and potentiation effects by GSK2830371 were p53-dependent.  
There were no detectable increases in Sub-G1 signals on the FACS histograms either after 
HDM201 treatment or after the combination with WIP1i, showing no evidence of apoptosis.  
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Figure 6.6: Cell cycle analysis showing the effect of GSK2830371 (2.5µM) WIP1i on the 
cell cycle distribution when combined with HDM201. Liver cancer cell lines with different 
TP53 status was treated with HDM201 alone and in combination with WIP1i for 24, 48 and 72 
hours. For p53WT cell lines the GI50 (30 nM for HepG2 and 60 nM for SK-Hep-1) and 10 times 
the GI50 of HDM201 was used alone and in combination with WIP1i 2.5 µM, while one high 
dose (1 µM) was used alone and in combination with WIP1i 2.5 µM in p53MUT/NULL cell lines.  
(A) HepG2, (B) SK-Hep-1, (C) Huh-7 and (D) Hep3B. Error bars represent standard error of 
the mean of three independent repeats.  
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6.8 GSK2830371 as a single agent or in combination with HDM201 does not 
induce apoptosis and does not inhibit the metabolic activity in liver 
cancer cell lines 
GSK2830371 WIP1i (2.5 µM) potentiated the growth inhibitory effect of HDM201 and induced 
changes in cell cycle distribution in p53WT cells but, despite reducing the clonogenic cell 
survival, did not cause an increase in Sub-G1 on FACS analysis and there was no evidence of  
PARP cleavage in western blotting (Figure 6.4). This means that although WIP1i is 
potentiating the effects of HDM201 through the p53 pathway, it is still not inducing any 
apoptosis in these cell lines. This lack of apoptosis was further supported by a caspase 3/7 
activity assay that showed no detectable increase in the caspase activity in the treated cells 
whether they were treated with WIP1i alone, HDM201 alone or in combination. Furthermore, 
this applied for both p53WT and p53MUT/NULL cells (Figure 6.7). 
 
Figure 6.7: Caspase 3/7 activity in liver cancer cell lines after treatment with HDM201 
alone and in combination with GSK2830371 (2.5µM) WIP1i. Liver cancer cell lines with 
different TP53 status were treated with HDM201 alone and in combination with WIP1i 2.5 µM 
for 24 hours. For p53WT cell lines the GI50 (30 nM for HepG2 and 60 nM for SK-Hep-1) and 
10 times the GI50 of HDM201 was used alone and in combination with WIP1i 2.5 µM, while 
one high dose (1 µM) was used alone and in combination with WIP1i 2.5 µM in p53MUT/NULL 
cell lines.  (A) HepG2, (B) SK-Hep-1, (C) Huh-7 and (D) Hep3B. No detectable increase in 
caspase activity was evident, whether for HDM201 alone or in combination treatment. Error 
bars represent standard error of the mean of three independent repeats.  
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The XTT assay that assesses the mitochondrial enzymatic activity and confirmed the cells were 
still metabolically active after HDM201 treatment in chapter 5, once again confirmed that 
WIP1i (2.5 µM) on its own did not affect the metabolic activity of the cells (Figure 6.8). Even 
after combination with HDM201 and despite the growth inhibition, the cells were still 
metabolically active and generally their metabolic activity was maintained after 96hours 
treatment (Figure 6.8; A and B). P53MUT/NULL cells showed no detectable difference in the 
metabolic activity between any of the treatment conditions (Figure 6.8; C and D).  
 
 
Figure 6.8: XTT assay measuring the metabolic activity in liver cancer cell lines in 
response to HDM201 alone and in combination with GSK2830371 (2.5µM) WIP1i. Liver 
cancer cell lines with different TP53 status were treated with HDM201 alone and in 
combination with WIP1i 2.5 µM for 96 hours. For p53WT cell lines the GI50 (30 nM for HepG2 
and 60 nM for SK-Hep-1), 10 times the GI50 of HDM201 and a high dose of (1 µM) was used 
alone and in combination with WIP1i (2.5 µM), while for p53MUT/NULL cell lines only the high 
dose (1 µM) was used alone and in combination with WIP1i (2.5 µM).  (A) HepG2, (B) SK-
Hep-1, (C) Huh-7 and (D) Hep3B. Y-axis represent the optical density (OD) at 450 nanometre 
wavelength. Data represent mean± standard error of the mean (SEM) of three independent 
repeats.  
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6.9 The effects of WIP1i as a single agent and in combination with HDM201 
on the level of expression of p53 and its downstream transcriptional 
target genes in liver cancer cell lines 
The GSK2830371 WIP1i potentiated the effect of HDM201 in terms of growth inhibition, 
clonogenic cell survival, cell cycle arrest, stabilization of p53 and increased expression of p53 
downstream transcriptional targets at the protein level. We also investigated the effect of the 
inhibitor combination at the mRNA level of gene expression (Figure 6.9).  Cell lines were 
treated with each compound alone and in combination for two time-points (6 and 24 hours) and 
RNA was extracted.  A qRT-PCR assay was used to determine the compound-induced changes 
in the levels of expression of selected genes that represent different pathways activated by p53, 
but all are p53 downstream transcriptional targets. This set of genes includes the negative 
regulators of p53 (PPM1D and MDM2), cell cycle arrest genes (CDKN1A (p21WAF1) and 
GADD45A) and pro apoptotic genes governing both the intrinsic pathway (BAX and BBC3 
(PUMA)) and extrinsic pathway (FAS and TNFRSF10B (DR5)). 
In p53WT cells, the combination of WIP1i (2.5 µM) and HDM201 showed a prominent 
potentiation of the effects of HDM201 at the transcriptional level for both time points (6 and 
24 hours). In HepG2 the combination showed a significant increase in the transcript levels of 
the growth arrest genes CDKN1A (p21WAF1) (p=0.005) and GADD45A (p=0.005), in addition 
to MDM2 (p=0.04), BAX (p=0.01) and FAS (0.02) transcripts at 6 hours. After 24 hours the 
potentiating effect on the GI50 dose was still significant for CDKN1A (p21WAF1) (p=0.02), 
GADD45A (p=0.007) and BBC3 (PUMA) (p=0.02) (Figure 6.9; A).   
The effect was more prominent in SK-Hep-1 cell line at both the GI50 and the 10X GI50 with a 
significant increase in the transcriptional levels of MDM2 (p=0.01), CDKN1A (p21WAF1) 
(0.001) and GADD45A (p=0.01), and PUMA (p=0.04, 0.003 for GI50 and 10X GI50
 respectively) 
at 6 hours. After 24 hours the potentiating effect on the GI50 dose of HDM201 was still 
statistically significant for MDM2 (p=0.01), GADD45A (p=0.03) and CDKN1A (p21WAF1) 
(p=0.008) (Figure 6.9; B). 
There was no significant change at the transcriptional level in any of the investigated genes in 
p53MUT/NULL cell lines (Huh-7/Hep3B) despite using a very high dose (1µM) alone and in 
combination with GSK2830371 WIP1i (Figure 6.9; C and D). 
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Figure 6.9: The expression of TP53 and its downstream transcriptional targets by qRT-
PCR in response to HDM201 alone and in combination with GSK2830371 WIP1i in liver 
cancer cell lines. Different doses of HDM201 were used (GI50 and 10X GI50 for p53
WT and 
1µM for p53MUT/NULL) alone and in combination with WIP1i (2.5 µM) for 6 and 24-hour time 
points. The expression was relative to DMSO control and GAPDH was used as an internal 
reference gene (A) HepG2, (B) SK-Hep-1, (C) Huh-7 and (D) Hep3B. Data represent mean ± 
SEM of three independent repeats.  
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6.10 GSK2830371 potentiate the HDM201 induced senescence in p53WT cell 
lines 
In Chapter 5 it was shown that HDM201 induced cell cycle arrest and senescence in p53WT 
HepG2 and SK-Hep-1 cells, particularly at high dose (5.5).  Combination treatment with the 
GSK2830371 WIP1i (2.5 µM) potentiated this effect and on Incucyte time lapse imaging, the 
number of cells that recovered from growth inhibition was much lower than for the 
corresponding HDM201 only treated cells (Figure 6.10; Figure 6.11).  
These results were further supported by SA-β-Gal staining for senescence, which showed 
potentiation of the effect of HDM201 by WIP1i, reflected by the increased percentage and 
intensity of positively stained cells (green-blue) for the combination treatment (Figure 6.12; 
Figure 6.13). This potentiation was statistically significant with p values of (0.01, 0.001) for 
WIP1i + 0.5 GI50 and (0.01, 0.026) for the WIP1i + GI50 of HDM201 in both SK-Hep-1 and 
HepG2 respectively (Figure 6.14).  
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Figure 6.10: Incucyte experiment showing the effect of HDM201 alone and in combination with GSK2830371 WIP1i on HepG2 p53WT 
liver cancer cell line. Cells were treated with the GI50 and 10X GI50 of HDM201 alone and in combination with WIP1i 2.5 µM for 96 hours. The 
compounds were removed by replacing the media and the cells were left to grow. Sequential pictures were taken every 6 hours. Magnification 
power 10X, Scale bar = 300 µM. 
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Figure 6.11: Incucyte experiment showing the effect of HDM201 alone and in combination with GSK2830371 WIP1i on SK-Hep-1 p53WT 
liver cancer cell line. Cells were treated with the GI50 and 10X GI50 of HDM201 alone and in combination with WIP1i 2.5 µM for 96 hours. The 
compounds were removed by replacing the media and the cells were left to grow. Sequential pictures were taken every 6 hours. Magnification 
power 10X, Scale bar = 300 µM. 
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Figure 6.12: GSK2830371 WIP1i potentiates HDM201 induced senescence in HepG2 p53WT liver cancer cell line. SA-β-Gal staining of 
HepG2 after treatment with DMSO, 0.5 GI50 and GI50 of HDM201 alone and in combination with WIP1i (2.5 µM) for 96 hours at 10X, 20X and 
40X magnification power. Positive cytoplasmic staining (blue-green) is shown in a few cells in the DMSO control but the number of positive 
stained cells and the intensity of staining increases with the dose of HDM201 and this was further potentiated after combining HDM201 with 
WIP1i to include most of the cells that are treated with the combination. 
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Figure 6.13: GSK2830371 WIP1i potentiates HDM201 induced senescence in SK-Hep-1 p53WT liver cancer cell lines. SA-β-Gal staining of 
SK-Hep-1 after treatment with DMSO, 0.5 GI50 and GI50 of HDM201 alone and in combination with WIP1i (2.5 µM) for 96 hours at 10X, 20X 
and 40X magnification power. Positive cytoplasmic staining (blue-green) is shown in a few cells in the DMSO control but the number of positive 
stained cells and the intensity of staining increases with the dose of HDM201 and this was further potentiated after combining HDM201 with 
WIP1i to include most of the cells that are treated with the combination. SK-Hep-1 cells also showed a change in morphology, becoming larger in 
size compared to DMSO control. 
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Figure 6.14: GSK2830371 WIP1i potentiation of HDM201 induced senescence in p53WT 
liver cancer cell lines. While there was no significant difference between the DMSO control 
and WIP1i (2.5 µM), both p53WT cell lines, HepG2 (A) and SK-Hep-1 (B) showed significant 
potentiation of senescence by WIP1i for both 0.5 GI50 (p=0.001, 0.01) and the GI50 doses of 
HDM201 (0.026, 0.01) respectively. ns= not significant. Data represent mean ± SEM of three 
independent repeats. 
 
 
Figure 6.15: Schematic summary representing the p53 pathway and the effect of MDM2 
and WIP1 inhibition. Linking p53 activation to downstream transcriptional targets that induce 
the dominant response of cell cycle arrest and senescence by MDM2 inhibition in HepG2 and 
SK-Hep-1 cells, which is potentiated by WIP1 inhibition.  
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6.11 The effect of GSK2830371 as a single agent and in combination with 
HDM201 on HepG2-Luc 
Because of the potential for in vivo xenograft imaging, a large number of experiments was 
carried out to test whether the luciferase transfected HepG2-Luc cell line retained its p53WT 
status and behaves in the same way as the parental HepG2 cell line. These experiments 
confirmed that HepG2-Luc response to GSK2830371 as a single agent and in combination with 
HDM201 was the same as HepG2, in terms of growth inhibition (Figure 6.16; A), clonogenic 
survival (Figure 6.16;B), caspase 3/7 activity (Figure 6.16; C and D), or metabolic activity 
(Figure 6.16; E and F), cell cycle changes (Figure 6.17; A and B) and mRNA expression of 
p53 transcriptional target genes (Figure 6.17; C and D).  
 
Figure 6.16: Comparison of the effect of GSK2830371 WIP1i alone and in combination 
with HDM201 on HepG2 and HepG2-Luc. (A) Growth inhibition assay (SRB) of HepG2 and 
HepG2-Luc after exposure to WIP1i (0.07-10 µM) for 96 hours. (B) Clonogenic survival assay 
of HepG2-Luc after exposure to HDM201 (1-156 nM) alone and in combination with WIP1i 
(2.5 µM) for 96 hours. (C) and (D) Caspase 3/7 assay of HepG2 and HepG2-Luc respectively 
after exposure to WIP1i (2.5 µM) alone and in combination with the GI50 and 10X GI50 of 
HDM201 for 24 hours. (E) and (F) XTT assay measuring the mitochondrial metabolic activity 
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of HepG2 and HepG2-Luc respectively after exposure to WIP1i (2.5 µM) alone and in 
combination with GI50 and 10X GI50 and 1µM of HDM201 for 96 hours. Error bars represent 
the standard error of the mean of three independent repeats. 
 
Figure 6.17: Cell cycle analysis and mRNA expression of p53 transcriptional target genes 
in HepG2 and HepG2-Luc. (A) and (B) FACS analysis of the cell cycle in HepG2 and HepG2-
Luc respectively in response to WIP1i (2.5 µM) alone and in combination with GI50 and 10X 
GI50 doses of HDM201 for 24, 48 and 72 hour time points. (C) and (D) represent the expression 
of TP53 and its downstream transcriptional targets by qRT-PCR in HepG2 and HepG2-Luc 
respectively in response to GSK2830371 WIP1i (2.5 µM) alone and in combination with GI50 
and 10X GI50 doses of HDM201 for 6 and 24 hour time points. The expression was relative to 
DMSO control and GAPDH housekeeping gene was used as an internal reference. Error bars 
represent ±SEM for three independent repeats.  
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6.12 Discussion 
The inhibitory effect of GSK2830371 on WIP1 phosphatase (239) was confirmed by Western 
blot analysis of p53ser15 phosphorylation status and WIP1 protein levels. Even at low doses of 
GSK2830371 as a single agent there was a prominent reduction in WIP1 protein level with an 
increase in the phosphorylation of p53ser15 and concomitant increased p53Lys382 acetylation, in 
addition to a mild induction of p21 in immunoblotting of p53WT HepG2 and SK-Hep-1 liver 
cancer cell lines. This is consistent with previous reports in other types of cancer cell lines (239, 
345, 346). The mild induction of p21 explains the small growth inhibitory effect of 
GSK2830371 alone at high doses in p53WT cell lines.   
Recent studies including those by our own group have reported that GSK2830371 can 
potentiate the p53-dependent effects of Nutlin-3 and our own group extended these observations 
to the clinically relevant RG7388 (Idasanutlin) MDM2 inhibitor (339, 345, 346). The work 
described in this thesis extends these studies to liver cancer cell lines and includes the more 
potent and specific HDM201 inhibitor. A low dose of GSK2830371 (2.5 µM) which had 
minimal effect on its own was shown to significantly potentiate the growth inhibitory effect of 
all the three tested MDM2 inhibitors and reduced their GI50 by 2-3-fold and also significantly 
reduced the clonogenic survival (LC50) of p53
WT liver cancer cell lines.   
Other studies have reported that potentiation of the effect of MDM2 inhibitors by combination 
with GSK2830371 and MDM2 inhibitors includes the induction of apoptosis (345, 346); but a 
major difference with the tested p53WT liver cancer cell lines was absence of the induction of 
apoptosis,  as evidenced by no change in Sub-G1 in FACS based cell cycle analysis, no increase 
in the caspase 3/7 catalytic activity, no evidence of PARP cleavage by western blot and 
continued evidence of mitochondrial metabolic activity despite sustained inhibition of 
proliferation. At the protein level there was marked stabilization of p53 and increase in the 
levels of the phosphorylated p53 and acetylated p53 in addition to prominent increases in p53 
downstream transcriptional targets MDM2 and p21.  
GSK2830371 potentiated the effect of HDM201 on the induction of senescence, manifested by 
increased SA-β-Gal staining, as well as the increased number of cells not recovering from 
growth inhibition and not dividing even 12 days after removal of the drug combination.  The 
lack of an apoptotic response and potentiation of MDM2i induced senescence by WIP1 
inhibition may be a feature of some liver cancers, which should be explored further. This was 
supported by the observed arrest of the cells in G1 and G2 phases, together with pronounced 
increases in CDKN1A (p21WAF1) transcript and p21WAF1 protein expression, which has been 
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reported to be necessary for senescence (347, 348). This is in accord with recent reports that 
combination of GSK2830371 treatment with Nutlin-3 can induce senescence in some breast 
and colon cancer cell lines (339, 345). 
Despite the fact that PPM1D was not mutated or amplified in either of the tested p53WT liver 
cancer cell lines, chemical inhibition of WIP1 nevertheless potentiated the sensitivity of these 
cell lines to MDM2 inhibitors, which opens the possibility for future use of this combination in 
the treatment of patients with liver cancers that warrants further exploration. 
In clinical trials, one of the reported dose-limiting main side effects of MDM2 inhibitors, 
including HDM201, is haematological (thrombocytopenia and neutropenia) (217, 314); by 
using combinations of HDM201 + WIP1i it may be possible to reduce the required dose of 
MDM2 inhibitors to induce tumour regression and growth inhibition without potentiating the 
side effects of using MDM2 inhibitors on their own.  This could allow patients to benefit from 
non-genotoxic activation of p53 with minimal side effects. However, for systemic treatment 
this would depend on the absence of a potentiating effect on the haematological toxicity, which 
would have to be explored first.   
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The incidence of HCC is increasing in many parts of the world. Despite the advances in 
treatment options for different types of cancers that have led to a decrease in the mortality rate 
over the last two decades, HCC stands out with a dramatic increase in the mortality rate.  This 
reflects incidence, but is also attributable to typically late diagnosis due to the lack of clinical 
manifestations in the earlier stages, and the lack of effective treatment for advanced cases (308). 
NAFLD is the commonest chronic liver disease in western populations and several studies have 
confirmed that NAFLD is a risk factor for HCC development. NAFLD is estimated to affect 
25% of the global population, and even though only 3-5% of those affected develop NASH, 
this still represents a huge number of people at risk of developing cirrhosis and cirrhosis related 
HCC (16). Recent reports also indicate that many NAFLD-HCC cases occur without cirrhosis 
(93). In combination, these reports suggest that the rising HCC mortality is partly attributable 
to NAFLD-HCC and highlight the urgent need to have a better understanding of this disease 
and to find a treatment for NAFLD, which would prevent the development of HCC in those 
patients. 
It has been reported that NAFLD related HCC patients have a shorter survival by 5 months 
compared to other causes of HCC like hepatitis (349). This has been attributed to the fact that 
viral hepatitis patients more often undergo frequent screening, and also that in obese NAFLD 
patients who are having surveillance, early stage HCC is more difficult to detect by abdominal 
ultrasound scanning – the standard technique used. Furthermore, NAFLD is part of a metabolic 
syndrome in which other comorbidities and risk factors like cardiovascular disease that increase 
mortality can limit patient treatment options like surgical resection and liver transplantation. 
Collectively all these factors can make NAFLD–HCC a sub-category of HCC with poorer 
prognosis (349).  
We have succeeded in our attempt to mimic the development of NAFLD and to have a better 
understanding of the course and progression of the disease, including the development of HCC 
in NAFLD. By feeding C3H/He mice the ALIOS diet (rich in trans-fatty acids and fructose 
sweetened water) for up to 1 year, we have created an animal model that recapitulates what 
happens in the general population. The mice developed obesity and NAFLD, with many of the 
histological features characteristic of NASH, as well as liver tumour development (shown in 
chapter 3). We explored two candidate interventions in an attempt to prevent HCC development 
in NAFLD, namely the antioxidant bucillamine and an FXR agonist (PX20606). Our 
hypotheses were that the use of antioxidant drug will prevent DNA damage induced by free 
fatty acid generated ROS, improve NASH and prevent HCC development, while the use of 
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FXR agonist would similarly alleviate steatosis and improve NASH through effects on the 
regulation of lipid metabolism.   
In the dietary animal model without interventions, the mouse livers showed increases in liver 
weight and steatosis and increased DNA damage manifested by the elevated levels of γ-H2AX 
positive nuclei and increased levels of p53. Notably, liver weight increased in the aging mice, 
which was attributed partly to accumulation of fat, but also to an elevation in hepatocyte 
proliferation manifested by the elevated levels of Ki67 positive nuclei in the ALIOS fed 
animals. Both DNA damage and Ki67 positive hepatocytes were most prominent around the 
portal tracts where the fat had accumulated (periportal steatosis), in keeping with a relationship 
with chronic liver injury.  
The main predictors of tumour development in the dietary animal model were the liver weight 
itself, steatosis, proliferation (Ki67) and lipogranuloma. As lipogranulomas are defined as fat 
surrounded by macrophages, we hypothesize that steatosis and macrophages are the main 
drivers of HCC development in our model, alongside the creation of a fatty liver disease induced 
proliferative environment.  
In chapter 4 we explored the impact of dietary supplementation with bucillamine and despite 
showing a highly significant reduction in the DNA damage levels (γ-H2AX), and despite 
showing a significant effect on improvement of the NASH score, through abolition of 
Ballooning and improvement of fibrosis, mice nevertheless still developed tumours. 
Bucillamine treatment did not result in any improvement of liver weight, steatosis nor 
lipogranuloma – supporting further our belief that these were the key predictors of tumour 
development in our dietary animal model. Additionally, bucillamine did not have any effect on 
the proliferative environment in ALIOS animal livers, as measured by Ki67. 
Presently, the mechanisms underlying the proliferative environment that promotes tumour 
development in this NAFLD model remain to be established.  Activation of the Hedgehog 
pathway offers one potential candidate mechanism worthy of consideration. The Hedgehog 
(HH) signalling pathway got its name from the abnormal hedgehog-like protrusions on the fly 
larva that had mutation in this pathway. This pathway has a role in embryonic liver 
development. It also controls cell proliferation, migration, differentiation and survival (350-
352). It consists of seven components which comprise the HH ligands, transmembrane Patched 
receptor (PTCH) which continuously represses the HH pathway, the transmembrane receptor 
smoothened (SMO) and Glioma associated oncoprotein (GLI). The pathway is repressed by 
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binding of PTCH to SMO in the absence of the ligand. In the presence of the ligand, the 
inhibitory effect of PTCH is abolished and SMO is activated, leading to re-localisation of the 
GLI transcription factors into the nucleus to induce transcription of several targets that controls 
cellular proliferation, differentiation and survival (350, 352, 353). These pathway components 
have been found to be mutated in different types of cancers (liver cancer, prostatic, ovarian and 
neuroblastoma) and contribute to their progression and development (114). Previous studies 
reported the expression levels of HH components to be higher than adjacent liver tissues in 65-
72% of HCC cases (354). 
In normal liver the HH pathway is inactivated but it has been found to be activated in chronic 
liver injury and responsible for hepatic progenitor cell fate - and the regeneration and 
development of hepatocytes. Activation of HH in hepatic stellate cells is also partly responsible 
for the transformation of hepatic stellate cells into myofibroblast-like cells which promote liver 
fibrosis (350, 351). During NAFLD there is continuous state of injury and healing therefore 
there is continual activation of the HH pathway, which may contribute to hepatocarcinogenesis.  
HH expression is reported to be increased in NAFLD liver and in ballooned hepatocytes and to 
correlate with the severity of NAFLD (355). Furthermore, interestingly, HH activation was 
found to be associated with macrophage recruitment into the liver through osteopontin 
production as a downstream transcriptional target of HH. Osteopontin is an extracellular matrix 
protein that plays a role in macrophage recruitment and activation, together with the secretion 
of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and monocyte chemotactic protein 1 
(MCP1)) (Figure 7.1) (350, 355).   
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Figure 7.1: Hedgehog signalling pathway in NAFLD adapted from Seki 2016 (350).In the 
absence of ligand, the PTCH binds to SMO and inhibits the HH signalling. In the presence of 
ligand (Shh), which binds to PTCH, the inhibitory effect of PTCH on SMO is relieved. This 
results in activation of the HH pathway. As a result, GLI (transcriptional factor) translocate to 
the nucleus and induces transcription of several targets. One of the transcriptional targets is 
osteopontin that is produced by ballooned hepatocytes. Osteopontin induces liver accumulation 
of macrophages that secrete chemokines and lead to progression of NAFLD. Additionally, 
ballooned hepatocytes activate HH in other cell types through a paracrine effect; in the stellate 
cells this leads to fibrosis, in the adipocytes it leads to insulin resistance, and via the 
macrophages to the progression of NAFLD. The use of a SMO inhibitor suppresses HH 
signalling and consequently helps to prevent NAFLD progression and insulin resistance.  
 
The second intervention in our animal model, was the FXR agonist (PX20606) (Chapter 4).  
Despite the previous reports that showed a beneficial effect of FXR agonist treatment in NASH, 
our FXR agonist PX20606 did not show a similar effect. PX20606 caused an increase in 
steatosis and inflammation and a significant increase in liver fibrosis. Liver enzymes were also 
increased. These changes were more prominent in the control diet animals. Furthermore, 
PX20606 did not prevent tumour development - on the contrary it caused more tumours in the 
control diet groups.  We have been unable to pursue further mechanistic studies with PX20606.  
It is worth noting, however, that the effects of PX20606 in the control animals was dose related.  
Ideally, an agent which may have a relatively narrow therapeutic window, or where this is not 
defined, should be given by gavage in a more controlled fashion, rather than as a supplement in 
the diet. It is unlikely that the observed toxicity was a result of a ‘class effect’, as similar effects 
have not been seen with similar agents in either animal of human studies. The other point to 
note, was the further increase seen in Ki67 induced proliferation. FXR agonists can contribute 
directly to liver regeneration and in our model this may have been exacerbated as a consequence 
of liver injury.  While this may be of benefit in the context of chronic liver injury, the association 
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between Ki67 and tumour formation was clear in our model.  While this may be a cause for 
caution, the elevated risk was in control animals.  While theoretically one might be concerned 
about a potential increase in non-cirrhotic HCC if FXR agonists are widely used, this concern 
should be academic only, as patients with mild NAFLD (less than F2 fibrosis in current clinical 
practice), should not be treated with agents to delay progression.   Ideally, the research 
community and Pharma should openly discuss these issues and how to manage them going 
forward. 
After our success in creating the animal model, in which we failed to prevent the development 
of HCC, with either intervention studied, we directed our interest to p53, and its potential role 
in the treatment of HCC. The incidence of TP53 mutation in liver cancer is in less than 30% of 
HCC cases and additional mechanisms of its inactivation are suspected.  RNA sequencing 
analysis of the HCC in the tumours from our animal model confirmed an absence of mutation 
in p53. Overall though, although the p53 pathway appeared intact, it was ineffective in our 
model.  In the ALIOS mice, the immunohistochemical staining for p53 showed increases in the 
percentage of positively stained nuclei in the areas of fat accumulation and DNA damage (γ-
H2AX) (periportal). The p53 protein showed a positive correlation with Cdkn1a (p21) mRNA, 
suggesting it was functional. Additionally, the percentage of p53 positive nuclei was higher in 
tumours compared to the peritumoural area. In addition, the p53 downstream target Cdkn1a 
(p21) showed a striking increase at the mRNA level in tumours compared to non-tumours. 
Despite the increase in p53 and the 14 fold increase in Cdkn1a (p21), a large number of tumours 
did not express p21 protein and this increase in p53 was not sufficient to stop tumour 
development and proliferation.   
Focused subsequently on p53, we hypothesised that exploiting the p53 pathway through non-
genotoxic activation of p53 would cause growth inhibition of p53WT liver cancer cell lines and 
could be of use in treating p53WT HCC. 
In chapter 5 we showed that small molecule inhibitors of MDM2 cause growth inhibition of 
p53WT liver cancer cell lines (HepG2 and SK-Hep-1) and that this can be achieved by nanomolar 
range doses of the clinically relevant MDM2 inhibitor, HDM201. This was shown by SRB 
growth inhibition and clonogenic cell survival assays. Supporting evidence of mechanism was 
provided by the prominent stabilisation of p53 and the increase in TP53 downstream 
transcriptional targets (CDKN1A (p21) and MDM2) by qRT-PCR and Western blotting analysis 
(Chapter 5). But notably, the growth inhibition by HDM201 was not accompanied by any signs 
of apoptosis; there was no increase in caspase 3/7 activity nor of the apoptotic markers on 
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Western blot analysis. Furthermore, the cells maintained their mitochondrial activity (measured 
by XTT assay) despite prolonged growth inhibition following MDM2 inhibition. This prompted 
us to further hypothesise that non genotoxic activation of p53 through MDM2-p53 inhibition 
will induce senescence in p53WT liver cancer cell lines.  
Leonard Hayflick and Paul Moorhead reported senescence more than 50 years ago (356). 
Senescence (which describes a permanent cell cycle arrest) is a potent tumour suppressor 
mechanism (357). Several reports indicated that activation of p53 in tumour cells, even if it was 
transient, can induce tumour regression, and this regression is tumour type dependent. It has 
been reported that activation of p53 induces apoptosis in some cells types but in the absence of 
apoptosis can produce reversible growth arrest, or induce senescence in other cell types, e.g. 
apoptosis in lymphoid cells and senescence in HCC and some types of sarcoma (357). The role 
of p53 and induction of senescence in liver cancer has been reported for KrasV12 transduced 
embryonic hepatoblasts injected subcutaneously or into the livers of mice, which then develop 
tumours. The mice in that study had doxycycline-inducible p53, and upon doxycycline 
treatment, even for 2 days, there was p53 activation which induced senescence shown by SA-
β-Gal positive staining and p16 and p15 positivity (210, 337). The tumours not only showed 
senescence, they showed regression. The regression was through recruitment of inflammatory 
cells (macrophages, neutrophils and natural killer cells) that caused the involution of tumours 
by immune clearance. This was achieved through the chemokines secreted by the senescent 
tumour cells, like monocyte chemoattractant protein1 (MCP1) that recruits macrophages. 
Neutrophil activating protein 3 or CXCL1 that attracts neutrophils was elevated, as was IL15 
that induces activation and proliferation of natural killer cells (210). This tumour regression 
was absent in tumours grown in immunocompromised NSG mice, confirming the role of innate 
immunity in tumour clearance (210, 337).  
In (chapter 5) and through our in vitro work and in vivo HepG2 xenograft model we confirmed 
our hypothesis. We showed for the first time that non-genotoxic activation of p53 through 
inhibition of MDM2-p53 caused p53-dependent growth inhibition resulting from the induction 
of senescence in p53WT liver cancer cell lines (HepG2 and SK-Hep-1). For this we used the 
small molecule inhibitor of MDM2, HDM201. This was evidenced by the significant increase 
in CDKN1A at both the mRNA level and the protein level, which was associated with cell cycle 
arrest and positive staining for the senescence marker, SA-β-Gal. In addition, Incucyte 
experiments showed through time-lapse image capture that the p53WT liver cancer cells failed 
to proliferate after removal of HDM201.  
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In the in vivo study, treatment of the NSG mice with HDM201 at a dose of 100 mg/kg/day for 
10 days caused sustained tumour growth delay after treatment was stopped. This was most 
probably through induction of senescence.  However, due to the experiment planning and the 
need to use severely immunocompromised NSG mice that lack natural killer, B and T 
lymphocytes, we could not investigate the presence of senescence in our treated xenografts, nor 
study the effect of senescence induced immune clearance of tumour cells. 
After the encouraging results with MDM2 inhibitors described in chapter 5, we decided to take 
a step further and explore the effect of GSK2830371, a small molecule inhibitor of WIP1, 
another downstream target of p53. WIP1 is part of an additional negative autoregulatory 
feedback loop, which in this case downregulates p53 function through dephosphorylation of 
p53 protein. From the literature it has been reported that WIP1 is overexpressed in 
approximately 59-65% of HCC cases and is associated with poor prognosis (229, 232). As it is 
a negative regulator of p53 function, we hypothesised that inhibition of WIP1 would help to 
maintain p53 in its active phosphorylated state and accentuate the effect of p53 release by 
MDM2 inhibitors, thereby potentiating growth inhibition by MDM2 inhibitors in p53WT HCC 
cell lines. In chapter 6 we showed that GSK2830371 (WIP1i) on its own did not have a big 
inhibitory effect on the growth of liver cancer cell lines. There was a mild growth inhibitory 
effect, but it did not exceed 23% at a dose of 2.5 µM in p53WT liver cancer cell lines, which was 
chosen for subsequent combination studies with MDM2 inhibitors.  
Combined targeting of both the PPM1D/WIP1 and MDM2 negative feedback suppressors of 
p53 in TP53 wild-type human liver cancer cells was confirmed to potentiate the growth 
inhibitory effects of these compounds. This was shown in vitro with a dose of GSK2830371 
(WIP1i), which had minimal effect on its own, producing several-fold reductions in the doses 
of MDM2 inhibitors to achieve GI50 and LC50 levels of growth inhibition and clonogenic 
survival for p53WT liver cancer cell lines (HepG2 and SK-Hep-1). The combination with 
GSK2830371 increased stabilisation of total and phosphorylated p53 and the expression of p53 
downstream targets (p21 and MDM2) at the mRNA and protein level compared to MDM2 
inhibitors alone.  GSK2830371 also potentiated the effect of HDM201 on arresting the cell 
cycle and on the induction of senescence, shown by increased numbers of SA-β-Gal positively 
stained liver cancer cell lines in the presence of combined GSK2830371 and HDM201 
treatment.   
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In summary,  
• Using a combination of C3H/He mice and the ALIOS diet, an animal model of the 
metabolic syndrome associated with NAFLD, NAFLD progression to NASH and 
fibrosis, and development of HCC was created.  
• DNA damage (γ-H2AX) was increased upon feeding ALIOS diet and DNA damage 
response (p53) was increased and both correlated with NAFLD progression. 
• Age, as well as steatosis contributed to the creation of a proliferative environment 
(Ki67) that associated with tumour development. 
• Liver weight, steatosis grade, lipogranuloma were independent predictors of tumour 
development 
• The Bucillamine intervention reduced DNA damage and reduced ballooning and 
fibrosis but did not reduce liver weight, steatosis, lipogranuloma nor Ki67 and did not 
prevent tumour development. 
• The FXR agonist (PX20606) did not improve NAFLD in ALIOS fed animals and caused 
worsening of NAFLD in the control diet animals, in association with an increase in the 
number of tumours in the control animals. 
• All NAFLD-HCC were of p53 wild type status. 
• p53 was not adequately functional as a tumour suppressor, despite its wild type status 
and despite elevated Cdkn1a(p21) expression. 
• We nevertheless showed the p53 pathway could be exploited through non-genotoxic 
activation of p53 by MDM2-p53 binding antagonists that caused growth inhibition of 
p53WT liver cancer cell lines in vitro and in vivo through induction of senescence. This 
may be relevant for the future treatment of patients with p53WT HCC. 
• Combined targeting of the PPM1D/WIP1 and MDM2 negative feedback suppressors of 
p53 in TP53 wild-type human liver cancer cells was demonstrated through the use of 
GSK2830371 (WIP1 inhibitor) which potentiated the effect of the MDM2 inhibitor 
(HDM201) on the induction of senescence in p53WT liver cancer cell lines.  
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Future directions: 
1)- Detailed comparative analysis of the RNAseq data from the dietary animal model liver 
samples, between samples from the control  and ALIOS treated mice and in the tumour samples 
will enable us to have a better understanding of the changes induced by the ALIOS diet and the 
changes that accompanied and led to hepatocarcinogenesis. 
2)- Immunophenotyping of the liver and HCC FFPE tissue section to have a better 
understanding of the role of immunity in NAFLD progression and tumour development - in 
light of our data showing steatosis and lipogranuloma (macrophages) to be the independent 
predictors of tumour development. Several markers of inflammatory cells are suggested for 
characterisation (F4/80, CD4, CD8, Ly6C and neutrophil elastase). 
3)- Exploring the expression of Hedgehog pathway components in our animal model. 
4)- To further support the evidence of MDM2 inhibition induced senescence in p53WT cell lines 
and xenografts, staining for Ki67 can be helpful, as the absence of Ki67 staining should help to 
recognise senescent cells. Additional markers of senescence that can be tested and probed for 
include p16 and p15 cyclin dependent kinase inhibitors, transforming growth factor-β (TGFβ), 
plasminogen activator inhibitor 1 (PAI1), insulin-like growth factor 1 (IGF1)-binding 
proteins, DEC1 (also known as TNFRSF10C) and decoy receptor 2 (DCR2; also known as 
TNFRSF10D) (356). 
4)- To further support that p21 is the main factor responsible for MDM2 inhibitor induced-
senescence, knocking down p21 expression in p53WT liver cancer cell lines (HepG2 and SK-
Hep-1) followed by treatment with MDM2 inhibitors for the same duration (96 hours), and then 
testing for markers of senescence, like SA-β-Gal staining, will clarify whether this senescence 
induction was p21 mediated and dependent.   
5)- The in vivo effects need further work. To clearly show that MDM2 inhibitor treatment 
activated p53 and lead to increase in TP53 downstream transcriptional targets in HepG2 
xenografts, we suggest repeating the xenograft model with the same dose but culling the 
animals immediately after stopping treatment. This would facilitate assessment of p53 
reactivation and evidence of its downstream targets p21 and MDM2 in the xenograft tumours 
at the protein level (IHC and Western blot) as well as detection at the RNA level, using real 
time PCR. Evidence of senescence could be tested using other markers of senescence, like SA-
β-Gal staining of the xenografts or other markers like p16 and p15.  
222 
 
6)- Loco regional delivery of MDM2 inhibitors as a treatment option for HCC. The main 
systemic side effects of MDM2 inhibitors are haematological, to reduce these side effects loco 
regional delivery of the MDM2 inhibitors to HCC may be useful to avoid or minimise these 
side effects. This can be achieved through TACE, but instead of loading the beads with 
doxorubicin that is commonly used in TACE, MDM2 inhibitors can be loaded onto the beads 
and in this way patients with HCC of p53WT status should benefit from the effect of p53 
activation through MDM2 inhibitors in their tumours without having to expose all the body 
tissues to the effect of these drugs. 
7)- Combining MDM2 inhibitors and other drugs in the treatment of HCC. The only first line 
systemic FDA approved treatment for HCC is the multikinase inhibitor sorafenib (308). We 
showed that the use of MDM2 inhibitors have a significant growth inhibitory effect on p53WT 
liver cancer in vitro and in vivo in chapter 5. Both drugs (HDM201 and sorafenib) are known 
to have side effects, sorafenib associated with the hand-foot syndrome and gastrointestinal 
disturbances, while HDM201/MDM2 inhibitors have dose dependent myelosuppression. The 
use of combination treatment of more than one compound aims at reducing the required dose 
and have a synergistic effect on inhibiting tumour growth. Several reports in acute myeloid 
leukemia and renal cell carcinoma indicated that the combined treatment of MDM2 inhibitors 
and sorafenib is synergistic, with increased growth inhibition and apoptosis and decreased 
migration of cancer cells (358, 359). Based on our initial in vitro data, another suggested 
combination worth pursuing is the combination of MDM2 inhibitors with a WIP1 inhibitor. 
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Limitations of our work:  
One of the main limitations of the dietary animal model and the interventions used was 
delivering accurate doses. Because of the large number of animals and the long duration of the 
study, delivering accurate doses of bucillamine and PX20606 through oral gavage was a big 
challenge, therefore we used an estimate method of delivering the drugs through calculating the 
weekly average consumption of food by mice and accordingly integrated the drug of choice 
with the food pellet, but having several mice per cage (4) made delivering accurate doses 
challenging. Assessing whether the drugs were reaching therapeutic levels in the treated 
animals after this method of drug delivery can be assessed. This can be achieved directly 
through checking drug levels in the collected blood samples from the treated mice or indirectly 
through assessing the expression of FXR-target genes (e.g. FGF19) at the protein level through 
IHC or western blotting. 
The second limitation was the difficulty in getting specific antibodies for immunohistochemical 
staining and Western blotting due to the fact that the vast majority of the specific and sensitive 
antibodies are mouse monoclonal antibodies designed against human versions of the protein 
targets. Our study was in mice, therefore it was not practically possible to use mouse antibodies 
and we had to search for antibodies from different species that were mostly polyclonal and less 
specific than the mouse monoclonal antibodies.  
Another limitation of the in vitro work was the lack of a p53 wild type hepatocellular carcinoma 
cell line, as both p53WT cell lines used were of Hepatoblastoma origin (HepG2) and 
cholangiocarcinoma (SK-Hep-1). The vast majority if not all the available HCC cell lines were 
of p53MUT and those that were supposed to be p53WT HCC cell lines, after thorough search at 
the time of the study appeared to be not HCC but other types of liver tumours e.g Huh-6 clone 
5 which is supposed to be p53 wild type was another hepatoblastoma cell line. To overcome 
this obstacle we tried to grow our own primary liver cancer cell line using surgical biopsy 
tumour sample taken from patient with HCC. Unfortunately, after few passages the cells 
stopped growing and underwent senescence manifested by morphological changes. This was 
probably mediated by p53, which might explain the rarity of p53WT HCC cell lines and that our 
two p53WT liver cancer cell lines were harbouring Ras mutations that probably enabled them to 
overcome this and continue to proliferate in cell culture.  
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135. Burt AD, Ferrell LD, Hübscher S. MacSween's pathology of the liver. Seventh edition. 
ed: Philadelphia, PA : Elsevier; 2018. 
136. Schlageter M, Terracciano LM, D'Angelo S, Sorrentino P. Histopathology of 
hepatocellular carcinoma. World Journal of Gastroenterology. 2014;20(43):15955-64. 
137. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 
48,900 necropsies. Cancer. 1954;7(3):462-503. 
138. Kojiro M. Pathology of hepatocellular carcinoma.: Blackwell Publishing Ltd.; 2009. 1–
184 p. 
139. Salomao M, Yu WM, Brown RS, Jr., Emond JC, Lefkowitch JH. Steatohepatitic 
hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C 
virus-related cirrhosis with associated NAFLD/NASH. The American Journal of Surgical 
Pathology. 2010;34(11):1630-6. 
140. Goldblum. JR, Lamps. LW, McKenney. JK, Myers. JL. Rosai and Acherman's surgical 
pathology. Eleventh edition. Philadelphia, PA: Elsevier; 2017. 
141. Park HS, Jang KY, Kim YK, Cho BH, Moon WS. Hepatocellular carcinoma with 
massive lymphoid infiltration: a regressing phenomenon?. Pathology Research and Practice. 
2009;205(9):648-52. 
142. Brierley DJ, Gospodarowicz MK, Wittekind C (Eds). TNM  classification of malignant 
tumours. Eighth edition.: Wiley-Blackwell; 2017. 
143. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging 
classification. Seminars in Liver Disease. 1999;19(3):329-38. 
144. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective 
validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology. 
2006;44(4):723-31. 
145. Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular 
carcinoma. World Journal of Gastroenterology. 2014;20(30):10223-37. 
146. Wang H, Liu H, Chen K, Xiao J, He K, Zhang J, et al. SIRT1 promotes tumorigenesis 
of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncology Reports. 
2012;28(1):311-8. 
147. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early 
hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434-40. 
235 
 
148. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular 
carcinoma at a Western center. Annals of Surgery. 1999;229(6):790-9; discussion 9-800. 
149. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 
2005;42(5):1208-36. 
150. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver 
transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. 
The New England Journal of Medicine. 1996;334(11):693-9. 
151. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in 
advanced hepatocellular carcinoma. The New England Journal of Medicine. 2008;359(4):378-
90. 
152. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 
Journal of Hepatology. 2012;56(4):908-43. 
153. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al. Small 
hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous 
microwave coagulation therapy. Radiology. 2002;223(2):331-7. 
154. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation 
or chemoembolisation versus symptomatic treatment in patients with unresectable 
hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-9. 
155. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled 
trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. 
Hepatology. 2002;35(5):1164-71. 
156. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. 
Hepatocellular carcinoma. Nature Reviews Disease Primers. 2016;2:16018. 
157. Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, et al. 
Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for 
hepatocellular carcinoma before liver transplantation. World Journal of Gastroenterology. 
2013;19(34):5622-32. 
158. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et 
al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: 
downstaging to resection, RFA and bridge to transplantation. Journal of Surgical Oncology. 
2006;94(7):572-86. 
159. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, et al. Long-term effect of 
stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local 
ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 
2010;10:475. 
236 
 
160. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of 
sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase 
III randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009;10(1):25-
34. 
161. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for 
patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a 
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66. 
162. Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current 
perspectives and recent advances. The Journal of Pathology. 2017;241(1):36-44. 
163. Eccleston HB, Andringa KK, Betancourt AM, King AL, Mantena SK, Swain TM, et al. 
Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide 
bioavailability, and modifies the mitochondrial proteome in mice. Antioxidants & Redox 
Signaling. 2011;15(2):447-59. 
164. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Model of nonalcoholic 
steatohepatitis. The American Journal of Clinical Nutrition. 2004;79(3):502-9. 
165. Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B. Pathology of 
the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. 
International Journal of Experimental Pathology. 2011;92(6):413-21. 
166. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic 
fibrogenic response to chronic liver injury. Journal of Hepatology. 2002;37(2):206-13. 
167. Yamada T, Obata A, Kashiwagi Y, Rokugawa T, Matsushima S, Hamada T, et al. Gd-
EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis 
(NASH) in mice. Magnetic Resonance Imaging. 2016;34(6):724-9. 
168. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and 
steatohepatitis research. International Journal of Experimental Pathology. 2006;87(1):1-16. 
169. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, et al. High-
fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 
in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 
2010;52(3):934-44. 
170. Dragani TA, Manenti G, Gariboldi M, De Gregorio L, Pierotti MA. Genetics of liver 
tumor susceptibility in mice. Toxicology Letters. 1995;82-83:613-9. 
171. Oren M, Levine AJ. Molecular cloning of a cDNA specific for the murine p53 cellular 
tumor antigen. Proceedings of the National Academy of Sciences of the United States of 
America. 1983;80(1):56-9. 
237 
 
172. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clinical 
Cancer Research. 2008;14(17):5318-24. 
173. Meek DW. Regulation of the p53 response and its relationship to cancer. The 
Biochemical Journal. 2015;469(3):325-46. 
174. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene 
product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 
1992;69(7):1237-45. 
175. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. 
Molecular and Cellular Biology. 1993;13(7):4107-14. 
176. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous 
p53 by MDM2 and human papillomavirus E6. Molecular and Cellular Biology. 
1998;18(12):7288-93. 
177. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. 
Nature. 1997;387(6630):296-9. 
178. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in 
Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553):206-8. 
179. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in 
mdm2-deficient mice by deletion of p53. Nature. 1995;378(6553):203-6. 
180. Loughery J, Meek D. Switching on p53: an essential role for protein phosphorylation? 
Biodiscovery. 2013(8). 
181. Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the MDM2-p53 
protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. Journal of 
Medicinal Chemistry. 2015;58(3):1038-52. 
182. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 
2000;408(6810):307-10. 
183. Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in 
cancer. Acta Biochimica et Biophysica Sinica. 2014;46(3):170-9. 
184. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 
2009;458(7242):1127-30. 
185. Gire V, Dulic V. Senescence from G2 arrest, revisited. Cell Cycle. 2015;14(3):297-304. 
186. Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, et al. p53, a novel 
regulator of lipid metabolism pathways. Journal of Hepatology. 2012;56(3):656-62. 
187. Parrales A, Iwakuma T. p53 as a Regulator of Lipid Metabolism in Cancer. International 
Journal of Molecular Sciences. 2016;17(12). 
238 
 
188. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and 
ovarian tumors. Critical Reviews in Oncology/Hematology. 2004;52(2):103-16. 
189. Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in cancer: accumulation, 
gain-of-function, and therapy. Journal of Molecular Biology. 2017;429(11):1595-606. 
190. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes & 
Development. 2012;26(12):1268-86. 
191. Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dotsch V, Vousden KH. Functional 
interplay between MDM2, p63/p73 and mutant p53. Oncogene. 2015;34(33):4300-10. 
192. Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, et al. Mutant 
p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in 
breast cancer cells. Genes & Development. 2015;29(12):1298-315. 
193. Zhao Y, Zhang C, Yue X, Li X, Liu J, Yu H, et al. Pontin, a new mutant p53-binding 
protein, promotes gain-of-function of mutant p53. Cell Death and Differentiation. 
2015;22(11):1824-36. 
194. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et al. Tumour-associated mutant p53 
drives the Warburg effect. Nature Communications. 2013;4:2935. 
195. Tomita K, Teratani T, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K, et al. 
p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis 
in humans and mice. Journal of Hepatology. 2012;57(4):837-43. 
196. Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR. Inhibition of p53 
attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. 
Journal of Hepatology. 2013;58(4):785-91. 
197. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic 
steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 
2008;48(6):1810-20. 
198. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nature Reviews Cancer. 
2002;2(8):594-604. 
199. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: 
somatic cancer genetics at high-resolution. Nucleic Acids Research. 2017;45(D1):D777-D83. 
200. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. Genetics 
of hepatocellular carcinoma. World Journal of Gastroenterology. 2007;13(16):2271-82. 
201. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of 
regulation, deregulation and therapeutic targets in cancer. Cell Proliferation. 2003;36(3):131-
49. 
239 
 
202. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & 
Development. 1995;9(10):1149-63. 
203. Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, et al. GADD45-induced cell cycle 
G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of 
p38 kinase activity. Oncogene. 2002;21:8696. 
204. Sobecki M, Mrouj K, Colinge J, Gerbe F, Jay P, Krasinska L, et al. Cell-cycle regulation 
accounts for variability in Ki-67 expression levels. Cancer Research. 2017;77(10):2722-34. 
205. Yang C, Zhang J, Ding M, Xu K, Li L, Mao L, et al. Ki67 targeted strategies for cancer 
therapy. Clinical & Translational Oncology. 2017. 
206. Esfandiari A. Modulation of p53 signalling and response to MDM2-p53 binding 
antagonists [PhD thesis]. Newcastle University, Faculty of Medical Sciences, 2015. 
207. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. 
Oncogene. 2013;32(43):5129-43. 
208. Chakradeo S, Elmore LW, Gewirtz DA. Is Senescence Reversible? Current Drug 
Targets. 2016;17(4):460-6. 
209. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. 
Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661. 
210. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. 
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. 
Nature. 2007;445(7128):656-60. 
211. Dashzeveg N, Yoshida K. Cell death decision by p53 via control of the mitochondrial 
membrane. Cancer Letters. 2015;367(2):108-12. 
212. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochemical and 
Biophysical Research Communications. 2005;331(3):851-8. 
213. Siddiqui WA, Ahad A, Ahsan H. The mystery of BCL2 family: Bcl-2 proteins and 
apoptosis: an update. Archives of Toxicology. 2015;89(3):289-317. 
214. Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical overview of 
MDM2/X-targeted therapies. Frontiers in Oncology. 2016;6:7. 
215. Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, et al. p53 
mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. 
Oncogene. 1999;18(11):1921-34. 
216. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo 
activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 
2004;303(5659):844-8. 
240 
 
217. Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical 
evaluation: perspectives for the management of hematological malignancies and pediatric 
cancer. Journal of Hematology & Oncology. 2017;10:133. 
218. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the 
p53 pathway in retinoblastoma. Nature. 2006;444(7115):61-6. 
219. Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, et al. Mdm2 is 
required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced 
p53 activity. Cell Stem Cell. 2010;7(5):606-17. 
220. Mahfoudhi E, Lordier L, Marty C, Pan J, Roy A, Roy L, et al. P53 activation inhibits 
all types of hematopoietic progenitors and all stages of megakaryopoiesis. Oncotarget. 
2016;7(22):31980-92. 
221. Hyman DM, Chatterjee M, Vos Fd, Lin C-C, Suárez C, Tai D, et al. Abstract CT150: 
Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-
finding Phase I study of NVP-HDM201 in pts with TP53wt advanced tumors. Cancer Research. 
2017;77(13 Supplement):CT150-CT. 
222. ClinicalTrials .gov. 
https://clinicaltrials.gov/ct2/results?cond=&term=HDM201&cntry1=&state1=&recrs= 
Accessed December 2017. 
223. Liu Y, Zhang Y, Bautista D, Tang S, Zhou J, Li C, et al. Trans-arterial p53-gene-
embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage 
B: single-center experience. Cell Biochemistry and Biophysics. 2015;71(1):99-104. 
224. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for 
treatment of cancers. Human Gene Therapy. 2005;16(9):1016-27. 
225. Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, et al. Biological 
activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial 
infusion in a Phase 1 colorectal cancer trial. Cancer Gene Therapy. 2006;13(2):169-81. 
226. Tian G, Liu J, Zhou JS, Chen W. Multiple hepatic arterial injections of recombinant 
adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for 
unresectable hepatocellular carcinoma: a pilot phase II trial. Anti-Cancer Drugs. 
2009;20(5):389-95. 
227. Yu M, Chen W, Zhang J. p53 gene therapy for pulmonary metastasis tumor from 
hepatocellular carcinoma. Anti-Cancer Drugs. 2010;21(9):882-4. 
228. Li GB, Zhang XL, Yuan L, Jiao QQ, Liu DJ, Liu J. Protein phosphatase magnesium-
dependent 1delta (PPM1D) mRNA expression is a prognosis marker for hepatocellular 
carcinoma. PLOS ONE. 2013;8(3):e60775. 
241 
 
229. Xu Z, Cao C, Xia H, Shi S, Hong L, Wei X, et al. Protein phosphatase magnesium-
dependent 1delta is a novel tumor marker and target in hepatocellular carcinoma. Frontiers of 
Medicine. 2016;10(1):52-60. 
230. Lowe J, Cha H, Lee MO, Mazur SJ, Appella E, Fornace AJ, Jr. Regulation of the Wip1 
phosphatase and its effects on the stress response. Frontiers in Bioscience (Landmark edition). 
2012;17:1480-98. 
231. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C 
phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response 
pathways. Cancer Metastasis Reviews. 2008;27(2):123-35. 
232. Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, et al. Novel 
hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World Journal 
of Gastroenterology. 2014;20(5):1268-88. 
233. William M. Bonner, Christophe E. Redon, Jennifer S. Dickey, Asako J. Nakamura, Olga 
A. Sedelnikova, Stéphanie Solier, et al. γH2AX and cancer. Nature Reviews Cancer. 2008;8. 
234. Nims RW, Sykes G, Cottrill K, Ikonomi P, Elmore E. Short tandem repeat profiling: 
part of an overall strategy for reducing the frequency of cell misidentification. In vitro Cellular 
& Developmental Biology Animal. 2010;46(10):811-9. 
235. Reid Y, Storts D, Riss T, Minor L. Authentication of Human Cell Lines by STR DNA 
Profiling Analysis. In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, 
Auld D, et al., editors. Assay Guidance Manual. Bethesda (MD): Eli Lilly & Company and the 
National Center for Advancing Translational Sciences; 2004. 
236. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New 
colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer 
Institute. 1990;82(13):1107-12. 
237. Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. Discovery of RG7388, a 
potent and selective p53-MDM2 inhibitor in clinical development. Journal of Medicinal 
Chemistry. 2013;56(14):5979-83. 
238. Furet P, Masuya K, Kallen J, Stachyra-Valat T, Ruetz S, Guagnano V, et al. Discovery 
of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based 
design starting from a conformational argument. Bioorganic & Medicinal Chemistry Letters. 
2016;26(19):4837-41. 
239. Gilmartin AG, Faitg TH, Richter M, Groy A, Seefeld MA, Darcy MG, et al. Allosteric 
Wip1 phosphatase inhibition through flap-subdomain interaction. Nature Chemical Biology. 
2014;10(3):181-7. 
242 
 
240. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that 
identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National 
Academy of Sciences of the United States of America. 1995;92(20):9363-7. 
241. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. 
Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer. 
2010;102(11):1555-77. 
242. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer 
statistics, 2012. CA: a Cancer Journal for Clinicians. 2015;65(2):87-108. 
243. Ferramosca A, Di Giacomo M, Zara V. Antioxidant dietary approach in treatment of 
fatty liver: New insights and updates. World Journal of Gastroenterology. 2017;23(23):4146-
57. 
244. Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, 
classification, and effect on drug metabolizing enzymes and transporters. Drug Metabolism 
Reviews. 2017;49(2):197-211. 
245. Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver 
disease-A Starter's Guide. Nutrients. 2017;9(10). 
246. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and 
hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 
2007;26(15):2166-76. 
247. Rudnick DA, Davidson NO. Functional relationships between lipid metabolism and 
liver regeneration. International Journal of Hepatology. 2012;2012:549241. 
248. Picard C, Lambotte L, Starkel P, Sempoux C, Saliez A, Van den Berge V, et al. Steatosis 
is not sufficient to cause an impaired regenerative response after partial hepatectomy in rats. 
Journal of Hepatology. 2002;36(5):645-52. 
249. Rao MS, Papreddy K, Abecassis M, Hashimoto T. Regeneration of liver with marked 
fatty change following partial hepatectomy in rats. Digestive Diseases and Sciences. 
2001;46(9):1821-6. 
250. Kele PG, van der Jagt EJ, Gouw AS, Lisman T, Porte RJ, de Boer MT. The impact of 
hepatic steatosis on liver regeneration after partial hepatectomy. Liver International. 
2013;33(3):469-75. 
251. Tanoue S, Uto H, Kumamoto R, Arima S, Hashimoto S, Nasu Y, et al. Liver 
regeneration after partial hepatectomy in rat is more impaired in a steatotic liver induced by 
dietary fructose compared to dietary fat. Biochemical and Biophysical Research 
Communications. 2011/03/05 ed2011. p. 163-8. 
243 
 
252. Cho JY, Suh KS, Kwon CH, Yi NJ, Lee KU. Mild hepatic steatosis is not a major risk 
factor for hepatectomy and regenerative power is not impaired. Surgery. 2006;139(4):508-15. 
253. Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, et al. The Kruppel-like 
factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. 
Gastroenterology. 2008;135(1):282-91.e1. 
254. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe 
NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose 
corn syrup equivalent. American Journal of Physiology Gastrointestinal and Liver Physiology. 
2008;295(5):G987-95. 
255. Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, et al. Fast 
food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and 
high physiological fidelity to the human condition. American Journal of Physiology 
Gastrointestinal and Liver Physiology. 2011;301(5):G825-34. 
256. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology. 
2014;147(4):754-64. 
257. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and 
pathogenesis. Annual Review of Pathology. 2010;5:145-71. 
258. Dowman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, et al. 
Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis 
induced by use of a high-fat/fructose diet and sedentary lifestyle. The American Journal of 
Pathology. 2014;184(5):1550-61. 
259. Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, et al. Progression of non-
alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger 
signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model 
in mice. Journal of Translational Medicine. 2015;13:193. 
260. Whitehead A, Ogle L, Patman GL, Anwar G, Tiniakos DG, Anstee QM, et al. P0267 : 
Ras and p-ERK in metabolic syndrome associated Hepatocellular Carcinoma (HCC). Journal 
of Hepatology. 2015;62(Supplement 2):S406. 
261. Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a 
morphologic indicator of associated metabolic risk factors: a study from India. Archives of 
Pathology & Laboratory Medicine. 2013;137(7):961-6. 
262. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in 
malignant transformation of hepatocellular adenoma. Gut. 2011;60(1):85-9. 
263. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 
2015;313(22):2263-73. 
244 
 
264. Delladetsima JK, Horn T, Poulsen H. Portal tract lipogranulomas in liver biopsies. 
Liver. 1987;7(1):9-17. 
265. Zhu H, Bodenheimer HC, Jr., Clain DJ, Min AD, Theise ND. Hepatic lipogranulomas 
in patients with chronic liver disease: association with hepatitis C and fatty liver disease. World 
Journal of Gastroenterology. 2010;16(40):5065-9. 
266. Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nature 
Reviews Immunology. 2017;17(5):306-21. 
267. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, et al. M2 
Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and 
nonalcoholic fatty liver disease. Hepatology. 2014;59(1):130-42. 
268. Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. 
Expert Review of Gastroenterology & Hepatology. 2011;5(2):189-200. 
269. Arango Duque G, Descoteaux A. Macrophage Cytokines: Involvement in Immunity and 
Infectious Diseases. Frontiers in Immunology. 2014;5(491). 
270. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. 
Immunity. 2014;41(1):49-61. 
271. Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, et al. Tim-3 fosters HCC development 
by enhancing TGF-beta-mediated alternative activation of macrophages. Gut. 
2015;64(10):1593-604. 
272. Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, et al. Metabolic 
activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and 
liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26(4):549-64. 
273. Wilson CL, Jurk D, Fullard N, Banks P, Page A, Luli S, et al. NFkappaB1 is a suppressor 
of neutrophil-driven hepatocellular carcinoma. Nature Communications. 2015;6:6818. 
274. Hatting M, Tacke F. From NAFLD to HCC: Is IL-17 the crucial link? Hepatology. 
2017;65(2):739-41. 
275. Wang C, Jurk D, Maddick M, Nelson G, Martin-Ruiz C, von Zglinicki T. DNA damage 
response and cellular senescence in tissues of aging mice. Aging Cell. 2009;8(3):311-23. 
276. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations 
and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58(4):1497-507. 
277. Delire B, Starkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and 
therapeutic implications. European Journal of Clinical Investigation. 2015;45(6):609-23. 
278. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and 
activity in primary human hepatocellular carcinoma. Biochemical and Biophysical Research 
Communications. 1997;236(1):54-8. 
245 
 
279. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous 
activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130(4):1117-
28. 
280. Townsend SA, Newsome PN. Review article: new treatments in non-alcoholic fatty 
liver disease. Alimentary Pharmacology & Therapeutics. 2017;46(5):494-507. 
281. Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, Yeh MM, et al. 
Hepatocellular carcinoma in the noncirrhotic liver. American Journal of Roentgenology. 
2014;203(1):W34-47. 
282. Nanke Y, Iwatani M, Kobashigawa T, Yago T, Yamanaka H, Kotake S. Radiographic 
repair in three Japanese patients with rheumatoid arthritis treated with bucillamine. Modern 
Rheumatology. 2009;19(6):681-6. 
283. Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a 
D-penicillamine analogue, in patients with active rheumatoid arthritis. Modern Rheumatology. 
2006;16(2):85-91. 
284. Bucillamine for the treatment of acute gout flare in subjects with moderate to severe 
gout.Clinal Trials.Gov https://www.clinicaltrials.gov/ct2/show/study/NCT02330796.  
Accessed 28/08/2017. 
285. Keenan RT, Schlesinger N. New and pipeline drugs for gout. Current Rheumatology 
Reports. 2016;18(6):32. 
286. Ceconi C, Curello S, Cargnoni A, Ferrari R, Albertini A, Visioli O. The role of 
glutathione status in the protection against ischaemic and reperfusion damage: effects of N-
acetyl cysteine. Journal of Molecular and Cellular Cardiology. 1988;20(1):5-13. 
287. Horwitz LD. Bucillamine: a potent thiol donor with multiple clinical applications. 
Cardiovascular Drug Reviews. 2003;21(2):77-90. 
288. Mazor D, Greenberg L, Shamir D, Meyerstein D, Meyerstein N. Antioxidant properties 
of bucillamine: possible mode of action. Biochemical and Biophysical Research 
Communications. 2006;349(3):1171-5. 
289. Yeung JH. The effects of bucillamine on glutathione and glutathione-related enzymes 
in the mouse. Biochemical Pharmacology. 1991;42(4):847-52. 
290. Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, et al. 
Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating 
drugs--the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological 
action of the drug. International Journal of Immunopharmacology. 1998;20(6):295-304. 
291. Evans RM, Mangelsdorf DJ. Nuclear Receptors, RXR, and the Big Bang. Cell. 
2014;157(1):255-66. 
246 
 
292. Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the 
treatment of fatty liver disease. Pharmacology & Therapeutics. 2017. 
293. Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X 
receptor agonists. Annals of Translational Medicine. 2015;3(1):5. 
294. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in 
metabolism. Cell Metabolism. 2013;17(5):657-69. 
295. de Boer JF, Schonewille M, Boesjes M, Wolters H, Bloks VW, Bos T, et al. Intestinal 
farnesoid X receptor controls transintestinal cholesterol excretion in mice. Gastroenterology. 
2017;152(5):1126-38.e6. 
296. Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver 
disease. Current Atherosclerosis Reports. 2015;17(4):500. 
297. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. 
Biochemical Pharmacology. 2013;86(11):1517-24. 
298. Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver 
lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatology International. 
2010;4(4):741-8. 
299. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed 
with anticholestatic activity. Journal of Medicinal Chemistry. 2002;45(17):3569-72. 
300. Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perovic-Ottstadt S, 
et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated 
transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl 
ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. The Journal of 
Pharmacology and Experimental Therapeutics. 2012;343(3):556-67. 
301. Copeland RA. The drug-target residence time model: a 10-year retrospective. Nature 
Reviews Drug Discovery. 2016;15(2):87-95. 
302. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect 
of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and 
vitamin E cancer prevention trial (SELECT). JAMA. 2009;301(1):39-51. 
303. Saremi A, Arora R. Vitamin E and cardiovascular disease. American Journal of 
Therapeutics. 2010;17(3):e56-65. 
304. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, et al. Lowering 
bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and 
diabetes through reduced energy expenditure. The Journal of Biological Chemistry. 
2011;286(30):26913-20. 
247 
 
305. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear 
receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver 
fibrosis. Gastroenterology. 2004;127(5):1497-512. 
306. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous 
hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28(5):940-6. 
307. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of 
liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Research. 
2007;67(3):863-7. 
308. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for 
hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology. 
2015;12(8):436. 
309. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. 
European Journal of Cancer. 2012;48(5):599-641. 
310. London WT MK, Liver cancer, In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer 
Epidemiology and Prevention. Third edition. New York, NY: Oxford University Press; 2006. 
pp 763–786. 
311. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer 
genomics portal: an open platform for exploring multidimensional cancer genomics data. 
Cancer Discovery. 2012;2(5):401-4. 
312. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative 
analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science 
Signaling. 2013;6(269):pl1. 
313. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. 
Genes & Development. 1993;7(7a):1126-32. 
314. Hyman D, Chatterjee M, Langenberg MHG, Lin CC, Suárez C, Tai D, et al. Dose- and 
regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) 
advanced tumors. European Journal of Cancer. 2016;69:S128-9. 
315. Holzer P, Chène P, Ferretti S, Furet P, Gabriel T, Gruenenfelder B, et al. Abstract 4855: 
Discovery of NVP-HDM201 - first disclosure of a next-generation Mdm2 inhibitor with 
superior characteristics. Cancer Research. 2016;76(14 Supplement):4855. 
316. Ferretti S, Rebmann R, Berger M, Santacroce F, Albrecht G, Pollehn K, et al. Abstract 
1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile 
Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials. 
Cancer Research. 2016;76(14 Supplement):1224. 
248 
 
317. Stachyra-Valat T, Baysang F, D’Alessandro A-C, Dirk E, Furet P, Guagnano V, et al. 
Abstract 1239: NVP-HDM201: Biochemical and biophysical profile of a novel highly potent 
and selective PPI inhibitor of p53-Mdm2. Cancer Research. 2016;76(14 Supplement):1239. 
318. Lakoma A, Barbieri E, Agarwal S, Jackson J, Chen Z, Kim Y, et al. The MDM2 small-
molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. 
Cell Death Discovery. 2015;1. 
319. Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, et al. Pre-
clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with 
chemotherapy in neuroblastoma. Oncotarget. 2015;6(12):10207-21. 
320. Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, et al. Activation of 
p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult 
T-cell leukemia cells. Leukemia. 2009;23(11):2090-101. 
321. Kumar R, Gont A, Perkins TJ, Hanson JEL, Lorimer IAJ. Induction of senescence in 
primary glioblastoma cells by serum and TGFbeta. Scientific Reports. 2017;7(1):2156. 
322. Mao Z, Ke Z, Gorbunova V, Seluanov A. Replicatively senescent cells are arrested in 
G1 and G2 phases. Aging (Albany NY). 2012;4(6):431-5. 
323. Mombach JCM, Bugs CA, Chaouiya C. Modelling the onset of senescence at the G1/S 
cell cycle checkpoint. BMC Genomics. 2014;15(7):S7. 
324. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical 
research. Nature Reviews Immunology. 2007;7(2):118-30. 
325. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude 
mouse. Journal of Surgical Oncology. 1986;31(4):229-34. 
326. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic 
(nude) mice. Cancer Chemotherapy and Pharmacology. 1989;24(3):148-54. 
327. Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, et al. 
Advancing animal models of neoplasia through in vivo bioluminescence imaging. European 
Journal of Cancer. 2002;38(16):2128-36. 
328. Caceres G, Zankina R, Zhu X, Jiao JA, Wong H, Aller A, et al. Determination of 
chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human 
tumors. Anti-Cancer Drugs. 2003;14(7):569-74. 
329. Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, et al. Bioluminescent 
imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. 
Clinical & Experimental Metastasis. 2003;20(8):733-44. 
330. Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, DeRyckere D, et 
al. Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of 
249 
 
monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. 
Journal of Hematology & Oncology. 2013;6:10. 
331. Jost SC, Collins L, Travers S, Piwnica-Worms D, Garbow JR. Measuring brain tumor 
growth: combined bioluminescence imaging-magnetic resonance imaging strategy. Molecular 
Imaging. 2009;8(5):245-53. 
332. Meng X, Franklin DA, Dong J, Zhang Y. MDM2-p53 pathway in hepatocellular 
carcinoma. Cancer Research. 2014;74(24):7161-7. 
333. Wang J, Zheng T, Chen X, Song X, Meng X, Bhatta N, et al. MDM2 antagonist can 
inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro. Journal 
of Gastroenterology and Hepatology. 2011;26(2):371-7. 
334. Lee M, Lee JS. Exploiting tumor cell senescence in anticancer therapy. BMB Reports. 
2014;47(2):51-9. 
335. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence 
surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 
2011;479(7374):547-51. 
336. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a 
distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer 
therapy. European Journal of Cancer. 2006;42(6):717-27. 
337. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent 
chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination 
by natural killer cells. The Journal of Experimental Medicine. 2013;210(10):2057-69. 
338. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 Phosphatase 
acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007;12(4):342-54. 
339. Sriraman A, Radovanovic M, Wienken M, Najafova Z, Li Y, Dobbelstein M. 
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. Oncotarget. 
2016;7(22):31623-38. 
340. Oliva-Trastoy M, Berthonaud V, Chevalier A, Ducrot C, Marsolier-Kergoat MC, Mann 
C, et al. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor 
kinase. Oncogene. 2007;26(10):1449-58. 
341. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and 
abrogates cell cycle checkpoints. Genes & Development. 2005;19(10):1162-74. 
342. Macurek L, Lindqvist A, Voets O, Kool J, Vos HR, Medema RH. Wip1 phosphatase is 
associated with chromatin and dephosphorylates gammaH2AX to promote checkpoint 
inhibition. Oncogene. 2010;29(15):2281-91. 
250 
 
343. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, et al. Oncogenic 
properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nature 
Genetics. 2002;31(2):133-4. 
344. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, et al. Association 
of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification 
of PPM1D and APPBP2 as likely amplification targets. Clinical Cancer Research. 
2003;9(6):1995-2004. 
345. Pechackova S, Burdova K, Benada J, Kleiblova P, Jenikova G, Macurek L. Inhibition 
of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist 
nutlin-3. Oncotarget. 2016;7(12):14458-75. 
346. Esfandiari A, Hawthorne TA, Nakjang S, Lunec J. Chemical Inhibition of Wild-Type 
p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to 
MDM2 Inhibitors in a p53-Dependent Manner. Molecular Cancer Therapeutics. 
2016;15(3):379-91. 
347. Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, 
et al. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the 
HDAC inhibitor sodium butyrate. Cell Cycle. 2010;9(19):3945-55. 
348. Kim YY, Jee HJ, Um JH, Kim YM, Bae SS, Yun J. Cooperation between p21 and Akt 
is required for p53-dependent cellular senescence. Aging Cell. 2017;16(5):1094-103. 
349. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. 
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) 
in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723-30. 
350. Seki E. Hedgehog Signal in hepatocytes mediates macrophage recruitment: a new 
mechanism and potential therapeutic target for fatty liver disease. Hepatology. 
2016;63(4):1071-3. 
351. Guillen-Sacoto MJ, Martinez AF, Abe Y, Kruszka P, Weiss K, Everson JL, et al. Human 
germline hedgehog pathway mutations predispose to fatty liver. Journal of Hepatology. 
2017;67(4):809-17. 
352. Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in 
development and disease. Nature Reviews Molecular cell Biology. 2013;14(7):416-29. 
353. Kwon H, Song K, Han C, Chen W, Wang Y, Dash S, et al. Inhibition of hedgehog 
signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease. 
Hepatology. 2016;63(4):1155-69. 
251 
 
354. Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, et al. 
Implication of the Hedgehog pathway in hepatocellular carcinoma. World Journal of 
Gastroenterology. 2017;23(24):4330-40. 
355. Matz-Soja M, Rennert C, Schonefeld K, Aleithe S, Boettger J, Schmidt-Heck W, et al. 
Hedgehog signaling is a potent regulator of liver lipid metabolism and reveals a GLI-code 
associated with steatosis. ELife. 2016;5. 
356. Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nature 
Reviews Molecular Cell Biology. 2014;15(7):482-96. 
357. Qian Y, Chen X. Senescence regulation by the p53 protein family. Methods of 
Molecular Biology. 2013;965:37-61. 
358. Vatsyayan R, Singhal J, Nagaprashantha LD, Awasthi S, Singhal SS. Nutlin-3 enhances 
sorafenib efficacy in renal cell carcinoma. Molecular Carcinogenesis. 2013;52(1):39-48. 
359. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, et al. The sorafenib 
plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells 
irrespectively of FLT3 and p53 status. Haematologica. 2012;97(11):1722-30. 
 
